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Abstract 
Hyperglycaemia stimulates a variety of biochemical abnormalities. The area 
of particular interest in this study is the influence of non-enzymatic glycation 
of proteins on iron homeostasis, and particularly on non-transferrin-bound 
iron (NTBI) and its possible relation to atherogenesis in both Type 2 diabetic 
and obese non diabetic subjects. The link between non-enzymatic glycation 
of proteins and iron homeostasis, and development of macrovascular 
disease may be mechanistically different in Type 2 diabetic and obese non 
diabetic subjects due to a difference in the protein glycation pattern. 
Because the following in vivo study required storage of samples for up to two 
years to complete the processing of all the samples, a storage study was 
carried out using different anticoagulants and addition of reduced glutathione 
(GSH) to samples to study the effects of storage, thawing and freezing of the 
samples on the level of malondialdehyde (MDA), a biomarker of lipid 
peroxidation. This storage study showed that EDTA attenuated the action of 
lipid oxidation compared with lithium heparin (LiH). A combination of GSH 
with either EDTA or LiH added more protection from lipid peroxidation in the 
first week of storage, but due to the thawing and freezing of the sample the 
action of GSH diminished through its autooxidation, meaning that addition of 
GSH to samples in the following in vivo study would be useless. 
An in vivo study was carried out on iron-related parameters in three subject 
groups: control (non-diabetic, non-obese), Type 2 diabetic and obese non 
diabetic. Glycated haemoglobin (HbA1C) was strongly correlated with NTBI in 
the diabetic group. Also the level of NTBI was significantly increased in Type 
2 diabetic subjects compared with other groups while the level of total iron 
was significantly decreased. The study showed a strong positive correlation 
between NTBI and a biomarker of endothelium dysfunction (E-selectin) in all 
groups studied. Although it is not possible from the current data to know if 
there is a causal relationship between these two parameters, it remains a 
possibility that iron released from its binding sites could initiate oxidative 
damage to the endothelial cells and begin the process of atherogenesis. 
Positive correlation at the 90% confidence level between NTBI and a 
biomarker of inflammation, high sensitivity C-reactive protein, is another 
indicator in this study of a link between increases in NTBI, inflammation, 
endothelium dysfunction and atherosclerosis. This study also showed for first 
time that NTBI is present in higher levels in the plasma of obese subjects 
compared to controls despite the obese subjects having significantly lower 
total iron. 
An in vitro study found that glycation of transferrin half saturated with iron 
increased with increasing glucose concentration, leading to decreased 
capacity of transferrin to hold iron and increased release of free iron. Also co-
incubation of transferrin half saturated with iron with low density lipoprotein 
(LDL) and glucose showed oxidation of LDL (measured as MDA). This may 
be explained by the effect of glycation, leading to release of free iron, which 
catalyses oxidation of LDL. In addition, glycation of LDL may enhance the 
oxidation of LDL catalysed by iron. 
Both studies indicate that the glycation of proteins has a major impact on iron 
homeostasis leading to release of non-enzymatic glycation and contributing 
to one of the most common complications of Type 2 diabetes, atherosclerosis. 
  IV  
 
LIST OF CONTENTS 
ABSTRACT III 
ABBREVIATIONS XIV 
ACKNOWLEDGEMENTS XVIII 
DEDICATION XIX 
AUTHOR’S DECLARATION XX 
LITERATURE REVIEW 1 
1.1 Diabetes mellitus 2 
1.2 Diagnosis of diabetes 3 
1.3 Classification of diabetes mellitus 5 
1.3.1 Type 1 diabetes mellitus 5 
1.3.2 Type 2 diabetes mellitus 6 
1.3.2.1 Risk factors for T2DM 8 
1.3.2.1.1 Age 8 
1.3.2.1.2 Excess weight 8 
1.3.2.1.3 Genetic factors (family history of diabetes) 8 
1.3.2.1.4 Physical inactivity 9 
1.3.2.1.5 Ethnicity 9 
1.3.3. Gestational diabetes mellitus 10 
1.4 Complications of diabetes 11 
1.4.1 Vascular disease 12 
1.4.2 Diabetic retinopathy 13 
1.4.3 Peripheral neuropathies 14 
1.4.4 Autonomic neuropathy 14 
1.4.5 Diabetic nephropathy 15 
1.5 Iron and Type 2 diabetes 17 
1.6 Iron 23 
1.6.1 Functions of iron in the human body 23 
1.6.2 Iron distribution 25 
  V  
 
1.6.3 Iron absorption 27 
1.6.4 Iron transport 30 
1.6.5 Iron uptake in the cells 30 
1.6.6 Transferrin receptors 33 
1.6.7 Iron storage 33 
1.6.8 Iron recycling 35 
1.6.9 Iron homeostasis 36 
1.6.10 Hepcidin 36 
1.6.11 Iron loading disorders 38 
1.6.12 Hereditary haemochromatosis 38 
1.6.13 Non-transferrin-bound iron 39 
1.6.14 Methods for measuring NTBI 43 
1.7 Protein glycation 46 
1.7.1 Maillard reaction and AGE synthesis in humans 46 
1.8 Oxidative stress in diabetes 49 
1.9 Obesity 53 
1.9.1 Iron and obesity 55 
1.9.2 Obesity and oxidative stress 56 
1.9.2.1 Increased fatty acid oxidation 56 
1.9.2.2 Antioxidant depletion 57 
1.9.2.3 Over consumption of oxygen 57 
1.9.2.4 Adipose tissue 57 
1.9.2.5 Diet 58 
1.10 Endothelium dysfunction 58 
1.11 Atherosclerosis 59 
1.11.1 Atherosclerotic risk factors 61 
1.11.2 Iron and atherosclerosis 62 
1.11.3 Oxidative stress and atherosclerosis 64 
1.12 Novelty of project 65 
1.13 Conclusions 68 
1.3 HYPOTHESES 70 
1.2 Aims and objectives 71 
  VI  
 
CHAPTER 2: AN IN VIVO STUDY ON THE RELATIONSHIP BETWEEN 
NON-TRANSFERRIN BOUND IRON AND OTHER COMMON IRON-
RELATED, INFLAMMATION AND ATHEROSCLEROSIS BIOMARKERS IN 
TYPE 2 DIABETES AND OBESITY 72 
2.1 Introduction 73 
2.1.1 Non-transferrin-bound iron and diseases 75 
2.1.2 Non-transferrin-bound iron and Type 2 diabetes 75 
2.1.3 Non-transferrin-bound iron and oxidative stress 77 
2.1.4 Non-transferrin-bound iron and atherosclerosis 78 
2.2 Stability of biomarkers in plasma samples during sample preparation and after storage
 79 
2.2.1 Background information about MDA 80 
2.2.2 Sources of malondialdehyde and health aspects 81 
2.2.3 Effect of storage of plasma on TBARS 82 
2.3 Aims of the study 82 
2.4. Materials and Methods 84 
2.4.1 Materials 84 
2.4.2 Venesection and sample handling 84 
2.4.3 Phlebotomy and experimental design for the effect of glutathione on the level of 
malondialdehyde in stored human plasma 85 
2.4.4 Determination of serum iron 86 
2.4.4.1 Principle of method 86 
2.4.4.2 Method 86 
2.4.5 Determination of total iron-binding capacity (TIBC) of plasma samples 87 
2.4.5.1 Principle of method 87 
2.4.5.2 Method 87 
2.4.6 Unsaturated iron binding capacity (UIBC) 88 
2.4.7 Transferrin saturation (TSAT) 88 
2.4.8 Non-transferrin-bound iron (NTBI) 88 
2.4.9 Estimation of total antioxidant activity 90 
2.4.9.1 Ferric-Reducing Ability of Plasma (FRAP) assay 90 
2.4.9.2 Preparation of FRAP reagent 91 
2.4.9.3 Procedure 91 
2.4.10 Determination of total and reduced ascorbate 92 
2.4.11 Thiobarbituric acid reactive substances (TBARS) assay 93 
2.4.11.1 Measurement of malondialdehyde in plasma 94 
2.4.11.2 Interference with the method 94 
2.4.12 Background information on human E-selectin 96 
  VII  
 
2.4.12.1 Principle of measurement of human E-selectin by enzyme-linked immunosorbent 
assay (ELISA) 97 
2.4.12.2 Procedure 98 
2.4.13 C-reactive protein (CRP) structure and function 99 
2.4.13.1 Storage of samples 100 
2.4.13.2 High sensitivity C-reactive protein (hs-CRP) 101 
2.4.13.3 High sensitivity C-reactive protein as a biomarker atherosclerosis 101 
2.4.13.4 Procedure 101 
2.4.14 Soluble transferrin receptor 103 
2.4.14.1 Principle of test 104 
2.4.14.2 Procedure 104 
2.4.14.3 Stability of sTfR 105 
2.5 Statistical analysis 106 
2.6 Results 107 
2.6.1 Effect of glutathione on the level of malondialdehyde in stored human plasma 107 
2.6.1.1 Method development and improvement 107 
2.6.1.2 Determination of MDA standards 109 
2.6.1.3 Changes in the level of measured MDA with time of storage 110 
2.6.2 Results of the in vivo study 114 
2.6.2.1 Iron indices in different groups 114 
2.6.2.2 Correlations between age and iron indices 117 
2.6.2.3 Correlation between age and all oxidative stress 119 
2.6.2.4 Oxidative stress indices in different groups 119 
2.6.2.5 E-selectin and high sensitivity C-reactive protein level differences between groups
 123 
2.6.2.6 Correlations between NTBI and other iron indices 123 
2.6.2.7 Correlation between NTBI and biomarkers of oxidative stress 125 
2.6.2.8 Correlation between NTBI and biomarkers of inflammation 125 
2.6.2.9 Correlation between NTBI and biomarkers of atherosclerosis 125 
2.6.2.10 Correlation between NTBI and HbA1c 127 
2.7 Discussion 128 
2.7.1 Storage of plasma with and without GSH 128 
2.7.2 Storage of plasma in EDTA and LiH without GSH 130 
2.7.3 Iron indices in Type 2 diabetes 131 
2.7.4 Oxidative stress in Type 2 diabetes 135 
2.7.5 Endothelial dysfunction in Type 2 diabetes 137 
2.7.6 Inflammation in Type 2 diabetes 138 
2.7.7 Iron indices in obese non diabetic subjects 138 
  VIII  
 
2.7.8 Oxidative stress in obese non-diabetic subjects 140 
2.7.9 Inflammation in obese non-diabetic subjects 141 
2.7.10 Endothelial dysfunction in obese non-diabetic subjects 142 
2.7.11 Correlations between age and measured parameters 142 
2.7.12 Correlations between NTBI and measured parameters 143 
2.7.13 Correlations between NTBI and HbA1c in T2DM 144 
CHAPTER 3: EFFECTS OF GLYCATION OF TRANSFERRIN IN VITRO ON 
IRON BINDING 147 
3.1 Introduction 148 
3.1.1 Serum transferrin structure 149 
3.1.2 Transferrin glycation 151 
3.1.3 LDL and atherosclerosis 152 
3.2 Aim 154 
3.3 Methods 154 
3.3.1 Transferrin loading with iron 154 
3.3.1.1 Preparation of Fe(NTA)2 solution 154 
3.3.1.2 Preparation of human apotransferrin solution 154 
3.3.1.3 Exposure of 50% loaded transferrin to glucose 154 
3.3.2 Buffer exchange 155 
3.3.3 Measurement of protein 156 
3.3.3.1 Preparation of Bradford reagent 156 
3.3.3.2 Procedure 156 
3.3.4 Measurement of glucose in samples 157 
3.3.5 Assessment of glycation 157 
3.3.6 Measurement of total iron 157 
3.3.7 Measurement of total iron-binding capacity 157 
3.3.8 Electrophoresis 158 
3.3.8.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (PAGE) 158 
3.3.9 LDL incubation with half-saturated transferrin and glucose 160 
3.3.9.1 Preparation of LDL suspension 160 
3.3.9.2 Procedure 160 
3.4 Results 161 
3.4.1 Spectrum of human apotransferrin solution 161 
3.4.2 Apotransferrin titration with iron 162 
3.4.3 Use of HPLC sample vials as cuvettes 162 
3.4.4 Glucose standards 164 
  IX  
 
3.4.5 Protein standards 164 
3.4.6 Recovery of protein following buffer exchange, and the separation of protein from 
glucose 165 
5.4.7 L-lysine standards 167 
3.4.8 Exposure of 50% ITf to different concentrations of glucose 167 
3.4.8.1 Effect of glucose on the absorbance spectrum 50% ITf 168 
3.4.8.2 Assessment of glycation 169 
3.4.8.3 Assessment of transferrin iron-binding capacity 170 
3.4.8.4 Free iron levels 172 
3.4.8.5 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 173 
3.4.9 Co-exposure of LDL and 50% ITf to glucose 174 
5.4.9.1 Assessment of oxidation of LDL using MDA 174 
3.4.9.2 Free iron 175 
3.5 Discussion 178 
CHAPTER 4 GENERAL DISCUSSION 183 
4.1 General discussion 184 
REFERENCES 197 
Appendix 1 correlation of other iron indices with age 242 
Appendix 2 correlation other oxidative stress indices with age 244 
Appendix 3 correlation between E-selectin and hsC-RP and age 246 
Appendix 4 correlation between NTBI and iron indices 247 
Appendix 5 correlation between NTBI and oxidative stress indices 249 
Appendix 6 correlation between NTBI hsC-RP 252 
Appendix 7 Validation of the NTBI method 253 
Appendix 8 Consent form 255 
Appendix 9 Questionnaire forms 256 
Appendix 10 Anthropometric indices 255 
 
  
  X  
 
List of figures 
Figure 1.1 nitric oxide synthesis ..................................................................................................... 12 
Figure 1.2 peroxynitrite formation and tyrosine nitration .............................................................. 13 
Figure 1.3 mechanisms by which hyperglycaemia stimulate superoxide over production.In 
mitochondria by activation four pathways. .......................................................................... 22 
Figure 1.4 Distribution of total body iron among tissues. From Hentze et al. (2004). ..................... 26 
Figure 1.5 Systemic iron transports. ............................................................................................... 29 
Figure 1.6 Iron uptake in cells. ....................................................................................................... 32 
Figure 1.7 Mechanism of lipid peroxidation induced by increase of NTBI ....................................... 41 
Figure 1.8 Role of NTBI in diabetes complications .......................................................................... 42 
Figure 1.9 The Maillard reaction. ................................................................................................... 47 
Figure 1.10 Chemical structure and formation of AGEs in the Maillard reaction ............................ 48 
Figure 1.11 Schematic representation of the sequence of events leading to the Fenton reaction. 
From Bogdanova and Nikinmaa (2001) ................................................................................. 52 
Figure 1.12 Possible mechanism that accounts for iron deficiency in obesity. ................................ 56 
Figure 2.1 Flow diagram showing the release of NTBI in uncontrolled Type 2 diabetes mellitus. ... 77 
Figure 2.2 Standard curve for detection of iron (as FeCl3) using method of Bothwell et al. (1971). 87 
Figure 2.3 Chromatograms A showing NTBI Standard 5 µM of NTBI and Chromatograms B showing 
NTBI for plasma sample ........................................................................................................ 90 
Figure 2.5 ELISA calibration curve for Human E-selectin (4-parameter) .......................................... 99 
Figure 2.6 ELISA calibration curve for Human C-RP (4-parameter) ................................................ 102 
Figure 2.7 ELISA calibration curve for Human sTfR (4-parameter) ................................................ 105 
Figure 2.8 Representative chromatograms showing multiple peaks obtained with the original 
Agarwal and Chase (2002) method with 40:50 (v/v) methanol/buffer as mobile phase (A). 108 
Figure 2.9 Representative chromatogram showing sharp peak for a plasma sample using 20:80 (v/v) 
methanol/buffer as mobile phase. ...................................................................................... 109 
Figure 2.10 Standard curve for detection of MDA using the method of Agarwal and Chase (2002).
 ........................................................................................................................................... 110 
Figure 2.11 Effect of storage at -80 °C on the MDA concentration in human plasma samples ...... 112 
Figure 2.12 MDA (means ± SEM) in plasma of 6 subjects stored with EDTA or with LiH, with or 
without GSH (A) at time zero and (B) on day 21 .................................................................. 113 
Figure 2.13 Total serum iron (means ± SEM) for control, T2DM and obese groups. ... 115 
Figure 2.14 % transferrin saturation (means ± SEM) for control T2MD and obese groups. ........... 116 
Figure 2.15 NTBI (means ± SEM) between control,T2MD and obese groups. ................................ 116 
Figure 2.16 STR (means ± SEM) between control, T2MD and obese groups. ................................ 117 
Figure 2.17 Correlations between age and TIBC. .......................................................................... 118 
Figure 2.18 Correlations between age and MDA .......................................................................... 119 
  XI  
 
Figure 2.19 Total ascorbate (means ± SEM) between control,T2MD and  obese groups. .............. 121 
Figure 2.21 DHA (means ± SEM) between control, T2MD and obese groups. ............................... 122 
Figure 2.22 Antioxidant capacities (means ± SEM) between control, T2MD and obese groups. ... 122 
Figure 2.23 E-selectin (means ± SEM) between control, T2MD and obese groups. ....................... 124 
Figure 2.24 Plasma hs-CRP levels (means ± SEM) between T2MD, obese and control groups. ..... 124 
Figure 2.25 Correlations between NTBI and sTfR (P = 0.050). R
2
 = 0.238, 0.099 and 0.346 for 
theT2DM, control and obese groups, respectively (control, n = 28; T2DM, n = 28; and obese, n 
=17). .................................................................................................................................... 125 
 
Figure 2.27 Correlations between NTBI and E-selectin (P = 0.001). R
2
 = 0.469, 0.017 and 0.232 for the diabetes, 
control and obese groups, respectively (control, n = 28; T2DM, n = 28; and obese, n =17). ........................... 126 
Figure 2.28 Correlation between NTBI and HbA1c (P < 0.0005; R
2 
= 0.742) in the T2DM group. ..... 127 
Figure 3.1 UV/visible spectrum of human apotransferrin. ............................................................ 161 
Figure 3.2 UV/visible spectra of transferrin during titration with iron.......................................... 162 
Figure 3.3 Comparison of the visible spectrum of a food dye. ...................................................... 163 
Figure 3.4 Calibration graph for the determination of glucose (means ± SEM) as described in 
Section 3.3.4. ...................................................................................................................... 164 
Figure 3.5 Calibration graph for the determination of protein using the Bradford assay (means ± 
SEM). Bovine serum albumin was used for the standards. .................................................. 165 
Figure 3.6 The recovery of bovine serum albumin(cheap compared to Tf)  following application of 1 
ml of 2 mg ml
-1
 of protein to a 10 ml Sephadex G-25 column. ............................................. 166 
Figure 3.7 The separation of bovine serum albumin (red) from glucose (blue), following application 
of 1 mg ml
-1
 of protein in Tris buffer containing 1 mM glucose (1 ml) to a 10 ml Sephadex G-
25 column. .......................................................................................................................... 166 
Figure 3.8 Calibration graph for the determination of –NH2 groups using the TNBSA assay (means ± 
SEM). .................................................................................................................................. 167 
Figure 3.9 Spectra for 50% ITf incubated with 1000 mM glucose on day 1 (red line) and on day 14 
(black line). ......................................................................................................................... 168 
Figure 3.10 Glycation of 50% ITf (means ± SEM) incubated with different concentrations of glucose 
for 14 days. ......................................................................................................................... 169 
Figure 3.11 Inverse relationship between concentration of glucose and number of amine groups 
found after incubation of 50% ITf with different concentrations of glucose for 14 days. R
2
 = 
0.851. (P = 0.021). n = 3 replicate measurements. ............................................................... 170 
Figure 3.12 TIBC of 50% ITf (means ± SEM) incubated with different concentration of glucose for 14 
days. ................................................................................................................................... 171 
Figure 3.13 correlation between TIBC and different concentrations of glucose. ........................... 171 
Figure 3.14 Free iron (means ± SEM) ‘released’ from 50% ITf incubated for 14 days with different 
concentration of glucose. .................................................................................................... 172 
  XII  
 
Figure 3.15 correlation between free iron and different concentrations of glucose incubated with 
50% ITf. R
2
 = 0.837 (P = 0.022). n = 3 replicate measurements. ........................................... 173 
Figure 3.16 SDS PAGE of 50% ITf incubated for 14 days at 37 °C with different concentration of 
glucose. ............................................................................................................................... 174 
Lane 1, apoTf; lane 2, 50% ITf without glucose; lane 3, 50% ITF with 1000 mM glucose; lane 4, 50% 
ITf with 750 mM glucose; lane 5, 50% ITf with 500 mM glucose; and lane 6, 50% ITf with 250 
mM glucose. ....................................................................................................................... 174 
Figure 3.17 Levels of MDA (means ± SEM) from oxidation of LDL. ................................................ 175 
Figure 3.18 Free iron (means ± SEM) ‘released’ from incubation of LDL with 50% ITf plus 500 mM 
glucose, free iron, apoTf and 500 mM glucose. ................................................................... 176 
Figure 3.19 TIBC (means ± SEM) after incubation of LDL with 50% ITf plus 500 mM glucose, free 
iron, apoTf and 500 mM glucose. ........................................................................................ 176 
Figure 3.20 Glycated LDL (means ± SD) after incubation LDL with 50% ITf plus 500 mM glucose, iron, 
apoTf and 500 mM glucose. ................................................................................................ 177 
Figure 4.1 A role for NTBI in atherosclerotic lesions in uncontrolled T2DM. ................................. 192 
Figure A1.1 Correlations between age and total serum iron levels (P = 0.356). ............................ 242 
Figure A1.2 Correlations between age and % saturation of transferrin (P = 0.440). .... 242 
Figure A1.3 Correlations between age and NTBI levels (P = 0.470). .............................................. 243 
Figure A1.4 Correlations between age and sTfR (P = 0.616). ......................................................... 243 
Figure A2.1 Correlations between age and total ascorbate (P = 0.895). ....................................... 244 
Figure A2.2 Correlations between age and ascorbate (P = 0.985). ................................................ 244 
Figure A2.3 Correlations between age and DHA (P = 0.896). ........................................................ 245 
Figure A2.4 Correlations between age and total antioxidant capacity (P = 0.682). ....................... 245 
Figure A3.1 Correlations between age and E-selectin levels (P = 0.0997). .................................... 246 
Figure A3.2 Correlations between age and hs-CRP (P = 0.221). .................................................... 246 
Figure A4.1 Correlations between NTBI and total serum iron (P = 0.396). .................................... 247 
Figure A4.2 Correlations between NTBI and TIBC (P = 0.527). ...................................................... 247 
Figure A4.3 correlation between NTBI and % transferrin saturation (P = 0.328). .......................... 248 
Figure A5.1 Correlations between NTBI and MDA (P = 0.390). ..................................................... 249 
Figure A5.2 Correlations between NTBI and total ascorbate (P = 0.396)....................................... 249 
Figure A5.3 Correlations between NTBI and DHA (P = 0.865). ...................................................... 250 
Figure A5.4 Correlations between NTBI and ascorbate (P = 0.563). .............................................. 250 
Figure A5.5 Correlations between NTBI and total antioxidant capacity (P = 0.593). ..................... 251 
Figure A6.1 Correlation between hs-CRP and E-selectin (P = 0.801). ............................................ 252 
 
  
  XIII  
 
 
List of Tables 
Table 1.1 Criteria for diagnosis of diabetes. ............................................................................. 4 
Table 1.2 Iron containing proteins and their biological function ........................................ 24 
Table 1.3 Radical and non-radical reactive oxygen species .................................................. 50 
Table 1.4 Classification of risk factors for atherosclerosis as presented by the AHA ....... 62 
Table 3.1 LDL incubated with 50% ITf, iron, apoTf and glucose (concentration of protein 
after ultra-centrifuge (0.435 µM), PH= 7.4 .................................................................. 160 
  
  XIV  
 
Abbreviations 
50% ITf Transferrin half saturated with iron 
2-DE Two-dimensional gel electrophoresis 
2hPG Two hours plasma glucose 
ACR Albumin: creatinine ratio 
ADA American Diabetic Association 
AGEs Advanced glycation end products 
AHA American Heart Association 
apoTf apotransferrin 
ATP Adenosine triphosphate 
BMI Body mass index 
CAT Catalase 
CRP C-reactive protein 
DCCT Diabetes Control and Complications Trial 
DCYTB Duodenal cytochrome b 
DG Deoxyglucosone 
DHAP Dihydroxyacetone phosphate 
DM Diabetes mellitus 
DMT1 Divalent metal transporter 1 
DPN Diabetic peripheral neuropathy 
DPN Distal peripheral neuropathy 
EDRF Endothelium-derived relaxing factor 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
FPG Fasting plasma glucose 
FPN Ferroportin 
  XV  
 
Fe1C-Tf Fe3+ ion bound to the C-terminal lobe 
Fe1N-Tf Fe3+ ion bound to the N-terminal lobe 
FRAP Ferric reducing ability of plasma 
g Gravitational acceleration at the Earth’s surface 
GA Glycated albumin 
GDM Gestational diabetes mellitus 
GPx Glutathione peroxidase 
GR Glutathione reductase 
GSH Reduced glutathione 
Hb Haemoglobin  
HbA1c Glycated haemoglobin 
HH Hereditary haemochromatosis 
HFE Haemochromatosis protein 
HO• Hydroxyl radical 
holoTf Holotransferrin 
HPLC High performance liquid chromatography 
HSA Human serum albumin 
hs-CRP High sensitivity C-reactive protein 
IDDM Insulin dependent diabetes mellitus 
IDF International Diabetes Federation 
IEF Isoelectric focusing 
IIDM Insulin independent diabetes mellitus 
IL-6 Interleukin 6 
LDL Low density lipoprotein 
LIP Labile iron pool 
MDA Malondialdehyde 
  XVI  
 
MPA Metaphosphoric acid 
NTA Nitrilotriacetic acid 
NTBI Non-transferrin-bound iron 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PKC Protein kinase C 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
SDS Sodium dodecyl sulphate 
SF Serum ferritin 
SOD Superoxide dismutase 
sTfR Soluble transferrin receptor 
T1DM Type 1 diabetes mellitus 
T2DM Type 2 diabetes mellitus 
TBA Thiobarbituric acid  
TBARS Thiobarbituric acid reactive substances 
Tf Transferrin 
TfR1 Transferrin receptor 1 
TfR2 Transferrin receptor 2 
TfRs Transferrin receptors 
TIBC Total iron binding capacity 
TNF-α Tumor necrosis factor-α 
TPTZ Tripyridyltriazine 
TSAT Transferrin saturation measurement 
UIBC Unsaturated iron binding capacity 
UKPDS UK Prospective Diabetes Study 
  XVII  
 
USD U.S. dollars 
WHO World Health Organisation 
  
  XVIII  
 
Acknowledgements 
In the name of Allah, the Most Gracious, the Most Merciful. Alhamdulillah, all 
praises to Allah for the strengths and His blessing in completing this thesis. 
First of all, I wish to express my sincere appreciation and deep sense of 
gratitude to my supervisors Dr John Moody and Dr Keith Collard for their 
scientific guidance, encouragement and supports through this work. I would 
like to express my deep gratitude and appreciation to Professor. Jonathan 
Pinkney (Department of Diabetes and Endocrinology, Plymouth Hospitals) for 
his help to encourage the diabetes patients to participate in my study, and 
also  I would like to express my deep gratitude and appreciation to Professor 
Paul Winyard and Dr Charles Affourtit  for their advice to complete my thesis.  
I also extend heartfelt thanks to my sponsor "The Ministry of Higher 
Education and Scientific Research, Baghdad, Iraq" for financing the 
scholarship that has enabled me to complete this work. Thanks to the 
members of the School of Biological Sciences and technical staff who have 
helped me at various times throughout this study:  Professor Waleed Al-
Murrani, Dr Michele Kiernan, Dr Desley White, Mrs Liz Preston (Senior 
Technician) and Mrs Natalie Sweet. 
Thank all my colleagues those gave me attention and time during this study 
Kasim Askar, Khwam Hussein, Ali Abid, I apologize if I have missed anyone 
to involve in this acknowledgment for their assistance in some parts of my 
work. Last but not least, it is a pleasure to thank my family, my parents, 
brothers, sisters, wife and children for their endless love, prayers and 
encouragement and gave me the incorporeal support during the preparation 
of this work.                                                                                          Husam 
  XIX  
 
 
 
 
 
 
 
Dedication 
This thesis is dedicated to my parents, brothers, sisters, wife, sons and 
daughters  
  XX  
 
AUTHOR’S DECLARATION 
At no time during the registration for the degree of Doctor of Philosophy has 
the candidate been registered for any other University award without prior 
agreement of the Graduate Committee. 
This study was financed by the Ministry of Higher Education and Scientific 
Research of Iraq .during this study blood was taken from volunteers after 
obtaining appropriate ethics committee approval. 
Word count of main body of thesis: 38,174 
 
                                                                                          
                                                                                                     Signature:  
                                                                                Date: 2015
  1  
 
Literature review 
  
  2  
 
1.1 Diabetes mellitus 
Humans around the world face many health threats. One of the most 
significant threats is diabetes mellitus (DM), often simply referred to as 
diabetes. Although it has been centuries since DM was first recognised, it is 
still not fully understood and managed. The global prevalence and incidence 
of diabetes can lead to a variety of disabling, life-threatening and expensive 
complications (Yang et al., 2012). Despite the efforts to control the growing 
number of diabetes patients, the burden of this disease, as well as from its 
complications, is set to increase globally (Wild et al., 2004). 
Of the world’s adult population, the estimated prevalence of all types of 
diabetes was 366 million in 2011, and it has been predicted that the number 
of people with diabetes will have risen to 552 million by 2030 according to 
new figures released by the International Diabetes Federation (IDF) (Whiting 
et al., 2011). The IDF estimated that in 2011 the five countries with the 
largest numbers of people with diabetes were China, India, the United States 
of America, Russia and Brazil. In 2011 about 2.9 million people had been 
diagnosed with diabetes in the UK; it is estimated that five million people will 
have diabetes in the UK by 2025 (Diabetes UK, 2012). Furthermore, it is 
estimated that there are around 850,000 people in the UK who have diabetes 
but are either unaware, or have no confirmed diagnosis. 
In addition to genetic factors there is a broad range of factors that have been 
implicated in this dramatic increase in the number of diabetes patients in 
recent decades. These factors are (a) overall growth in population; (b) 
increased life expectancy resulting in a higher level of aged population more 
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prone to diabetes; (c) increasing obesity; (d) unhealthy diets; and (e) 
sedentary lifestyles. Interventions such as dietary modification and physical 
inactivity play a significant role in controlling diabetes (Shaw et al., 2010). 
The high prevalence of diabetes has economic impact on countries due to 
direct costs for treatment and care, and also indirect costs relating to the time 
taken off work and reduced productivity of people with diabetes (Ryan, 2009, 
Shaw et al., 2010). In economic terms, it was estimated that diabetes 
accounted for 12% of health expenditure in 2010 (WHO, 2013). The global 
health expenditure on diabetes is expected to total at least $376 bn in 2010 
and $490 bn in 2030. The expenditure varies by region, age group, gender 
and country’s income level (Zhang et al., 2010a). In the UK, diabetes cost 
approximately £23.7 bn in 2010⁄2011 (Hex et al., 2012). 
1.2 Diagnosis of diabetes 
Diabetes is characterized by temporarily or permanently elevated blood 
glucose that results from a defect in insulin production or insulin action (or 
both) (ADA, 2011), associated with chronic hyperglycaemia and disorders in 
carbohydrate, fat, protein and electrolyte metabolism (ADA, 2011). The 
common diabetic symptoms are polyuria (the urge to urinate frequently), 
polydipsia (the desire to drink large amounts of water to quench constant 
thirst), polyphagia (the frequent urge to eat), weight loss over a short period 
of time, dehydration, vomiting, mental state changes and weakness (ADA, 
2011, Kitabchi et al., 2006). 
In the absence of symptoms above, the following criteria should be applied to 
confirm the presence of diabetes: fasting plasma glucose (FBG)  
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≥ 7.0 mmol l-1 or whole blood ≥ 6.1 mmol l-1, and the two hours plasma 
glucose test (2hPG) ≥ 11.1 mmol l-1. The latter test requires the use of a 
glucose load containing the equivalent of 75 g anhydrous glucose dissolved 
in water given orally two hours before testing plasma glucose. These criteria 
should be confirmed by repeating the testing on a different day. If the fasting 
or random values are not diagnostic, the 2 h value post glucose load should 
be used. 
Glycated haemoglobin (HbA1c), which reflects an average plasma glucose 
level over the previous 8 to 12 weeks, has also been used as a diagnostic 
test for diabetes (Nathan et al., 2007). Diabetes may be diagnosed on any of 
the criteria shown in Table 1.1 (John, 2012). A repeat confirmatory test is 
required in most cases. 
Table 1.1 Criteria for diagnosis of diabetes 
 Diabetes 
Impaired or  
‘pre-diabetes’ 
Normal 
HbA1c ≥ 48 mmol mol
-1 42-47 mmol mol-1 ≤ 41 mmol mol-1 
Fasting glucose ≥ 7.0 mmol l-1 6.1-6.9 mmol l-1 ≤ 6.0 mmol l-1 
2-h glucose 11.1 mmol l-1 7.8-11.1 mmol l-1 ≤ 7.7 mmol l-1 
Random glucose 11.1 mmol l-1   
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1.3 Classification of diabetes mellitus 
The classification of glucose metabolism disorders is principally derived from 
aetiology, and includes staging of pathophysiology based on the degree of 
deficiency of insulin action. These disorders are classified into four groups: (i) 
Type 1 diabetes mellitus (T1DM); (ii) Type 2 diabetes mellitus (T2DM); (iii) 
diabetes mellitus due to other specific mechanisms or diseases; and (iv) 
gestational diabetes mellitus (Alberti and Zimmet, 1998). 
1.3.1 Type 1 diabetes mellitus 
Previously this type was called insulin-dependent diabetes mellitus (IDDM) 
and T2DM was called non-insulin-dependent diabetes mellitus (NIDDM). This 
nomenclature is not currently used because it is confusing and has frequently 
resulted in patients being classified based on treatment rather than on 
pathogenesis (Kuzuya et al., 2002). 
The incidence and prevalence of T1DM is increasing worldwide (Soltesz et 
al., 2007). The disease occurs mostly in individuals under the age of 30 years 
and is therefore also termed juvenile-onset diabetes, even though it can 
occur at any age. It accounts for about 10% of all cases of diabetes. The 
particular manifestation of T1DM is characterized by a loss of pancreatic -
cell function and an absolute insulin deficiency (Harrison et al., 1996). 
Autoimmunity is the predominant effector mechanism in T1DM resulting in 
damage to the -cells in the Islets of Langerhans and insulin deficiency (van 
Belle et al., 2011). Since insulin is the primary anabolic hormone that 
regulates blood glucose levels, Type 1 diabetics require a continuous supply 
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of insulin for survival (ADA, 2011, Standl et al., 2006). Until the present time, 
known solutions to prevent T1DM have not been discovered. 
One of the main complications suffered by Type 1 diabetic patients is diabetic 
ketoacidosis, which is uncommon in other types of diabetes. The aetiology of 
T1DM is complex; environmental factors coupled with a genetic 
predisposition for diabetes trigger an autoimmune response that results in 
destruction of the pancreatic -cells over several years (Williams and Pickup, 
2004). 
1.3.2 Type 2 diabetes mellitus 
This form is the most common form of diabetes. It has reached epidemic 
proportions in both developed and developing countries, and is now 
recognized as a major global health problem. More than 90% of diabetic 
patients have T2DM. The prevalence of T2DM has been rising worldwide. 
Among adults (20-79 y of age), an increase in prevalence from 6.4% (285 
million) in 2010 to 7.7% (439 million) in 2030 has been estimated (Shaw et al., 
2010). This type of diabetes frequently goes undiagnosed for many years 
because the hyperglycaemia develops gradually and is often not severe 
enough for the individual to notice any of the classic symptoms of diabetes. 
T2DM occurs when insulin secretion is inadequate to meet the increased 
demand posed by insulin resistance (Druet et al., 2006). The state of insulin 
resistance is characterised by a reduced ability of insulin to suppress hepatic 
glucose production and to promote peripheral glucose disposal. T2DM 
occurs when this condition is accompanied by a failure of the pancreatic -
cells to secrete enough insulin to overcome the degree of insulin resistance 
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(ADA, 2011). The specific reasons for the development of these 
abnormalities are not yet known. Genome-wide association studies have 
identified over 50 new genetic loci for T2DM (Pasquale et al., 2013). 
Offspring of diabetic people who share similar environments have more 
chance of developing diabetes (Doria et al., 2008). Both environment and 
lifestyle are involved in the development of T2DM, in addition to genetic 
factors (Qi et al., 2008). 
Overall obesity and abdominal adiposity, are by far the most important risk 
factors for the development T2DM (Wang et al., 2005). Obesity continues to 
increase in children and adolescents (Goran et al., 2003), and rising levels of 
obesity are leading to a rapid increase in the prevalence of T2DM. Recent 
studies have provided evidence that release of non-esterified fatty acids from 
adipose tissue is chronically elevated (Heilbronn et al., 2004), which can 
mediate many adverse metabolic effects, most notably insulin resistance 
(Karpe et al., 2011). Adipose tissue also produces a variety of biologically 
active molecules (adipocytokines) (Matsuzawa et al., 1999). Hotamisligil et al. 
(1993) reported that tumour necrosis factor- (TNF-) overproduced in 
adipose tissue in obesity contributes to the development of insulin resistance. 
Other biologically active molecules called leptins (specific hormones 
contributing to the regulation of energy expenditure and food intake) also 
affect insulin sensitivity and may participate in the development of 
hypertension (Shimomura et al., 1999, Masuzaki et al., 1999). 
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1.3.2.1 Risk factors for T2DM 
1.3.2.1.1 Age 
The risk of developing T2DM increases with age (Wild et al., 2004, Klein et 
al., 2004). Those aged ≥ 45 y are more prone to T2DM in developing 
countries, while in developed countries the largest number is found in those 
aged ≥ 65 (Whiting et al., 2011). Previously, T2DM was predominantly a 
disease of middle-aged and older people. In recent decades, the age of 
onset has decreased and T2DM has been reported in adolescents and 
children worldwide (Alberti et al., 2004). 
1.3.2.1.2 Excess weight 
Obesity is the most critical risk factor for T2DM (Kahn et al., 2006). Increase 
in body mass index (BMI) is associated with escalation of the incidence of 
diabetes (Mokdad et al., 2003, Klein et al., 2004). Recent evidence from 
some studies has suggested that obesity and visceral fat accumulation are 
closely related to the incidence of T2DM (Nagaya et al., 2005). Diabetes UK 
state that those with a normal BMI but a large waist – defined as 80 cm or 
more for women and 94 cm or more for men – are most at risk from 
developing T2DM. 
1.3.2.1.3 Genetic factors (family history of diabetes) 
Although promoting factors for the pathogenesis of T2DM are increasingly 
sedentary lifestyles and overeating, genetic elements are also involved. 
Family history, by itself, is the most useful predictor of disease when multiple 
family members are affected. A positive family history confers a 2.4 fold 
increased risk for T2DM, and about 15-25% of first-degree relatives of 
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patients with T2DM develop impaired glucose tolerance or diabetes (Pierce 
et al., 1995). Both family history and obesity are strong risk factors for T2DM 
(Hu et al., 2009). A family history of diabetes provides significant 
improvements in the detection of additional cases of undiagnosed diabetes 
(Yang et al., 2010). 
1.3.2.1.4 Physical inactivity 
The main culprit for the worldwide epidemic of obesity and T2DM is 
sedentary lifestyles (Hu et al., 2003, Temelkova-Kurktschiev and Stefanov, 
2012). Regular physical activity raises HDL cholesterol; lowers LDL levels; 
leads to lower blood pressure; reduces insulin resistance; and favorably 
influences cardiovascular function (Health, 2001). Evidence from prospective 
studies points to physical inactivity as an independent risk factor for T2DM 
(Gill and Cooper, 2008). Long periods of inactivity lead to insulin resistance in 
humans (Smorawiński et al., 2000). Increased physical activity is associated 
with a better glucose and insulin profile, and enhanced β-cell function (Chen 
et al., 2013). Recent studies demonstrate that enhanced physical activity 
may delay or prevent the transition from impaired glucose tolerance to T2MD 
(Tuomilehto et al., 2001). Even people with T2DM have reduced risk of 
cardiovascular disease when they have regular physical activity (Kirk et al., 
2004). 
1.3.2.1.5 Ethnicity 
Epidemiological studies have shown that T2D has a global distribution, and 
its prevalence varies from country to country, and in different ethnic groups 
in the same country. African Americans are more likely to develop diabetes 
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than white Americans (Egede and Dagogo-Jack, 2005). Also, Asian Indians 
who immigrated to Western countries are found to be at risk for the 
development of T2DM due to the metabolic impact of a westernized diet or 
reasons based on tissue resistance to insulin (Lee et al., 2011). Other risk 
factors include the history of gestational diabetes, impaired fasting glucose 
or impaired glucose tolerance, hypertension, dyslipidaemia, polycystic ovary 
syndrome and history of vascular disease (Klein et al., 2004). 
1.3.3. Gestational diabetes mellitus 
Gestational diabetes mellitus (GDM) is a temporary condition which occurs 
during pregnancy (usually during the second and third trimester) (Park et al., 
2001). In other women, it may be found during the first trimester of 
pregnancy, and in these women, the condition most likely existed before the 
pregnancy. The incidence of GDM has been increasing over the last 20 
years (Ferrara, 2007). GDM is defined as glucose intolerance that occurs 
only during the pregnancy in some pregnant women. GDM-related risk 
factors have not been completely identified yet. However, family history of 
T2DM in first-degree relatives, older age, obesity, hypertension, elevated 
blood platelet count, and increased haemoglobin (Hb) and ferritin levels 
have been identified as potential risk factors for GDM (Teh et al., 2011, 
Casanueva and Viteri, 2003). GDM is associated with both insulin 
resistance and impaired insulin secretion (Ryan et al., 1985, Damm, 1998). 
The mechanisms behind insulin resistance induced by pregnancy are still 
not fully understood; it occurs because the body produces insufficient insulin 
to meet the extra needs of pregnancy (ADA, 2011). Knopp et al. (1981) 
reported that insulin levels in pregnant rats are reduced due to increased 
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removal of insulin by the placenta. There are also different hormonal and 
metabolic changes during the second half of pregnancy which facilitate 
insulin resistance. One is the high level of progesterone in plasma during 
the second part of pregnancy (Wada et al., 2010). Oxidative stress is 
implicated in the development of insulin resistance during pregnancy (Patil 
et al., 2007). 
1.4 Complications of diabetes 
Chronic hyperglycaemia clustering with other risk factors such as arterial 
hypertension and dyslipidaemia, as well as genetic factors, can affect 
diverse parts of the body and, over time, can lead to serious complications. 
Even with tight glucose control, improved treatment of hypertension and 
hyperlipidaemia, diabetic complications occur frequently with time (Gallego 
et al., 2007). The major types of diabetes complications are microvascular 
and macrovascular. As a consequence of its microvascular pathology, 
diabetes affects the renal system (nephropathy), causes eye damage 
(retinopathy) and causes nerve damage (neuropathy). The macrovascular 
complications of diabetes are associated with effects on the large arteries 
that supply the heart, brain and lower limbs. As a result, patients with 
diabetes have a much higher risk of myocardial infarction, stroke 
(Janghorbani et al., 2007) and limb amputation (Singh et al., 2005). Also 
there are many other health problems associated with the presence of 
diabetes such as hip fracture; infertility and negative pregnancy outcome; 
psychological problems; and cancer (Zhu et al., 2013). 
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1.4.1 Vascular disease 
Vascular abnormalities begin early in diabetic patients. High glucose 
concentrations alter vascular function, leading to endothelial dysfunction 
due to imbalance between nitric oxide (NO) bioavailability and accumulation 
of reactive oxygen species (ROS) (Creager et al., 2003). NO is the most 
important endothelium-derived relaxing factor (EDRF) and is derived from L-
arginine via the action of endothelial nitric oxide synthase (Figure 1.1). 
 
 
Figure 1.1 nitric oxide synthesis (Torreilles, 2001)  
NO induces vasodilatory effects by activation of soluble guanylate cyclase 
via an interaction with the ferrohaem centre of the enzyme resulting in the 
generation of increased cyclic guanidine monophosphate (cGMP) levels. 
This in turn leads to activation of cGMP-dependent protein kinase which 
catalyses the phosphorylation of specific muscle proteins, and causes 
smooth muscle relaxation and subsequent dilation of vasculature. 
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Hyperglycaemia-induced generation of superoxide anion radical (O2
•-) via 
different mechanisms (Figure 1.3) causes inactivation of NO through the 
formation of peroxynitrite (ONOO), a powerful oxidant which easily crosses 
phospholipid membranes and induces substrate nitration (Creager et al., 
2003). Nitrosylation has been shown to inhibit antioxidant enzymes and 
endothelial NO synthase activity (Hink et al., 2001). 
 
Figure 1.2 peroxynitrite formation and tyrosine nitration 
1.4.2 Diabetic retinopathy 
Diabetic retinopathy is one of the most common causes of blindness 
(Forbes and Cooper, 2013). It is highly prevalent and is positively 
associated with the duration of diabetes (Lutale et al., 2013). The retina is a 
thin layer of nervous tissue in the back of the eye from which focussed 
images are carried to the brain via the optic nerve. Diabetic retinopathy is 
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characterized by changes in the retinal blood vessels. Constriction and 
dilation of these vessels can cause obstruction of normal blood flow, 
haemorrhage, and leakage of fluid into rear of the eye causing vision 
problems. 
1.4.3 Peripheral neuropathies 
Peripheral neuropathy and specifically diabetic peripheral neuropathy (DPN) 
is one of the most severe complications of diabetes, occurring in 30-50% of 
all diabetic patients (Deshpande et al., 2008). Both the age of the patient 
and the duration of diabetes are independent risk factors for DPN (Adler et 
al., 1997). DPN is associated with loss of protective limb mechanical 
sensations, traumatic ulceration injures and therefore amputations (Boulton 
et al., 2005). 
1.4.4 Autonomic neuropathy 
Autonomic neuropathy affects the nerves that control involuntary activities of 
the body. It is among the least recognized and understood complications of 
diabetes, despite its significant negative impact on survival and quality of life 
in people with diabetes (Vinik and Ziegler, 2007). The action of many organs 
such as the stomach, intestine, bladder, penis and sometimes the heart can 
be affected. The clinical manifestations include orthostatic hypotension, 
exercise intolerance, gastroparesis, diarrhea, constipation and urinary 
incontinence (Watkins, 2003). 
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1.4.5 Diabetic nephropathy 
Diabetic kidney disease, also called diabetic nephropathy, is a complication 
that occurs in some people with diabetes. It can progress to kidney failure in 
some cases. Approximately 40% of people with diabetes will develop 
nephropathy. A number of risk factors for the progression of nephropathy 
have been identified including poor glycaemic control, hypertension, 
smoking, genetic susceptibility, age, race and obesity. The diabetes control 
and complications trial (DCCT) and United Kingdom Prospective Diabetes 
Study (UKPDS) demonstrated that improved glycaemic control reduces the 
risk of diabetic nephropathy in both T1DM and T2DM patients (Turner et al., 
1993, Turner et al., 1998). 
The first sign of renal problems in patients with diabetes is microalbuminuria. 
This is defined by the ratio of urinary albumin:creatinine (ACR). In men 
microalbuminuria is defined as a ratio greater than 2.5 mg mmol-1 and in 
women greater than 3.5 mg mmol-1 (Burden and Tomson, 2005). This 
affects over 20% of Type 1 and Type 2 diabetic patients 10-15 years after 
the onset of diabetes and subsequently may evolve to macroalbuminuria or 
proteinuria (ACR > 30 mg mmol-1) (Remuzzi et al., 2002). Once 
macroalbuminuria is present, the glomerular filtration rate declines at an 
average rate of 10-12 ml min-1 y-1 in untreated patients (Remuzzi et al., 
2002). 
Several factors may take charge in diabetic nephropathy, but the main 
factors are the persistence of high levels of blood glucose due to poor blood 
sugar control and the decline of insulin signaling due to insulin resistance or 
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insulin depletion. The precise mechanisms which are responsible for 
diabetic nephropathy are still being determined. Hyperglycaemia initiates, 
sustains and promotes the progression of diabetic nephropathy pathology. 
Extracellular and intracellular proteins are often exposed to glycation 
reactions. Outside the cell the major toxicity is from accelerated formation of 
advanced glycation end products (AGEs) (described in detail later) such as 
imidazole, carboxy-methyl-lysine (CML), carboxy-ethyl-lysine (CEL), 
glyoxal-lysine dimer (GOLD) and methyl-glyoxal-lysine dimer (MOLD). 
These are derived from glycation reactions of proteins with glucose or its 
metabolites, and result in production of stable, covalent modifications of 
proteins. These modifications may include cross links within or between 
proteins. AGE-modified proteins increase in several compartments of 
diabetic kidneys (Tanji et al., 2000). Collagen and other long-lived 
extracellular matrix proteins are particularly prone to accumulate AGE 
crosslinks (Susic et al., 2004); these crosslinks prevent degradation of the 
extracellular matrix and accumulation of the extracellular matrix leads to 
thickening of basement membranes (Lubec and Pollak, 1980). 
Circulating levels of AGE-modified proteins also increase in diabetics 
(Penfold et al., 2010). These soluble AGE-modified proteins are ligands for 
a receptor known as the advanced glycation end product receptor (RAGE); 
this receptor is increased in several cells in diabetic kidneys including 
podocytes (Tanji et al., 2000). This increase leads to promotion of the 
inflammation process (Ramasamy et al., 2011). Binding to the RAGE 
receptor also increases intracellular production of reactive oxygen species 
(ROS) leads to activate  of NADPH oxidase, which promotes intracellular 
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damage (Goldin et al., 2006). Inside the cell hyperglycaemia causes cell 
damage or death through several mechanisms such as the aldose 
reductase pathway, the intracellular AGE and hexosamine pathways, the 
PKC pathway and the hexosamine pathway (Giacco and Brownlee, 2010). 
The abnormal signaling of insulin may act to disrupt important paracrine 
signaling between podocytes and endothelial cells required for normal 
maintenance of the filtration membrane (Welsh et al., 2010). 
Other factors such as high blood pressure, high cholesterol and smoking 
increase the leakage of albumin across the glomerular podocyte filtration 
barrier. In addition, the raised blood glucose level may cause some proteins 
in the glomeruli to cross link. These cross-linked proteins can trigger a 
localised scarring process. This scarring process in the glomeruli is called 
glomerulosclerosis. It usually takes several years for glomerulosclerosis to 
develop and it only happens in some people with diabetes. 
As the condition becomes worse, scarred tissue (glomerulosclerosis) 
gradually affects smooth muscle cells surrounding the glomerular capillaries 
(diffuse mesangial sclerosis). Then there is progressively greater mesangial 
expansion. As a result the kidneys become less capable of blood filtration. 
This gradual 'failing' of the kidneys may gradually progress to what is known 
as end-stage kidney failure. 
1.5 Iron and Type 2 diabetes 
The body requires two types of nutrients, micronutrients and macronutrients. 
Both types are essential for the proper functioning of cells in the body and 
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are vital for good health. The impacts of macronutrients on human 
physiology have been studied extensively. Many of these studies have been 
carried out into the relationships between macronutrients, especially lipids, 
carbohydrates and protein, and the aetiology of T2DM (Schulze and Hu, 
2005), but the certain role of micronutrients in general and iron in particular 
in the aetiology of T2DM is not well established (Fernández-Real et al., 
2002a). Nevertheless, plausible evidence has emerged recently to explain 
the positive association between excess iron stores and risk of T2DM 
(Rajpathak et al., 2009, Smotra et al., 2007), although the underlying 
mechanisms still remain to be fully determined. 
The involvement of iron in the risk of T2DM has generated substantial 
interest over the past 15 years, initially sparked by an association with 
increased serum ferritin and the observation that diabetes frequently 
develops in those individuals with iron-overload diseases such as 
haemochromatosis and recurrent transfusions in diseases like thalassaemia 
(Sanctis et al., 2013). Also, a large body of epidemiological evidence 
suggests that an increase in dietary iron (as haem, mainly from meat and 
meat products) is associated with an increased risk of diabetes (Shah and 
Fonseca, 2011). It is recognized that iron influences glucose metabolism, 
even in the absence of significant iron overload (Fernández-Real et al., 
2002a). 
Firstly, iron is a redox-active transition metal and this property makes it a 
first-line pro-oxidant that promotes the generating of hydroxyl radicals (HO•) 
via the Haber-Weiss reaction. 
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Fe3+ + O2
• Fe2+ + O2 
Fe2+ + H2O2   Fe
3+ + OH + OH•     (Fenton reaction) 
The net reaction is: 
O2
• + H2O2  OH
 + OH• + O2    (Haber-Weiss reaction) 
Hydroxyl radicals may attack pancreatic -cells through increased oxidative 
stress, and thus result in impaired insulin synthesis and excretion (Evans et 
al., 2002, Cooksey et al., 2010). Also there are lower levels of antioxidant 
enzymes such as superoxide dismutase, catalase and glutathione 
peroxidase in pancreatic islets than in other tissues; thus pancreatic Islets 
are particularly susceptible to oxidative damage (Tiedge et al., 1997). 
Iron reduces hepatic extraction and metabolism of insulin, leading to 
peripheral hyperinsulinaemia, and may increase oxidative stress, which 
inhibits the internalization and action of insulin (Tuomainen et al., 1997). 
Insulin also influences iron metabolism by stimulating ferritin synthesis and 
facilitating iron uptake by the cell through the translocation of transferrin 
receptors from the intracellular compartment to the cell surface (Davis et al., 
1986, Jehn et al., 2004). 
Genetic iron-overload disease, haemochromatosis, where serum iron levels 
may exceed 10× the normal values compared to healthy individuals, is a risk 
factor for T2DM (Moczulski et al., 2001). Interestingly, the pathophysiology 
of diabetes in haemochromatosis is thought to be due primarily to defects in 
the early insulin response to glucose. 
Increased iron stores are associated with the development of glucose 
intolerance and increased risk of T2DM (Fernández-Real et al., 2002a, 
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Barbieri et al., 2001, Fernández-Real et al., 1998, Ford and Cogswell, 1999, 
Jiang et al., 2004). In contrast, serum ferritin is a biomarker for iron stores 
which increase in response to inflammatory stress (De Domenico et al., 
2008), so increased ferritin in diabetes could simply reflect the inflammatory 
component of that disease (De Domenico et al., 2008). Nevertheless, 
phlebotomy improves insulin sensitivity (Fernández-Real et al., 2002b), 
supporting the argument that iron may play a causal role in diabetes. 
In the general population, higher dietary intake of haem is positively 
associated with risk for T2DM (Rajpathak et al., 2006, Bao et al., 2012). 
Dietary total iron, non-haem iron, or supplemental iron intakes are not 
significantly associated with T2DM risk (Vlassara et al., 2002). In contrast, 
patients with T2DM and high levels of serum ferritin who undergo frequent 
phlebotomy have been shown to have decreased levels of glycated proteins 
(e.g. HbA1c) and improved insulin sensitivity (Silva and Hider, 2009). Other 
iron status parameters have been shown to be altered among people with 
T2DM. For example, circulating non-transferrin-bound iron (discussed in 
detail on section 1.6.13) levels were found to be higher in people with T1DM 
compared to healthy controls (Lee et al., 2006). 
Increased oxidative stress is widely accepted as contributing towards the 
development and progression of diabetes, and its complications (Baynes 
and Thorpe, 1999, Houstis et al., 2006). Acceleration in the process of 
atherosclerosis is very common in diabetes, leading to increased 
prevalence of coronary artery disease and stroke. There are probably 
multiple mechanisms for the initiation and progression of atherosclerotic 
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lesions. While the typical cardiovascular risks, such as hypertension, 
hyperlipidaemia and obesity, are known to be more widespread in diabetic 
patients, recent studies have provided evidence that hyperglycaemia plays 
a vital role in diabetic complications (Nathan et al., 2003, Stratton et al., 
2000, Cerami et al., 1985). Hyperglycaemia stimulates a variety of 
biochemical abnormalities (Figure 1.3), for instance activation of the polyol 
pathway; enhanced non-enzymatic glycation with formation of advanced 
glycation end-products (AGEs); increased hexosamine pathway flux and 
changed protein kinase C (PKC) activities, which have been implicated in 
the pathogenesis of diabetic complications. Recent evidence suggests that 
they are also concerned in the pathogenesis of diabetic atherosclerosis 
(Massi-Benedetti and Orsini Federici, 1999, Cerami et al., 1985, Bucala and 
Vlassara, 1995, Berg et al., 1997, Renier et al., 2003, Ruef et al., 2000). 
In contrast to the findings in diabetes, there is evidence that obese non-
diabetic subjects have low serum iron levels (Chambers et al., 2006, 
Freixenet et al., 2009, Tussing-Humphreys et al., 2009b), and this does not 
appear to be due in all cases to dietary iron deficiency (Menzie et al., 2008). 
The likely mechanism of the hypoferraemia of obesity is the chronic 
inflammatory state which accompanies obesity (Yanoff et al., 2007, 
McClung and Karl, 2009). However, other studies in particular groups of 
subjects suggest that the cause might be true body iron deficiency rather 
than a response to inflammation due to poor dietary iron Intake or increased 
iron requirements (Tussing-Humphreys et al., 2009a). Thus the cause is 
currently unclear. 
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Figure 1.3 mechanisms by which hyperglycaemia may cause oxidative stress  
Over production of superoxide reduces glucose utilization via glycolysis due to inhibition of the 
glycolytic enzyme GAPDH. This results in increased flux of dihydroxyacetone phosphate (DHAP) 
to the protein kinase C pathway and of triose phosphates to methylglyoxal, the main 
intracellular AGE precursor. Also excess superoxide leads to increased glucose flux through 
the polyol pathway, increased sorbitol and decreased NADPH levels, hence leading to the 
depletion of GSH. The oxidation of sorbitol to fructose is catalysed by the enzyme sorbitol 
dehydrogenase, with NAD
+
 reduced to NADH; fructose-3-phosphate (F3P) is produced by 
enzymatic phosphorylation of fructose. F3P is an unstable compound, and its spontaneous 
decomposition leads to formation of 3-deoxyglucosone (3-DG), an AGE precursor. Modified 
from Brownlee (2001). 
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1.6 Iron 
1.6.1 Functions of iron in the human body 
Nearly all living organisms require iron in order to survive. Iron is a vital 
element for most biological processes such as growth and metabolism 
(Prakash, 2007). In humans and all aerobic organisms, it is an essential 
mineral for good health. It has several important functions in the body. The 
capability of iron to readily donate or accept electrons makes it essential for 
important cellular redox processes. However, this redox reactivity can also 
be deleterious if uncontrolled. It is involved in numerous enzymatic electron 
transfer reactions (Chua et al., 2007). Mitochondrial function is dependent 
on iron in several ways. Iron is a metal cofactor for haemoproteins involved 
in the mitochondrial electron transport chain, the ‘engine’ of cellular energy 
production. Both haem-containing enzymes (cytochromes) and iron-
containing non-haem enzymes (NADH dehydrogenase and succinate 
dehydrogenase) play an essential role in the generation of ATP by oxidative 
phosphorylation of ADP via the citric acid cycle. Iron is an integral part of the 
protein compounds such as Hb and myoglobin, where it is the binding site 
for oxygen. Thus, Hb and myoglobin perform the important function of 
oxygen transport in human body (Beard, 2001). Iron is vital for brain 
development, neurogenesis, as well as normal brain function (Crichton et al., 
2011). In the central nervous system (CNS), iron is essential for multiple 
functions, including gene expression, DNA synthesis, neurotransmission, 
myelination, oxygen transport, storage and activation, mitochondrial electron 
transport, numerous important metabolic processes and as a cofactor for 
several key enzymes of neurotransmitter biosynthesis, such as dopamine 
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(DA) and noradrenaline. It also plays an important role in cellular immune 
response (McKie et al., 2001, Muñoz et al., 2009). It is essential for many 
enzymes including catalase. Table 1.2 summarizes iron-containing proteins 
and their biological functions. 
Table 1.2 Iron containing proteins and their biological function 
Protein Function 
Haemoglobin Oxygen transport 
Myoglobin Oxygen storage and transport 
Ribonucleotide reductase Deoxyribonucleotide synthesis 
Aconitase Citric acid cycle 
Transferrin Iron transport 
Lactoferrin Iron binding, antimicrobial 
Ferritin Iron storage 
Cytochromes Electron transport/ATP synthesis 
Monooxygenases Detoxification 
Haemopexin Haem delivery 
Nitric oxide synthases Synthesis of nitric oxide 
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1.6.2 Iron distribution 
Human adults contain about 2-4 g of iron (Andrews, 2005, Nathan et al., 
2007), but this amount greatly depends on gender, age, nutrition and health. 
Thus iron levels are usually lower in women due to their smaller size, a 
reduced liver mass, and iron loss through menstruation (Andrews, 1999a). 
More than 50% of the body's iron in normal individuals is found in the Hb of 
blood erythrocytes and their precursors. Nearly 25% of the iron is 
maintained as storage iron (ferritin and hemosiderin) (Cheng and Li, 2007) 
mainly in the liver. The remainder exists in myoglobin, reticuloendothelial 
macrophages and haem enzymes. 
In humans, about 20-25 mg of iron is the daily requirement for adults to 
produce new erythrocytes (Figure 1.4), most of which comes from recycling 
of iron already in the body. Daily absorption of approximately 1-2 mg is 
needed to replace the normal iron losses (around 1-2 mg per day) through 
the stools (0.6 mg d-1), urine (0.15-0.2 mg d-1) and skin (0.2-0.25 mg d-1) 
(Green et al., 1968). The tissues and cells that generate major iron flows 
into the blood plasma include the duodenal enterocytes involved in dietary 
iron absorption; hepatocytes that are the main site of iron storage; 
macrophages that recycle iron from senescent red blood cells; and the 
placental syncytiotrophoblasts involved in iron transfer from mother to fetus 
during pregnancy (Abdul-Ghani et al., 2006, Andrews, 2005, Nathan et al., 
2007). 
The human excretory system has no active mechanism to excrete iron 
through the kidney or liver; iron is lost from the body only when cells are 
  26  
 
lost, particularly epithelial cells from the gastrointestinal tract, epidermal 
cells of the skin, and red blood cells in menstruating women (Nathan et al., 
2007). As a result, iron homeostasis must be tightly regulated and the 
balance is achieved by control of absorption rather than by control of 
excretion (Sun et al., 2008). 
 
Figure 1.4 Distribution of total body iron among tissues. From Hentze et al. (2004). 
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1.6.3 Iron absorption 
Normally, mammals obtain iron exclusively from the diet (Ganz and Nemeth, 
2006). The daily diet contains two forms of iron which are typically classified 
as either haem or non-haem iron (Rajpathak et al., 2009). Both two types 
are absorbed by distinct pathways and in different amounts. Non-haem iron 
is found in a wide variety of plant and animal foods (Rajpathak et al., 2009), 
in the intestinal tract many complexes containing non-haem iron are formed, 
which can decrease or increase absorption. Foodstuffs contain phytates 
(high-fibre diets), calcium, phenolic compounds (coffee, tea) and 
phosphates which tend to form insoluble complexes with iron and therefore 
limit its absorption. The absorption of non-haem iron can be diminished by 
co-administration of tetracycline, proton pump inhibitors and antacid 
medication. In addition, Helicobacter pylori infection produces gastric 
atrophy, which can lead to profound iron-deficiency anaemia (Marignani et 
al., 1997), whereas ascorbate and compounds from meats can increase 
absorption (Rajpathak et al., 2009, Hurrell, 2002). 
Dietary haem iron is derived from the proteolytic breakdown of Hb and 
myoglobin found in meat products in the intestinal lumen (Dunn et al., 
2007). Haem iron is absorbed more efficiently than non-haem iron 
(Anderson et al., 2005, Majuri and Gräsbeck, 1987). Also haem iron 
absorption is little affected by dietary iron chelators or enhancers (Rajpathak 
et al., 2009). Most iron absorption takes place in the duodenum and 
proximal jejunum (Johnson et al., 2012). Non-haem iron is primarily present 
in the ferric form (Fe3+). Duodenal cytochrome b (Dcytb), a ferric reductase, 
which is expressed in the duodenal brush border, plays an important role in 
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dietary iron absorption by reducing ferric to ferrous iron (Fe2+) (Figure 1.5), 
which is then taken up by the protein involved in ferrous iron absorption, 
divalent metal transporter 1 (DMT1) (Donovan et al., 2006, Anderson et al., 
2005). Haem iron seems to be transported intact by haem carrier protein 1 
from the gut lumen into the enterocytes (Krishnamurthy et al., 2007), but the 
process is less well understood (Anderson et al., 2005). Once internalised 
inside the enterocyte it is likely that most dietary haem is metabolised by 
haem oxygenase to release Fe2+; part of the iron is oxidized back to the 
ferric state and bound to the ferritin for storage (Andrews and Schmidt, 
2007). 
Most of the iron is transferred across the basolateral membrane of the 
enterocyte surface and oxidised to Fe3+ via hephaestin before being bound 
by plasma transferrin. The major molecule that carries iron across the 
membrane is ferroportin (FPN; also known as SLC40A1, IREG1 and MTP1) 
(Ganz and Nemeth, 2006). As the sole known iron exporter, FPN is highly 
expressed in duodenal enterocytes, hepatocytes, macrophages and 
placental cells (Ganz and Nemeth, 2006). 
The critical role of FPN in intestinal iron absorption and macrophage iron 
release was confirmed in FPN knockout mice (Donovan et al., 2005). Similar 
to DMT1, FPN likely conducts ferrous (Fe2+) ions. However, Fe2+ must be 
oxidized to Fe3+ before it can enter the circulation and load onto plasma 
transferrin. Thus another ferroxidase protein, hephaestin in enterocytes or 
ceruloplasmin in macrophages, is also required for cellular iron export (Ganz, 
2005, Chen et al., 2006). Hephaestin is a membrane-bound multicopper 
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ferroxidase expressed mainly in the mammalian small intestine. The 
ferroxidase activity of hephaestin is thought to play an important role during 
iron export from intestinal enterocytes and the subsequent iron loading of the 
blood protein transferrin, which delivers iron to the tissues (Chen et al., 
2003). 
 
Figure 1.5 Systemic iron transport 
Dietary ferric iron (Fe
3+
) is converted to ferrous iron (Fe
2+
) by ferric reductase in the duodenum 
proximal jejunum, then DMT1 transports Fe
2+
 into enterocytes. Intact haem from the diet is also 
imported into enterocytes by haem carrier protein 1 and then converted into ferrous iron by 
HO1. Ferrous iron is then exported into the bloodstream by FPN. Most of the iron is transferred 
across the basolateral membrane of the enterocyte surface and oxidised to Fe
3+
 via hephaestin 
and ceruloplasmin before being bound by plasma transferrin. Iron export by FPN can also be 
inhibited by the peptide hepcidin. In the bloodstream, ferric iron binds to Tf, which enables 
import into target cells by binding to TfR. Once bound to the cell membrane, Tf changes shape 
and releases the iron. It then returns to the portal circulation to bind more iron. DMT1: Divalent 
metal transporter 1. FPN: Ferroportin. Hp: Hephaestin. Ce: Ceruloplasmin. Tf: Transferrin. TfR: 
Transferrin receptor. From Rines and Ardehali (2012). 
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1.6.4 Iron transport 
Iron released into the circulation binds to transferrin (Tf) and is transported to 
sites of use and storage. Tf is an abundant protein mainly found in blood 
plasma and lymph (2.5 mg ml-1) (Crichton et al., 2008). It is the primary iron 
transporter in the plasma (Anderson et al., 2007, Atanasiu et al., 2007). Tf is 
a  globulin and is produced in the liver. Each molecule of Tf can bind and 
transport two molecules of iron in the Fe3+ state. In the circulation, Tf carries 
nearly all serum iron while small amounts of iron may be loosely associated 
with other proteins including albumin (Andrews and Schmidt, 2007). Tf 
saturation rapidly responds to local circumstances and is usually used as an 
indicator of body iron status. Under normal circumstances, approximately one 
third of the Tf is bound with iron (Beutler, 2006, Donovan et al., 2006). In 
mice, the Tf saturation is much higher, ranging from 60% to 80% (Andrews 
and Schmidt, 2007). The majority of transferrin-bound iron uptake occurs in 
the bone marrow, where erythroid precursors incorporate the iron into the 
haem moiety during synthesis of Hb (Donohue et al., 1958). but also other 
organs uptake iron if the bone marrow is damaged or excessive amounts of 
iron are already stored in the bone marrow (Andrews, 2005). Once bound to 
the cell membrane, Tf changes shape and releases the iron. It then returns to 
the portal circulation to bind more iron. 
1.6.5 Iron uptake in the cells 
Precursor erythroid cells, hepatocytes, macrophages, placental cells and 
most other cells can take up the transferrin-bound iron from the circulation 
using transferrin receptors (TfR) (Donovan et al., 2006, Ganz and Nemeth, 
2006). Erythroid bone marrow is the largest consumer of iron. Normally, 
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around two thirds of the body iron is found in developing erythroid precursors 
and mature red blood cells (Donovan et al., 2006). Erythroid precursors 
express cell-surface TfR that take up Fe-Tf by receptor-mediated endocytosis 
(Abdul-Ghani et al., 2006). 
The affinity of the TfR for Tf depends on two parameters, pH and Tf iron 
saturation. The affinity is highest for fully saturated Tf. However, when the pH 
decreases to the pH of the endosomes, pH 5.5, the TfR affinity for 
apotransferrin increases, whereas the affinity for saturated Tf decreases 
(Huebers et al., 1983, Welch, 1992). Although TfRs are widely expressed, 
most cells apparently can use non-TfR mechanisms to assimilate iron. 
However, the utilization of iron by muscle cells and other cell types such as 
neurons is far less well understood (Andrews and Schmidt, 2007). Once iron 
leaves the endosome (Figure 1.6), it moves to the mitochondria for 
incorporation into protoporphyrin IX via the action of ferrochelatase to form 
haem. 
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Figure 1.6 Iron uptake in cells 
Transferrin receptor 1 on the cell surface binds to transferrin-bound iron from the circulation 
(holotransferrin). The resulting complex is internalized and acidified through the action of a 
proton pump to the pH of the endosomes, 5.5. Iron is subsequently released from transferrin 
and transported out of endosomes via the divalent metal transporter DMT1. Once iron leaves 
the endosome, it moves to the mitochondria for incorporation into protoporphyrin IX via the 
action of ferrochelatase to form haem. Apotransferrin and transferrin receptor 1 both returned 
to the cell surface, where they dissociate at neutral pH, and both participate in another round 
cycle of iron uptake. From Qian et al. (2002). 
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1.6.6 Transferrin receptors 
The transferrin receptor (TfR) is an essential glycoprotein involved in iron 
uptake and the regulation of cell growth. This glycoprotein has a molecular 
weight of approximately 180 kDa. The human transferrin receptor has 
homodimeric structure composed of two subunits linked by two disulphide 
bridges. Each monomer can be divided into an extracellular region, an 
intermediate transmembrane region and an intracellular part. The intracellular 
part is necessary for normal endocytosis of the receptor (Rothenberger et al., 
1987, McGraw and Maxfield, 1990). All cells express a TfR on their surface; 
the quantity of receptor molecules reflects the cellular iron requirement. 
There are two different TfRs, TfR1 and TfR2. TfR1-mediated endocytosis is 
the usual pathway of iron uptake by body cells. TfR2 participates in low-
affinity binding of Tf, supporting growth in a few cell types, but the true role of 
TfR2 is unknown (Halliwell and Gutteridge, 2007, Gkouvatsos et al., 2012). 
1.6.7 Iron storage 
Two cell types are important for systemic storage of iron (Ganz, 2005, Ganz 
and Nemeth, 2006), macrophages and hepatocytes. Macrophages can 
recover iron from senescent erythrocytes. Hepatocytes can acquire both Tf-
bound and non-Tf-bound iron from the plasma, and also have a large 
capacity for iron storage. Inside the cells, iron storage occurs primarily in 
ferritin which can frequently be found within lysosomes (Beutler, 2007). 
Ferritin, like Hb, is a major iron storage protein. The iron complex with ferritin 
is water soluble and nontoxic yet the iron is in a bioavailable form. Ferritin 
consists of 24 subunits, each subunit containing up to 4500 hydrated and 
polymerized ferric iron ions within a protein shell with a hollow interior of 
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approximately 9 nm diameter. In vertebrates the molecules of ferritin are 
composed of two types of subunit, L and H, while in plants and bacteria there 
is only the H type (Briat et al., 2010, Welch et al., 2002).  
The protein shell surrounding the iron core is penetrated by six channels 
through which ferrous iron enters to interact with a ferroxidase at the centre 
of the molecule (Harrison and Arosio, 1996). Iron is able to exit after it has 
been reduced. This iron depot is readily accessible for Hb synthesis. Ferritin 
binds iron in a catalytically inactive manner; accordingly, oxidative reactions 
cannot be promoted by iron bound to ferritin. Because the main iron pool of 
most cells is located within the ferritin core, it is important to know under what 
circumstances this pool may become a source of free iron capable of causing 
oxidative damage (Rudeck et al., 2000). Ferritin iron can be removed by 
strong iron chelators but this occurs extremely slowly (Chasteen, 1997, Linert 
and Jameson, 2000), due to their ability to reduce tightly bound Fe3+ to the 
more mobile iron Fe2+ form. Direct chelation of Fe3+ may also mobilize iron 
from ferritin with or without reduction to Fe2+. In the absence of chelators, the 
reduced core of ferritin iron appears to remain within the protein shell (Hynes 
and Ó Coinceanainn, 2002). 
Another iron-storage complex, haemosiderin, also deposits iron in the Fe3+ 
state but in a water-insoluble form (Chen et al., 2006). Haemosiderin is most 
commonly found in macrophages and is especially abundant in situations 
following haemorrhage (Ganz, 2005). Deposition of iron in haemosiderin can 
cause organ damage and has been found to be associated with several 
diseases (Chen et al., 2006). 
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Ferritin is often elevated by infections, inflammation, chemotherapy, radiation 
and liver injury (Nielsen et al., 2000). Small amounts of ferritin are normally 
found in the circulating plasma within the range 15-300 µg l-1. Serum ferritin 
levels increase as a result of iron overload, aging, infection, inflammation, 
liver disease, juvenile rheumatoid arthritis, leukaemia and Hodgkin's disease, 
and they decrease as a result of iron deficiency (Forouhi et al., 2007, Muñoz 
et al., 2011). 
1.6.8 Iron recycling 
Due to lack of a regulated mechanism for iron excretion, iron absorption is 
controlled. Each day less than 0.1% of the total body iron (1-2 mg) enters the 
circulation through intestinal absorption (Andrews and Schmidt, 2007), and 
most circulating iron comes from senescent erythrocytes recycled by 
macrophages. Tissue macrophages recognize old and damaged erythrocytes 
(particularly in the spleen), and then remove them from circulation (Donovan 
et al., 2006). Within the macrophages the erythrocyte membranes are broken 
and the Hb is degraded. Haem oxygenase catalyzes the release of iron from 
haem. The amount of iron daily recycled by macrophages approximates the 
amount needed for erythropoiesis (about 20 mg). Some iron remains in 
macrophages while another portion is exported to blood plasma (Ganz, 
2005). FPN is critical for macrophage iron export and is involved in the 
regulation of the ratio between stored and released iron (Ganz, 2005, 
Donovan et al., 2005). 
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1.6.9 Iron homeostasis 
The content of iron in the human body is regulated by a complex mechanism 
for maintaining homeostasis. Iron homeostasis is achieved by regulating the 
major iron flows into the plasma; absorption of dietary iron by duodenal 
enterocytes; release of stored iron from hepatocytes; and release of iron from 
macrophages recycling senescent red blood cells (Ganz and Nemeth, 2006). 
The stimuli known to modulate the iron homeostatic mechanism are erythroid 
iron needs, hypoxia, iron deficiency, iron overload and inflammation 
(Andrews, 2005). For a long time, it was believed that there are two 
regulators (iron store regulator and erythroid regulator) responsible for iron 
homeostasis although the identities of these were not known (Finch, 1994). 
Since the beginning of this century, the discovery of hepcidin (Krause et al., 
2000, Park et al., 2001, Pigeon et al., 2001) and the ferroportin receptor 
(McKie et al., 2000) has allowed a fuller appreciation of the regulation of iron 
homeostasis. 
1.6.10 Hepcidin 
Hepcidin is small cysteine-rich cationic peptide hormone responsible for 
controlling the amount of circulating iron. It circulates in the serum in free 
form or in combination with β-2 microglobulin and is eliminated mainly with 
the urine (Atanasiu et al., 2007). Hepcidin is mainly produced by hepatocytes 
(Shayeghi et al., 2005, Hentze et al., 2010). It is also synthesised by other 
cells and organs such as monocytes, macrophages, heart, kidney, brain and 
adipose tissue. Hepcidin acts as a key regulator by binding to the iron 
transporter ferroportin resulting in internalization and lysosomal degradation 
of ferroportin, and preventing egress of iron from cells into plasma (Ganz, 
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2011, Nemeth et al., 2004). Most types of hereditary haemochromatosis 
result from the mutations that target hepcidin or ferroportin themselves or the 
pathways that control hepcidin expression. This emphasizes that hepcidin 
and ferroportin are main players in regulation the systemic levels of iron 
(Brissot et al., 2011). 
The process of regulation of plasma iron by hepcidin takes place in three 
ways, by regulation of the absorption of dietary iron from the intestine (Laftah 
et al., 2004); by the release of recycled iron by macrophages (Knutson et al., 
2005); and by the movement of stored iron from hepatocytes. Decrease in 
hepcidin concentration may be the main cause of hereditary 
haemochromatosis, and elevated levels of hepcidin may be responsible for 
effects observed in patients with anaemia of inflammation and chronic 
disease (Ganz and Nemeth, 2012). 
The expression of hepcidin is increased in response to increased serum iron, 
iron overload and inflammatory signals such as interleukin-6 (IL-6) and 
lipopolysaccharide (LPS), as well as by leptin (Chung et al., 2007), and is 
diminished in response to increased erythroid production, hypoxia and iron 
deficiency (Pigeon et al., 2001, Nicolas et al., 2002), all of which are known 
to affect iron homeostasis. Moreover, all forms of genetic haemochromatosis 
are found to be associated with decreased hepcidin production or activity 
(Bridle et al., 2003, Papanikolaou et al., 2003, Roetto et al., 2002). Hepcidin 
has been shown to be the linker between inflammation and anaemia (Ganz, 
2003). 
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1.6.11 Iron loading disorders 
Under normal circumstances the iron concentration in plasma and 
extracellular fluid remains in a relatively narrow range despite fluctuating iron 
supply and demand. Any factor that leads to alterations in iron requirements 
has the potential to influence iron entry into the plasma. Disorders of iron 
deficiency and iron overload occur when iron balance is disrupted. Andrews 
(2005) listed four situations that lead to measurable changes in intestinal iron 
absorption and tissue iron distribution: abnormal iron availability (iron 
overload or deficiency), accelerated erythropoiesis, hypoxia and 
inflammation. Under iron overload or inflammatory conditions, iron absorption 
and plasma availability will be decreased, while they are increased in 
response to iron deficiency, accelerated erythropoiesis and hypoxia 
(Anderson et al., 2007). 
1.6.12 Hereditary haemochromatosis 
This is a genetic phenomenon resulting from uncontrolled iron absorption, 
that can lead to iron overload, which causes tissue damage (Allen et al., 
2008). The most common type of primary iron overload is HFE-related 
haemochromatosis (Pietrangelo, 2002). Patients with homozygous 
haemochromatosis have a mutation within the HFE gene on chromosome 6 
consisting of a substitution of cysteine to tyrosine at position 282 (Cys282Tyr) 
(Andrews, 1999a). Haemochromatosis that is not associated with mutations 
in HFE is termed non-HFE haemochromatosis. This results from mutations in 
the genes encoding TfR2, hepcidin and haemojuvelin. The pattern of iron 
deposition is similar to that seen in HFE-related disease (Bomford, 2002). 
Other primary types of haemochromatosis are FPN-related haemo-
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chromatosis, which shows a difference in its histological appearance. The 
untreated condition can result in pathologies such as hepatic cirrhosis, 
hepatocellular carcinoma, diabetes, changes in skin pigment, endocrine 
failure, heart disease and arthritis (Edwards and Kushner, 1993, O'Neil and 
Powell, 2005). This hereditary disease can be avoided by preventing 
accumulation of iron in the sites of storage in two ways, by frequent donation 
of blood or by therapeutic venesection (Falize et al., 2006). 
1.6.13 Non-transferrin-bound iron 
In normal physiological conditions Tf carries iron safely from sites of supply to 
all needy cells which express the TfR (Hider et al., 2010). The form of iron 
found in plasma unbound to Tf or other proteins, and composed of 
complexes of iron-citrate and phosphates or iron-ligands bound to proteins, is 
called non-transferrin-bound iron (NTBI); this form appears when Tf is 
saturated with iron due to high absorption of iron or frequent blood 
transfusion. 
Body fluids and tissues which contain NTBI are prone to oxidative stress due 
to ability of NTBI to catalyse the Fenton reaction and hence its potential for 
catalysing the formation of free radicals (Gutteridge et al., 1985), thereby 
inducing cellular toxicity (Anderson, 2007). 
Fe2+ + H2O2 → Fe
3+ + OH + OH•                                      (Fenton reaction) 
There is normally little or no NTBI present in the serum of healthy individuals 
(Breuer et al., 2000b). NTBI is typically present in concentrations up to 10 μM 
(Porter et al., 1996) and its existence correlates with high levels of transferrin 
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saturation (Jacobs et al., 2005a). NTBI appears in patients that are very 
severely iron overloaded such as those with haemochromatosis, who have 
100% transferrin saturation (Lee and Jacobs, 2004) and other diseases like 
haemoglobinopathy, as well as during chemotherapy and after cardiac 
operation (von Bonsdorff et al., 2002) and in people with liver cirrhosis due to 
alcohol addiction (Feo et al., 2006). However, the existence of NTBI has also 
been shown in patients with partially saturated transferrin (Gutteridge et al., 
1985, Lee et al., 2006). 
Although the existence of NTBI was discovered over 30 years ago its precise 
definition and chemical nature still needs to be clarified. The form and nature 
of serum NTBI is not fully understood (Espósito et al., 2002, Hider, 2002). 
According to Grootveld et al. (1989), a significant portion of NTBI in 
haemochromatosis is in the form of citrate and, possibly, acetate complexes. 
The ability of iron to form large iron-polymers under physiological conditions 
could lead to different types of iron-citrate complexes, varying in size from 
monomeric to large oligomer complexes with even 17-19 iron ions (Hider, 
2002). Albumin could also act as an iron binding ligand due to the presence 
of large number of negatively charged carboxylate sites (He and Carter, 
1992). The mechanism of uptake of NTBI does not require a receptor, which 
may cause iron accumulation in the cells (Kaplan et al., 1991). Excess NTBI 
in haemochromatosis may directly initiate the formation of free radicals and 
enhanced lipid peroxidation which destroys membrane structure resulting in 
increased oxidative stress and cellular damage (Gutteridge et al., 1985) 
(Figure 1.7). Peroxidation of LDL is an important step in the process of 
atherogenesis and is catalyzed by iron (De Valk and Marx, 1999). 
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Figure 1.7 Mechanism of lipid peroxidation induced by increase of NTBI 
Inside the cell the equivalent of NTBI is called the labile iron pool (LIP), which 
is bound mainly to low molecular weight compounds. The labile iron pool is 
catalytically active and capable of initiating free radical reactions. The 
expansion of the LIP and simultaneously increased NTBI may trigger cell 
toxicity. Generation of LIP leads to unregulated iron uptake and subsequent 
intracellular storage either within ferritin molecules or as haemosiderin. The 
adverse effects of iron overload can arise from the elevation of NTBI and LIP 
in plasma, and might also cause organ damage mediated by the 
accumulation of tissue iron in target organs. The equilibrium between the LIP 
and iron locked in the ferritin shell is critical to maintain the normal function of 
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cellular iron enzymes. Imbalance in this equilibrium results in the uncontrolled 
loading of organs, such as the liver, heart and endocrine glands causing cell 
damage such as liver, endocrine glands and heart (Lee and Jacobs, 2004, 
Malcovati, 2007). 
NTBI is capable of participating in oxidative injury, and plays a pathogenic 
role in diabetes and its complications such as microangiopathy and 
atherosclerosis (Figure 1.8). Glycation reduces the Tf concentration in 
diabetes due to elevated urinary Tf excretion rates (Narita et al., 2006) and 
increased glycation may reduce iron binding to transferrin, which may result 
in an increase in NTBI. 
 
Figure 1.8 Role of NTBI in diabetes complications 
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1.6.14 Methods for measuring NTBI 
Several assays have been developed to detect NTBI in body fluids. In all 
these methods different laboratory techniques have been used such as 
chromatography, fluorimetry, atomic absorption spectroscopy and 
spectrophotometry. However, none of them is still widely accepted or 
considered to be a gold standard (Jacobs et al., 2005b); because of the 
heterogeneous structure of NTBI different iron species may occur in different 
diseases, and in different tissues (Evans et al., 2008). An additional problem 
in some cases is the high complexity of methodology, requiring sophisticated 
specialized instruments and accessories, as well as debatable reliability 
(Patel and Kushwaha, 2013). 
The oldest method, based on indirect determination of NTBI with the help of 
the antibiotic bleomycin, was first suggested by Gutteridge et al. (1981). This 
method was based on ability of the bleomycin iron complex to catalyse the 
generation of extremely reactive hydroxyl radicals (OH•) which lead to DNA 
damage. Only iron in the ferrous form can catalyze such a reaction, and so to 
facilitate the reaction all the ferric ions are converted to the ferrous form by 
using a reducing agent such as ascorbate. The degradation of DNA present 
in the reaction mixture is measured in the form of malondialdehyde. This 
method has many problems, important ones being the difficulty in controlling 
the pH of the medium and the variable purity of commercial bleomycin 
(Graham et al., 1979). Another important aspect is that the ascorbate which 
is used as reducing agent may not convert all the ferric iron to ferrous iron 
and so can lead to false low results. The procedure also includes a heating 
step for production of the end point coloured complex [(thiobarbituric acid) 2-
  44  
 
malondialdehyde], which adds to the complexity of the assay (Burkitt et al., 
2001). Another drawback of this method is the indirect way in which NTBI is 
detected. Jacobs et al. (2005b) found that the bleomycin method showed 
significantly lower values for mean NTBI than other assays, with poor 
correlation between values obtained by this method compared to the others. 
An alternative biological method, recommended by Halliwell & Gutteridge 
(2007), but rarely used in practice, involves use of the enzyme aconitase, 
following mobilisation by apoconalbumin, which was found to provide NTBI 
levels close to those found by the earlier bleomycin assay. Most recently, 
research has concentrated on development of fluorescent iron-chelating 
probes which can scavenge iron from iron-citrate complexes, and have a 
very slow exchange with apotransferrin (Ma and Hider, 2009). Another 
method uses fluorescein-apotransferrin (Fl-aTf) to chelate unbound iron, with 
readings taken as a ratio of two reagents of varying fluorescence. The serum 
apotransferrin sites are first blocked with gallium (GaCl3), then reaction-
available iron is mobilised with oxalate. Serum and reagents are mixed in 
multiwell plates, with fluorescence determined after 1 h in a microplate reader 
(Breuer and Cabantchik, 2001). Drawbacks are that not all the apotransferrin 
sites are filled, leading to some false positives, and that efforts to overcome 
this leads to underestimation of NTBI, and failure to detect it at low levels. 
The Fl-aTf assay was included in the study of Jacobs et al. (2005a) on 
different methodologies, and was performed in three different laboratories 
using identical blockers and scavengers, but differing equipment, reagent 
preparation, and procedures. Jacobs et al. found that of all the methods 
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tested, the Fl-aTf assay, whilst variations in results were seen, had the 
optimal profile for reproducibility. 
Among these different systems for measuring NTBI, the HPLC method which 
is used in this study is one of the most convenient methods that was 
developed initially and has been widely used. Consequently because many 
of the previous methods are complex or inaccurate or require a large quantity 
of sample often making them unsuitable for clinical use (Paffetti et al., 2006), 
HPLC has been considered to be a ‘gold standard method’ for NTBI 
measurement (Sasaki et al., 2011). The assay shows excellent linearity, 
reproducibility and compatibility. In the method used here NTBI is measured 
using a slight modification of the HPLC methods of Kime et al. (1996a) and 
Paffetti et al. (2006). These methods have two steps. In the first step iron is 
chelated using a chelating agent such as EDTA, oxalate or NTA. Chelating 
iron by NTA is better than other chelators because it exhibits minimum iron 
mobilisation from Tf (Singh et al., 1990). NTA concentration is also found to 
play a critical role in this assay; with 80 mM NTA more than 5-fold higher 
NTBI values are found compared to using 10 mM NTA (Kolb et al., 2009). 
This chelated fraction of iron is separated from plasma protein using 30 kDa 
Amicon ultrafilters (Millipore) (Jacobs et al., 2005b). The method also uses a 
specialized HPLC instrument, which is free of stainless steel, to reduce 
contamination from iron, and 1,2-dimethyl-3-hydroxy-4(1H)-pyridinone (DHP) 
is used as the chromogen for detection of the iron. 
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1.7 Protein glycation 
In general, non-enzymatic oxidation and glycation of proteins, lipids and 
nucleic acids produces heterogeneous compounds called Advanced 
Glycation End products (AGEs) (Thorpe and Baynes, 2003). The glycation 
reaction is a process that involves the non-enzymatic reaction between any 
reducing sugars (sugars such as glucose, fructose, lactose and maltose that 
contain aldehyde or ketone groups that are oxidised to carboxylic acids are 
classified as reducing sugars) and peptides or proteins such as Hb, albumin, 
collagen, transferrin, insulin, erythrocyte membrane proteins, lens crystallins, 
enzymes and immunoglobulins. The rate of glycation of any protein or 
peptide is dependent on both the ambient glucose concentration and the 
duration of exposure (the biological half-life) of the protein, and the number of 
available free amine groups. Glycation often leads to alterations in the 
conformation and/or function of proteins (Olufemi et al., 1987). For example, 
the glycation of erythrocyte Cu-Zn superoxide dismutase leads to a 
significant reduction in enzyme activity (Arai et al., 1987). This reaction was 
first recognized by a French chemist Louis-Camille Maillard in 1911, who 
noticed a characteristic yellowing that took place when a solution containing 
glycine was incubated with D-glucose. It was later determined that this 
characteristic colouring was due to complex reactions that eventually led to 
the formation different classes of heterogeneous compounds. 
1.7.1 Maillard reaction and AGE synthesis in humans 
Maillard’s reactions have been extensively studied in food chemistry; 
however, it was only in the ‘70s that they were also shown to occur in vivo, 
due to the high concentration of D-glucose, which is found in human plasma 
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(Koch et al., 2010). The Maillard reaction starts as a reaction between the 
carbonyl group of a reducing sugar such as glucose and an amine group on 
proteins, lipids or nucleic acids (Figure 1.9) leading to the production of an 
unstable compound known as a Schiff base (Lapolla et al., 2005, Lapolla et 
al., 2006). 
 
Figure 1.9 The Maillard reaction 
The first step of Maillard reaction is reversible and usually takes a few hours to occur, leading 
to the formation of an unstable compound (Schiff base). Over weeks the Schiff base turns into a 
more stable compound called the ‘Amadori’ product through various molecular rearrangements. 
The Amadori product undergoes further structural changes over months/years through a series 
of reactions such as oxidation, dehydration and degradation to finally yield highly stable AGE 
compounds. From Hegab et al. (2012). 
The predominant amine groups involved in glycation are therefore lysine 
residues and the N-terminus of a given polypeptide. This step is reversible 
and usually takes a few hours to occur (Figure 1.9). Over weeks the Schiff 
base turns into a more stable compound called the ‘Amadori’ product through 
various molecular rearrangements (Ahmed and Thornalley, 2003). Over 
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months and years, the Amadori products undergo further structural changes 
through a series of reactions such as oxidation, dehydration and degradation 
(Figure 1.10) to finally yield highly stable AGE compounds (Brownlee, 1995, 
Taguchi et al., 2000). Under physiological conditions, non-enzymatic 
glycation can be detected in the process of ageing, but the reactions are 
considerably faster and more extensive in pathophysiological conditions such 
as diabetes mellitus that are associated with a persistently elevated 
concentration of glucose (Peppa et al., 2003, Wendt et al., 2003). 
 
Figure 1.10 Chemical structure and formation of AGEs in the Maillard reaction 
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1.8 Oxidative stress in diabetes 
Studies concerning oxidative stress parameters have increased because 
oxidative stress has been implicated in the etiopathogenesis of many 
diseases including cancer, atherosclerosis and other cardiovascular diseases, 
diabetes, rheumatoid arthritis, Alzheimer's disease and other neurological 
disorders, and pulmonary diseases (Yorek, 2003, Marlatt et al., 2008). 
Oxidative stress has been defined as when the balance of formation of 
oxidants exceeds the ability of antioxidant systems to remove or scavenge 
them (Bonnefoy et al., 2002). Under this definition oxidants are electron 
acceptors that damage proteins, DNA and lipids whereas antioxidants are 
electron donors that are insufficient to neutralize them. 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are two 
main classes of oxidants produced continuously in all cells. Each class 
contains two types of oxidant, free radical and non-free radical species. Free 
radicals are defined as “any species capable of independent existence that 
contains one or more unpaired electrons” (Halliwell & Gutteridge 2007). 
Transition metal ions are also free radicals by this definition, and may donate 
or accept electrons depending on their electronic state. Table 1.3 lists some 
ROS and RNS. 
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Table 1.3 Radical and non-radical reactive oxygen species 
Radical non-radical 
superoxide, O2
•- hydrogen peroxide, H2O2 
hydroxyl, OH• hypochlorous acida, HOCl 
peroxyl, RO2
• ozone, O3 
alkoxyl, RO• singlet oxygen, 1O2 
hydroperoxyl, HO2
• peroxynitriteb, ONOO- 
nitric oxide, NO•  
nitryl, NO3
•  
hydrogen atoms, H•  
chlorine atoms, Cl• 
 
a can also be called a reactive chlorinating species, b can also be called 
reactive nitrogen species. 
The production of oxidant species is inevitable as a by-product of metabolic 
pathways such as aerobic metabolism and oxidative phosphorylation in 
mitochondria (Stadtman and Berlett, 1998, Aruoma et al., 1989). Low 
concentrations of these species are important for cell proliferation, but high 
concentrations are also used for defense against invading pathogens and in 
regulation of the activation of several signaling pathways (Apel and Hirt, 2004, 
Stadtman and Berlett, 1998). For example, NO is essential for the regulation 
of vascular tone while superoxide is necessary for proper immune function 
(Oury et al., 1996), but unneutralized ROS and RNS can cause oxidative 
damage to lipids, proteins and nucleic acids, thus leading to aberrant 
molecular activities (Avery, 2011). 
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Accumulating evidence indicates that overproduction of ROS is associated 
with insulin resistance and obesity, and may be a major risk factor in the 
onset and progression of diabetes (Maritim et al., 2003), as well as to its later 
complications (Wolff, 1993). However, the link between oxidative stress and 
the development and progression of T2DM and its complications is still not 
fully understood. It has also emerged from various studies that diabetes and 
the associated hyperglycaemia increase oxidative stress by different 
mechanisms and elevated oxidative stress plays an important role in the 
pathogenesis of vascular dysfunction and subsequent diabetic complications 
including the diabetic retinopathy (Fiorentino et al., 2013, Giugliano et al., 
1996). 
The management of iron absorption and distribution in the organism, and 
inside cells must be tightly regulated in order to avoid the deleterious 
consequences of free iron-induced oxidative stress. Iron becomes a harmful 
element in cells due to its ability to participate in the generation of ROS (Kell, 
2009). ROS are formed in the course of normal metabolism through leakage 
of electrons from the electron transport chain and by activities of 
oxidoreductase enzymes such as NADPH oxidase, myeloperoxidase, 
xanthine oxidase, glucose oxidase, cytochromes P450 and cyclooxygenases 
(Andrews, 1999a). Under normal conditions, up to 1% of the mitochondrial 
electron flow leads primarily to the formation of O2
•-. Interference with 
electron transport can dramatically increase O2
•- production, which is rapidly 
converted within the cell to H2O2 and O2 via superoxide dismutase (SOD). 
2O2
•‾ + 2H+ H2O2 + O2 
SOD 
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H2O2 can react with the reduced transition metal Fe
2+ via the Fenton reaction 
(Figure 1.11) to produce the highly reactive hydroxyl radical. Alternatively, 
H2O2 may be converted into water catalysed by the enzymes catalase and 
glutathione peroxidase (Stadtman and Berlett, 1997). The modification of 
proteins is initiated mainly by the reactions with OH•, however, the oxidation 
process is determined by the availability of O2 and O2
•-. 
 
Figure 1.11 Schematic representation of the sequence of events leading to the Fenton reaction. 
From Bogdanova and Nikinmaa (2001) 
Cells are protected against oxidative stress by an interacting network of 
antioxidants. These include antioxidant enzymes such as catalase, 
superoxide dismutase and glutathione peroxidase as well as low molecular 
weight scavengers such as vitamins C and E, and reduced glutathione 
(GSH). Under normal conditions there is a well-managed balance between 
formation and neutralization of ROS, so there is little or no modification of 
biomolecules. 
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1.9 Obesity 
Obesity is a chronic disease in which abnormal or excessive body fat has 
accumulated in adipose tissue to the extent that health may be adversely 
affected and poor health increases mortality (WHO, 2013). Globally, the 
prevalence of obesity has doubled in the last two decades, leading to obesity 
being considered as a global epidemic. In 2008, more than 1.6 billion adults 
over 20 years old were overweight. Of these, over 200 million men and 
nearly 300 million women were obese meaning that more than 1 in 10 of the 
world’s population was obese (De Onis et al., 2010). The majority of the 
world’s adult population will be either overweight or obese by 2030 (Kelly et 
al., 2008). 
In most large-scale studies, obesity is estimated from body mass index, BMI, 
a measurement obtained by dividing a person's weight in kilograms by the 
square of the person's height in metres. BMI tends to overestimate body fat 
in people who are very muscular and underestimate body fat in people who 
are highly sedentary. People who are very muscular, particularly men, may 
have a BMI higher than the normal range of 20 to 25, and still appear to have 
a normal weight and be healthy. In addition the BMI does not show where the 
body fat is located. New research shows that there are better ways to work 
out the level of obesity by waist circumference and waist-to-hip ratio (Snijder 
et al., 2006), although waist circumference and waist/hip ratio have been 
used as measures of central obesity (where visceral adipose tissue is stored), 
and BMI has been used as a measure of general obesity (Molarius and 
Seidell, 1998). 
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Obesity, especially of visceral fat, causes or exacerbates large numbers of 
diseases, including hypertension (Matsumura et al., 2001), dyslipidaemia, 
insulin resistance, T2DM (Kishida et al., 2012, Greenberg and Obin, 2006), 
metabolic syndrome, coronary heart disease (Paeratakul et al., 2002), stroke, 
non-alcoholic fatty liver disease, osteoarthritis, sleep apnea (Young et al., 
1993, Peppard et al., 2013), and several forms of cancer. 
Many factors contribute to causing obesity. In addition to genetic factors, the 
main factors relate to increased consumption of high energy density foods 
and a sedentary lifestyle that leads to a positive energy balance with 
subsequent accumulation of fat. Other factors which have effect on the 
energy balance include increased meal size, drinking sweet drinks and 
frequent consumption of carbohydrate. Obesity is linked with increased risk 
of developing insulin resistance and T2DM. Excess adipose tissue in obese 
individuals leads to release of increased amounts of non-esterified fatty acids, 
glycerol, hormones, pro-inflammatory cytokines and other factors which are 
involved in the development of insulin resistance. When insulin resistance 
and dysfunction of the -cells occur together, the subsequent fall in insulin 
secretion results in a failure to control blood glucose levels leading to T2DM 
(Kahn et al., 2006). Many genes interact with the environment leading to 
obesity and in some also to diabetes. 
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1.9.1 Iron and obesity 
A large number of studies have revealed a link between being overweight or 
obese and having poor iron status (Yanoff et al., 2007, Nead et al., 2004), but 
the mechanisms that underlie this are still poorly clarified (Tussing-
Humphreys et al., 2009a). A first, unexpected, study found a significantly 
lower mean serum iron concentration in obese compared with non-obese 
adolescents (Wenzel et al., 1962). 
Obesity is regarded as a pro-inflammatory condition characterised by the 
presence of chronic, low grade systemic inflammation (Ausk and Ioannou, 
2008). Adipose tissue is known as an active endocrine organ and releases a 
number of cytokines and adipokines (Rosen and Spiegelman, 2006), which 
may in turn influence iron metabolism. Secretion of IL-6 and leptin from 
adipose tissue triggers hepcidin production. Increased hepcidin production 
leads to down regulation of iron absorption by the gut (McClung and Karl, 
2009), associated with lower iron levels, transferrin saturation and higher 
serum transferrin receptor levels (Tussing-Humphreys et al., 2009a). This 
mechanism was reinforced by the observation that bariatric surgery improved 
iron status in obese patients, as it reduced the adipose mass and 
inflammation in the patients (Anty et al., 2008). There is a possible 
mechanism (Figure 1.12) that connects iron and obesity: the initial step is 
possibly related to an increased iron excess and hepatic iron loading followed 
by increased visceral adiposity, inflammation and hepcidin up-regulation, 
leading to iron deficiency (Ruivard et al., 2009). 
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Figure 1.12 Possible mechanism that accounts for iron deficiency in obesity. 
1.9.2 Obesity and oxidative stress 
Oxidative stress is a manifestation of obesity (Keaney et al., 2003). Several 
mechanisms contribute to the formation of free radicals during obesity, which 
leads to oxidative stress. 
1.9.2.1 Increased fatty acid oxidation 
Free fatty acids (FFAs) are oxidised inside the mitochondria after 
peroxisomal breakdown of very long chain fatty acids through β-oxidation, 
and this oxidation results in the overproduction of ROS which causes 
oxidative stress. The excessive production of ROS could also be due to 
preexisting conditions such as increased leptin and decreased activity of 
antioxidant enzymes that allow for overproduction of ROS (Inoguchi et al., 
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2000). Oxidative stress can cause changes in mitochondrial DNA, which may 
result in abnormal changes in the structure of mitochondria and reduced ATP 
production. 
1.9.2.2 Antioxidant depletion 
Low molecular mass antioxidant sources can be depleted due to the increase 
of ROS production. Also the expression of antioxidant enzymes such as 
catalase, SOD and GPx is decreased in the adipose tissue of obese 
individuals which may lead to decrease in the level of these enzymes and 
also the activity of the enzymes may be decrease through the detrimental 
effects of ROS (Furukawa et al., 2004). Depletion of antioxidants leads to 
many health problems in obesity (Ozata et al., 2002). 
1.9.2.3 Over consumption of oxygen 
Total body oxygen consumption increases as weight increases (Gibson, 
2000). The consequence of increasing oxygen consumption is increased 
production of ROS by the mitochondrial respiration process due to the loss of 
electrons from the electron transport chain, resulting in the formation of the 
superoxide radical (Amirkhizi et al., 2010, Khan et al., 2006). 
1.9.2.4 Adipose tissue 
Adipocytes produce various biologically active substances, such as tumour 
necrosis factor  (TNF-) (Hotamisligil et al., 1993), IL-6 (Fried et al., 1998), 
monocyte chemoattractant protein 1 (MCP-1) (Sartipy and Loskutoff, 2003) 
and leptin (Friedman and Halaas, 1998). Thus, obesity is considered a state 
of chronic inflammation. These cytokines are potent stimulators for the 
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production of reactive oxygen and nitrogen species by macrophages and 
monocytes; therefore, a rise in the concentration of cytokines could be 
responsible for increased oxidative stress. 
1.9.2.5 Diet 
A diet with high calorific value is likely to lead to the formation of ROS due to 
altered oxygen metabolism. Stored fat in the body is susceptible to oxidation 
reactions and the production of ROS. If the production of these ROS exceeds 
the antioxidant capacity of the cell, oxidative stress resulting in lipid 
peroxidation, which could contribute to the development of atherosclerosis 
(Khan et al., 2006). 
1.10 Endothelium dysfunction 
Circulating blood from the heart to the smallest capillaries is separated from 
vascular smooth muscle by a simple monolayer of cells called the 
endothelium; this layer acts as an endocrine organ, producing a variety of 
bioactive substances that play a crucial role in the maintenance of vascular 
homeostasis and endothelial integrity (Hirase and Node, 2012), as well as in 
the maintenance of blood fluidity. To fulfil this range of functions the 
endothelium produces or releases several vasoactive agents including the 
vasodilators, NO, prostacyclin and endothelium-derived hyperpolarising 
factors (EDHFs), and the vasoconstrictors angiotensin II and endothelin-1 
(Cooke, 2000). Under physiological conditions, the endothelium acts as an 
inhibitory regulator of vascular contraction, leukocyte adhesion, vascular 
smooth muscle cell growth and platelet aggregation (Moncada et al., 1991). 
However, a growing list of conditions, including hypercholesterolaemia, 
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systemic hypertension, smoking, diabetes, congestive heart failure, 
pulmonary hypertension, estrogen deficiency, hyperhomocysteinaemia, and 
the aging process itself, have been associated with impaired function of the 
endothelium. Diabetes mellitus in humans is associated with impaired 
endothelium-dependent relaxation (De Vriese et al., 2009). 
1.11 Atherosclerosis 
Atherosclerosis is an chronic inflammatory disease resulting in plaque 
formation in the arterial vessel wall and is generally a disease of the large 
arteries that leads to myocardial infarction, stroke and lower limb ischaemia 
(Ross, 1986). The plaque may start already as a fatty streak during the fetal 
period and continues to develop throughout childhood, adolescence and 
adulthood (Napoli et al., 1999, McGill et al., 2000). In the early stages, 
atherosclerosis remains asymptomatic for decades, but in the progressive 
stage symptoms arise which depend on the affected vascular site (Murray 
and Lopez, 1997). If the extremities are targeted by these plaques the 
patients suffer from claudication. If these plaques present in the coronary 
artery then angina pectoris or myocardial infarction can occur. Transient 
ischaemia attack or stroke takes place if the carotid arteries are affected 
(Davies, 1996, Rothwell et al., 2000). 
Inflammation and hyperlipidaemia play important roles in initiating and 
advancing atherosclerosis (Epstein and Ross, 1999, Libby et al., 2002). 
Inflammation is boosted by many factors including cigarette smoking, insulin 
resistance, diabetes and hypertension, particularly that mediated by renin 
angiotensin aldosterone, which is associated with atherosclerosis (Libby and 
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Aikawa, 2002). Many studies have mentioned the fundamental role of 
cholesterol in the atherosclerosis process (Steinberg, 2004, Steinberg, 2005, 
Steinberg, 2006). The first step in atherosclerosis process starts in the 
endothelial cells (EC). The activation of EC results in the increase expression 
of adhesion molecules such as P-selectin, E-selectin, intercellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on the 
EC surface. Circulating leucocytes migrate to the intimal layer, where 
differentiation of migrated monocytes into macrophages occurs. 
Macrophages have a great capacity to take up exogenous material, such as 
oxidatively modified low density lipoproteins (oxLDL). OxLDL is taken up into 
macrophage lysosomes via receptor-mediated endocytosis, but poorly 
degraded, resulting in foam-cell formation and generation of fatty streaks. 
Further recruitment of inflammatory cells and proliferation of smooth muscle 
cells lead to the development of an atherosclerotic plaque (Epstein and Ross, 
1999, Libby et al., 2002). 
Smooth muscle cells form a fibrous cap covering the atherosclerotic plaque. 
Thinning of the fibrous cap has been shown to be caused by decreased 
collagen production as a result of decreased smooth muscle cell content, or 
degradation by matrix metalloproteinases excreted by macrophages (Galis et 
al., 1994). In end-stage atherosclerosis the fibrous cap overlying the 
atherosclerotic plaque can rupture (Finn et al., 2010). As a result, the content 
of these unstable plaques is passed to blood stream resulting in thrombus 
formation. Very small particles can embolise and end up in smaller vessels of 
a target organ’s tissue, leading to local occlusion and ischaemia. Problems 
with vision can occur if these particles end up in the retinal artery. Transient 
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ischaemic attack or stroke can occur if these small particles are stuck in a 
small blood vessel (artery) in the brain. 
Poor glycaemic control, low grade inflammation and low HDL-cholesterol 
(HDL-c), are all established promoters of atherosclerosis, and have been 
reported to correlate with each other in patients with T2DM (Gatti et al., 2009). 
There is compelling evidence that iron plays a significant role in the 
development of atherosclerotic plaques (Sullivan, 2009, Sullivan, 2007). The 
major findings in support of this are those that have demonstrated that 
reducing iron bioavailability through chelation therapy (Duffy et al., 2001), 
dietary restriction (Lee et al., 2003) or by frequent blood donation (Zheng et 
al., 2005), reduces the size of the atherosclerotic lesions in animal studies 
(Minqin et al., 2005) and improves vascular function in humans (Duffy et al 
2001, Zheng et al 2005). Obesity is a major risk factor for vascular disease 
due to changes in adipokine secretions from the enlarged adipose tissue 
mass (Hajer et al., 2008, Gustafson, 2010). 
1.11.1 Atherosclerotic risk factors 
There are number risk factors that accelerate atherosclerotic process (Table 
1.4). Although the American Heart Association (AHA) Conference statement 
in 1999 suggested a classification which divides risk factors into three 
classes, the method for classification of these factors has not been agreed 
around the world. The three categories are: major independent risk factors, 
predisposing and conditional risk factors (Grundy et al., 1999). 
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Table 1.4 Classification of risk factors for atherosclerosis as presented by the AHA 
Major independent Predisposing Conditional 
Smoking Obesity* 
Elevated serum 
triglycerides 
Elevated serum total and 
LDL cholesterol 
Physical inactivity* Small LDL particles 
Low serum HDL 
cholesterol 
Abdominal obesity 
Elevated serum 
homocysteine 
Diabetes mellitus 
Family history of 
premature CHD 
Elevated serum 
lipoprotein(a) 
Advancing age Ethnic characteristics Prothrombotic factors 
Elevated blood pressure Psychosocial factors Inflammatory markers 
* These risk factors are designated major risk factors by the AHA. 
1.11.2 Iron and atherosclerosis 
The link between iron and atherosclerosis has been proposed by Siperstein 
et al. (1953), and this suggestion was built on the information which was 
gathered from clinical observations and experimental studies in the early 
1950s. In 1981, Sullivan spotted that people with high serum ferritin 
concentrations have a risk of myocardial infarction and therefore he 
suggested the hypothesis, which is called the “iron hypothesis”. He also 
observed that chronic iron depletion by blood donation has a protective effect 
against ischaemic heart disease (Sullivan, 1981). Before this hypothesis 
oestrogen was considered to be a possible explanation for difference in risk 
of vascular disease between sexes, while Sullivan argued that iron is more 
likely culprit than oestrogen (Sullivan, 1989, Sullivan, 1992, Sullivan, 2001, 
Sullivan, 2003, Sullivan, 2005, Sullivan, 2007). Inflammation plays a major 
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role in the atherosclerosis process. Increasing levels of hepcidin due to the 
inflammation process lead to an increase in the deposition of iron in 
macrophages which are critical cells in the formation and fate of 
atherosclerotic plaques. Increased deposition of iron is an important 
contributor to promoting the generation of reactive oxygen species, and could 
therefore promote lipid peroxidation and accelerated development of 
atherosclerosis plaque instability (Ramakrishna et al., 2003). 
Iron induces the production of ROS locally which impairs vascular function, 
decreasing the bioavailability of NO, impairing vasorelaxation, and promoting 
platelet adhesion and aggregation (Russo et al., 2002). Zheng et al. (2005) 
provided evidence in support of the Sullivan hypothesis when they found that 
high frequency blood donors have decreased levels of serum ferritin (a 
marker of body iron store); decreased levels of serum 3-nitrotyrosine (a 
marker of oxidative stress); and greater flow-mediated dilation in the brachial 
artery (a marker of vascular function). An interesting study noted that iron 
chelation with deferoxamine improved endothelial function in patients with 
coronary artery disease (Duffy et al., 2001). 
Evidence from experimental studies has shown that decreased vascular iron 
content following dietary iron restriction in Apo E-deficient mice leads to lower 
matrix degradation capacity and increased plaque stability, and significantly 
attenuates the progression of atherosclerotic lesions in these animals (Lee et 
al., 1999, Lee et al., 2003). 
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1.11.3 Oxidative stress and atherosclerosis 
Several lines of evidence support the potential role of oxidative stress in 
accelerating the atherosclerosis process (Nishikawa et al., 2000, Baynes and 
Thorpe, 1999, Baynes, 1991). Studies in experimental animals have 
demonstrated that increased production of ROS from the layers of arteries 
are common risk factors for atherosclerosis (Cai and Harrison, 2000). 
All conditions and diseases such as diabetes, hypertension, nitrate 
intolerance, smoking and aging which increase the production of ROS via 
several mechanisms have the ability to initiate several processes which 
contribute to atherosclerosis, by stimulating several processes which lead to 
atherosclerosis. In the diabetic condition ROS are produced by different 
pathways and are involved in development of atherosclerosis in different 
aspects such as activation of glycation reactions and increased electron flux 
on the mitochondrial electron transport chain. Increased ROS are involved in 
the development of atherosclerosis in various aspects. First, endothelial 
dysfunction is an early key event in atherosclerosis (Cai and Harrison, 2000). 
It has been thought that ROS are involved in the progression of endothelial 
cell dysfunction, which is accompanied by inactivation of endothelial nitric 
oxide synthase (eNOS) and decrease of NO levels (Madamanchi et al., 
2005). Second, ROS also induce expression of adhesion molecules such as 
intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion  
molecule-1 (VCAM-1), which facilitates inflammatory cell recruitment and lipid 
deposition in the intimal layer. The subsequent ingestion of excess oxidized 
LDL particles by macrophages and monocytes leads to release of various 
inflammatory cytokines and growth factors. Finally, proliferation of vascular 
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smooth muscle cells (VSMCs) is a key step in the development of 
atherosclerosis. 
Obesity is characterized by an increase in ROS production and endothelial 
dysfunction, which leads to a reduction in the bioavailability of vasodilators, 
particularly NO. Several mediators and mechanisms are involved in the 
decrease in NO including leptin and homocysteine (Guzik et al., 2006). 
Elevated leptin and homocysteine concentrations in obese individuals with 
and without hypertension induce oxidative stress, which leads to a free-
radical-induced decrease of NO (Konukoglu et al., 2006). 
Lipid peroxidation, which is often developed during oxidative stress, leads to 
production of the end products of lipid peroxidation, reactive aldehydes. The 
most relevant in current biomedicine are malondialdehyde (MDA) and  
4-hydroxynonenal (HNE). These aldehydes are able to ‘simulate’ complex 
oxidative stress and its harmful consequences, hence it is commonly 
accepted that these molecules are considered as ‘second toxic messengers’ 
of oxygen free radicals. Metal ions like Cu2+ or Fe2+ are frequently used to 
initiate LDL oxidation in vitro, since the resulting oxyLDL by metal ions has 
similar biological activation to that oxidized in vivo (Esterbauer et al., 1992). 
1.12 Novelty of project 
Most of the recent studies in this area (the relationship between iron oxidative 
stress, protein glycation and development of atherosclerosis in T2DM) have 
provided conflicting findings with regard to both Type 2 diabetic and non-
diabetic obese subjects. There is a number of reasons that account for these 
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discrepancies (see below), and these are addressed here by using more 
appropriate methodology to measure the factors involved. There are several 
studies that question the validity of traditional methods of measuring iron 
status in subjects with obesity and/or diabetes (Swaminathan et al., 2007, 
Jiang et al., 2004). For example, ferritin is often considered a marker of body 
iron stores but it is an acute-phase reactive protein that may be influenced by 
coincidental infections and, more importantly, in this setting, by the presence 
of low-grade inflammation associated with obesity (Yanoff et al., 2007, Ausk 
and Ioannou, 2008, McClung and Karl, 2009). Moreover, ferritin itself does 
not participate directly in the oxidant reactions related to iron. Critical to iron’s 
importance in biological processes is its ability to cycle reversibly between its 
ferrous and ferric oxidation states. This precise property, which is essential 
for its functions, also makes it dangerous, because free iron can catalyse the 
formation of free radicals that can damage the cell. Thus, from a 
pathophysiological standpoint, it is important to measure iron pools that 
consist of chemical forms that can participate in redox cycling. This pool is 
referred to as labile iron, and extracellularly as non-transferrin bound iron 
(NTBI). A recent editorial concluded that progress into the relationship 
between iron, oxidative stress and the causes and consequences of diabetes 
will not occur unless the involvement of the physiological pool (NTBI) is fully 
investigated (Shah and Fonseca, 2011). The aim of this study was to initiate 
these essential investigations into the role of NTBI in these conditions. 
There is no ‘gold standard’ for measuring NTBI. An improved method for 
doing this has been developed in our laboratory. NTBI is measured using a 
slight modification of the high performance liquid chromatography (HPLC) 
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methods of (Kime et al., 1996b, Paffetti et al., 2006). Recent studies have 
revealed the involvement of iron and oxidative stress in the development of 
atherosclerosis (Sullivan, 2007, Sullivan, 2009). Both obesity and diabetes 
are high risks for developing atherosclerosis. Iron overload is commonly 
reported in T2DM, and this fits with the current view. In contrast, obesity is 
commonly reported as being an iron deficient state (Tussing-Humphreys et 
al., 2009a, Pinhas-Hamiel et al., 2003). This does not fit with the view 
proposed above. However, no studies have investigated NTBI in obesity. It is 
theoretically possible to have low iron status (as indicated by classical 
measures) yet still have high circulating NTBI. This current study was aimed 
to address this dilemma. 
In addition to the points raised above, this study related changes in iron 
status as measured by circulating soluble transferrin receptors (sTfR) (which 
are unaffected by inflammation) (Yanoff et al., 2007), total serum iron, iron 
binding capacity, to NTBI and atherogenesis as indicated by the biomarkers 
E-selectin and high sensitivity C-reactive protein (hs-CRP). A number of 
studies have validated the value of hs-CRP and hence it has been used 
extensively as a biomarker of atherosclerosis and cardiovascular risk (Ridker, 
2007, Ridker and Silvertown, 2008, Calabrò et al., 2009). 
Most recent studies have found that obese subjects tend to have higher Hb 
and ferritin concentrations, and lower transferrin saturation compared to the 
non-obese subjects. The higher ferritin and lower transferrin saturation is 
consistent with the mechanism of obesity related inflammation (Yanoff et al., 
2007). However, assessment of other biomarkers such as sTfR (which is 
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elevated in iron deficiency) in concert with clearly defined obesity population 
are required to clarify the causal relationship between obesity and disturbed 
iron metabolism. 
1.13 Conclusions 
Iron is a vital element in many biological processes and the body has an 
efficient system to maintain iron homeostasis. However, elevated body iron 
levels may be associated with the development of several diseases including 
T2DM, and contributes to the progression of its complications, such as 
atherosclerosis, due to ability of iron to catalyse the production of ROS 
through Fenton chemistry. Excess iron is known to be one of the major 
contributing causes for oxidation of LDL, which plays a major role in 
atherosclerosis plaque formation. In obesity, iron distribution is altered both 
at the cellular and tissue levels with adipose tissue playing a predominant 
role in this change. On other hand, high levels of circulating glucose (which 
occur in diabetes) leads to the deposition of glucose onto proteins (protein 
glycation) which interferes with their normal function. Iron binding proteins 
are altered by glycation and may consequently be impaired in their various 
functions, resulting in plasma and sub-endothelial redox active non-
transferrin-bound iron. Such iron forms are capable of contributing to 
endothelial, and renal diabetic pathologies, and possibly others, although 
direct evidence of their involvement is elusive. This process may further 
enhance iron availability because some of these proteins function to store 
and transport iron. Increases in the availability of iron may lead to the 
production of ROS, and these can lead to tissue damage which occurs in 
diabetes such as damage to the blood vessels. There are many gaps in the 
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research in the area of iron and T2DM, and its complications, some of which 
are listed below. 
1) The impact of iron on T2DM and its complications has been studied 
recently but many of these studies deal with total iron and not with the 
redox active form of iron (NTBI). Furthermore, some previous studies 
have used newly diagnosed T2DM subjects and have not mentioned 
the duration of diabetes, which may have a great impact on glycation 
of proteins, and hence on the release of NTBI. 
2) In previous studies, standard tests of iron status have been used, 
which are affected by inflammation; sTfR is a better indicator of iron 
status because it is unaffected by inflammation. 
3) No previous research has assessed NTBI in obese non-diabetic 
subjects. Because obese subjects are already iron deficient, it would 
be interesting to know whether NTBI is present in this group. 
4) In addition, studies in which NTBI has been measured have not used 
the most up-to-date methods for measuring it. Current methods of 
measuring NTBI have higher sensitivity and this may allow detection 
of lower concentrations of NTBI. 
5) Although there have been previous studies on the effects of glycation 
on Tf these have used either apoTf or holoTf, neither of which are 
normally present in plasma. A study in which partially iron loaded Tf is 
used would be more physiologically relevant than previous studies. In 
addition, the effects of co-incubation with LDL remain to be studied. 
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1.3 Hypotheses 
Release of NTBI from transferrin and possibly other proteins in vivo due to 
glycation processes may have a great effect on T2DM and its complications 
due to the induction of oxidative stress by a variety of different mechanisms. 
This leads to a decrease in antioxidant defence and an increase in oxidative 
damage in the major organs responsible for glucose homeostasis such as 
the liver and pancreas. 
Obesity is known to be associated with low iron status, suggesting that the 
absence of diabetes in some cases and not in others may be due to lower 
levels of NTBI in some obese individuals compared to others. 
In vitro the incubation of 50% ITf with glucose may have a major effect on the 
iron-binding capacity of Tf and the release of NTBI, but less so than for the 
incubation of glucose with holoTf, which is less physiologically relevant, and 
for which there is likely to be some NTBI already present. In addition, the 
presence of LDL during the incubation with glucose should enhance the 
effects of glycation of 50% ITf leading to increased NTBI release. 
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1.2 Aims and objectives 
The purpose of this study was to determine in lean healthy controls, obese 
non diabetic subjects and subjects with diagnosed Type 2 diabetes the 
following relationships: 
1. the degree of haemoglobin glycation (HbA1c), and the plasma level of 
‘free’ non transferrin-bound iron [NTBI]; 
2. the level of NTBI and the degree of oxidative stress as indicated by 
the plasma levels of malondialdehyde (a marker of lipid peroxidation), 
and the levels and redox state of the major small molecular weight 
antioxidants ascorbate, urate and glutathione; 
3. the relationship between NTBI, oxidative stress, biomarkers of 
atherosclerosis and central obesity; and 
4. the relationship between the NTBI, oxidative status, and biomarkers of 
atherosclerosis in advanced diabetes. 
In addition to this in vivo study, an in vitro study on transferrin glycation with 
different concentrations of glucose to confirm the influence of glycation in iron 
binding to transferrin was carried out, as well as another to show the 
influence of glycation on oxidation of LDL. 
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Chapter 2: An in vivo study on the relationship 
between non-transferrin bound iron and other 
common iron-related, inflammation and 
atherosclerosis biomarkers in Type 2 diabetes and 
obesity 
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2.1 Introduction 
In recent years the prevalence of Type 2 diabetes mellitus (T2DM) has 
increased worldwide (Shaw et al., 2010). Iron overload has been implicated 
in T2DM and other diseases such as cancer, Alzheimer’s disease and 
cardiovascular disease (Jomova and Valko, 2011). Organs such as the 
pancreas, liver, muscle and adipose tissue, which are heavily involved in 
glucose and lipid metabolism are affected by iron overload (Fernández-Real 
and Manco, 2013). The precise mechanisms by which iron induces T2DM 
are not clear, but iron overload initiates abnormalities in glucose metabolism, 
including insulin resistance and hyperinsulinaemia, followed by impaired 
insulin secretion (Wilson et al., 2003). The ability of iron to participate in the 
generation of powerful oxidant species such as the hydroxyl radical may be 
considered as a link between iron overload and risk of T2DM (Halliwell and 
Gutteridge, 1989). The formation of hydroxyl radicals induces oxidative stress 
and may contribute to insulin resistance or long-term pancreatic failure 
(Swaminathan et al., 2007). 
Hereditary haemochromatosis (HH), a genetic disorder of iron metabolism, 
provides further evidence of an association between iron and T2DM due to 
impaired glucose tolerance which leads to insulin resistance and increased 
risk of diabetes; about 30% to 60% of patients with HH have diabetes 
(Hatunic et al., 2010). An increased incidence of diabetes is also seen in 
hereditary aceruloplasminaemia, a condition where the lack of synthesis of 
apoceruloplasmin affects the distribution of tissue iron and leads to a 
progressive accumulation of iron (Miyajima, 2003). Pancreatic cells have the 
tendency to express the divalent metal transporter (DMT1), and so facilitate 
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the entry and accumulation of iron in comparison to other cells (Andrews, 
1999b). Another study found a strong association between clinically raised 
ferritin, below the range indicative of clinical haemochromatosis, and 
development of diabetes (Forouhi et al., 2007). These observations have 
opened new avenues to study the relationships between iron and many 
diseases. 
Under normal conditions, iron circulates in the plasma bound with three major 
proteins: transferrin, Hb and ferritin. Transferrin is responsible for the delivery 
of iron to all cells in the body which need iron to perform cellular functions, 
such as red blood cells during erythropoiesis (Hentze et al., 2010). In serum, 
transferrin is usually only 30% saturated so that it has the capacity to bind 
excess iron and thus help in controlling the build-up of toxic amounts of 
excess iron. Circulating iron, which is not bound to transferrin, referred to as 
non-transferrin-bound iron (NTBI), becomes important in iron overload 
disorders, in which plasma iron is present in excess of transferrin-binding 
capacity, due to its redox activity through Haber-Weiss and Fenton chemistry 
(Breuer et al., 2000a, Esposito et al., 2003). When NTBI appears in the 
plasma, due to iron overload or lack of transferrin (apotransferrinaemia), it is 
rapidly cleared by the membrane-bound transport system constitutively 
present on parenchymal cells of organs particularly those of liver, heart, 
pancreas and the adrenal glands. This system does not require endocytosis 
for iron transport. 
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2.1.1 Non-transferrin-bound iron and diseases 
The presence of NTBI is associated with pathological conditions; in healthy 
individuals NTBI is found in very low concentrations, which do not exceed 1 
µmol l-1 and are often undetectable by most of the methods available 
(Anderson, 1999). NTBI is a form of iron most susceptible to redox activity, 
and plays an important role in acceleration the pathogenicity of diseases. 
NTBI has found in different iron overload diseases such as 
haemochromatosis, β-thalassaemia, sickle cell anaemia and myelodysplastic 
syndrome (Hershko et al., 1978, Walter et al., 2006, Le Lan et al., 2005). 
NTBI is also present in megaloblastic anaemia (Gafter-Gvili et al., 2004); the 
end stage of renal disease patients on haemodialysis (Prakash et al., 2005); 
patients with end stage of renal disease on supplemental iron therapy (Zager 
et al., 2002); and alcoholic cirrhosis. The presence of NTBI in non-iron 
overloaded conditions such as myocardial infarction, renal disease, diabetes 
and liver disease (Lee et al., 2006, Lele et al., 2009), has led investigators to 
consider NTBI as a potential mediator for complications of these diseases. 
NTBI appears in serum when transferrin is fully iron saturated (Batey et al., 
1980). However, recent work has shown the existence of NTBI in some 
conditions even when transferrin is not fully saturated (Breuer et al., 2000a, 
Valk and Marx, 2000). 
2.1.2 Non-transferrin-bound iron and Type 2 diabetes 
The first study which reported the presence of NTBI in uncontrolled Type 2 
diabetic patients was carried out by Lee et al. (2006); this study also found 
that the existence of NTBI in diabetes patients even when transferrin was not 
fully saturated due to the persistent high plasma glucose levels causing an 
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increase in the rate of protein glycation reactions (Armbruster, 1987, Garlick 
and Mazer, 1983). The initial and end stages of glycation of proteins can 
significantly impair the function and structure of extracellular proteins such as 
Hb, albumin and transferrin (Singh et al., 2001). AGEs are known to bind with 
higher amounts of transitional metals such as iron and extract more iron from 
stable iron compounds thereby increasing the redox activity of AGEs (Qian et 
al., 1998), which act as Fenton reagents, and catalyse the production of ROS 
particularly hydroxyl radicals. This causes increased oxidative stress, which 
is widely accepted as contributing towards the development and progression 
of diabetes, and its complications such as atherosclerosis. Uncontrolled 
T2DM is characterized by autooxidation; this process leads to generation of 
ROS, which can also release the iron from stable forms such as ferritin and 
haem, which exacerbates the condition (Chau, 2000) (Figure 2.1). 
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Figure 2.1 Flow diagram showing the release of NTBI in uncontrolled Type 2 diabetes mellitus 
2.1.3 Non-transferrin-bound iron and oxidative stress 
Under normal physiological conditions the amount of redox-active iron is 
tightly controlled; the transferrin (Tf) molecule is adapted to hold iron safely 
and prevent its participation in redox reactions that could give rise to ROS 
(Gutteridge and Halliwell, 2000). NTBI is associated with the generation of 
hydroxyl radicals and lipid peroxidation which lead to oxidative stress 
(Gutteridge et al., 1985, Kartikasari et al., 2006), but higher NTBI 
concentrations do not always correlate with lipid peroxidation (Dani et al., 
2004, Driss et al., 2005, Scheiber-Mojdehkar et al., 2004). Walter et al. 
(Walter et al., 2006) studied the relationship between biomarkers of oxidative 
damage and NTBI in both thalassaemia and sickle cell disease (SCD), and 
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noticed that they are increased in both of these conditions. NTBI 
concentration is inversely related to plasma vitamin E concentration in SCD 
(Marwah et al., 2001) and patients with idiopathic haemochromatosis have a 
considerable ascorbate deficiency (Young et al., 1994). Bongiorno et al. 
(2011) observed that thalassaemia patients, who are continuously exposed 
to iron-induced oxidative injury through repeated blood transfusion, have 
altered patterns of all serum antioxidants. Published data on serum NTBI 
levels in obesity and T2DM are scarce. Obesity may increase hepcidin 
production which in turn lowers circulating iron levels by decreasing intestinal 
absorption and decreasing release from macrophages (Means Jr, 2004). 
2.1.4 Non-transferrin-bound iron and atherosclerosis 
The potential relationship between iron and heart disease arose from the 
observation that the incidence of this disease is much higher in men and 
postmenopausal women than premenopausal women (Sullivan, 1981). Data 
obtained from epidemiological and experimental work may strengthen the 
potential role of iron in atherosclerosis (De Valk and Marx, 1999). Excess 
body iron is associated with increased cardiovascular disease risk, possibly 
via NTBI mediated enhancement of inflammation and oxidation of low density 
lipoprotein (LDL). The relationship between iron and atherosclerosis is 
complex, and remains contradictory. It is hypothesized that free iron-
catalyzed oxidation of LDL which may lead to injury of the arterial wall and 
hence, initiate atherosclerosis (Chisolm and Steinberg, 2000). Oxidized LDL 
is pro-inflammatory; it attracts monocytes via induction of chemokines, and 
up regulated scavenger receptor expression on macrophages. The 
scavenger receptors subsequently recognize oxidized LDL and mediate its 
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uptake into the cells. This process leads to lipid accumulation in the vessel 
wall and fatty streak formation, the beginning of atherosclerosis (Steinberg et 
al., 1989). 
The association between NTBI and increased LDL oxidation has not been 
observed in vivo in subjects with the C282Y mutation of the 
haemochromatosis gene (Tits et al., 2006). Also NTBI was not associated 
with in vitro LDL oxidation in a healthy population study (Derstine et al., 2003). 
In a cross-sectional haemochromatosis screening study, NTBI showed a 
relationship with intercellular adhesion molecule-1 (ICAM-1), a critical 
molecule in recruiting monocytes to the extravascular compartment and 
initiating atherosclerosis (van Tits et al., 2007). A similar study also found that 
NTBI was associated with ICAM-1, vascular adhesion molecule-1 (VAM-1) 
and E-selectin expression, and increased cellular stress (Kartikasari et al., 
2006). 
2.2 Stability of biomarkers in plasma samples during sample 
preparation and after storage 
In clinical research the stability of biomarkers in serum or plasma samples 
during sample preparation and after storage is of great importance (Lippi et 
al., 2011). In clinical studies it is usually essential to store samples because 
of several potential difficulties such as the requirement to collect samples 
over a period of time, plus funding and instrument problems. For example, in 
the present study the samples were stored for up to two years until all the 
analysis was completed. For this reason, some understanding of the 
influence of storage on the parameters measured would be useful. 
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In this study the effect of storage, freezing and thawing of plasma sample on 
a biomarker of oxidative stress (MDA) was examined using tubes treated with 
different anticoagulants. Other parameters were either previously examined 
in our laboratory or the manufacturer’s instructions contained information 
about the conditions for sample storage. 
2.2.1 Background information about MDA 
Cells produce reactive oxygen species (ROS) as part of metabolic activity. 
Over production of these species may result in oxidative stress, and this 
oxidative stress has been implicated in the etiopathogenesis of a number of 
diseases and clinical conditions. These include atherosclerosis, cancer and 
other chronic diseases, and oxidative stress may also play an important role 
in the aging process (Sastre et al., 2000). Many biological molecules are 
targets of oxidative damage but lipids and lipoproteins are the most 
susceptible classes of these biomolecules. Lipid peroxidation occurs when a 
strong oxidant is generated close to the cell membrane. This, after 
combination with oxygen through peroxyl radical formation, leads to lipid 
hydroperoxidation with associated membrane disruption and formation of a 
great variety of compounds which including highly cytotoxic products such as 
malondialdehyde (Ceconi et al., 2003). At neutral pH the enolate anion form 
of malondialdehyde has relatively low chemical reactivity (Esterbauer et al., 
1991). Nevertheless, several different adducts are formed between the 
enolate anion form of MDA and nucleic acid bases such as deoxyadenosine, 
deoxycytidine and deoxyguanosine (Marnett, 1999). The major adduct is a 
pyrimidopurinone. Other work has reported that deoxyadenosine is the first 
endogenous DNA lesion found to be a target of nucleotide excision repair 
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enzymes, and may be a major endogenous DNA adduct that significantly 
contributes to cancer (Wang et al., 2004). MDA also reacts in vivo with 
primary amines and including lysine. 
2.2.2 Sources of malondialdehyde and health aspects 
MDA is a highly reactive organic compound (dialdehyde of malonic acid) with 
the formula CH2(CHO)2. It is produced as a by-product of polyunsaturated 
fatty acid peroxidation (Janero, 1990), and also during prostaglandin and 
thromboxane synthesis (Shimizu et al., 1981, McMillan et al., 1978). MDA 
can be found in most biological samples including foodstuffs, serum, plasma, 
tissues and urine, as a result of lipid peroxidation. It was suggested that the 
bulk of MDA in human plasma is bound to protein; this would explain the low 
levels of MDA in plasma as measured under standard assay conditions 
(Lefèvre et al., 1996). The concentration of MDA in both men and women 
increases with age, which may be relevant to the increasing prevalence of 
atherosclerosis with age (Rumley et al., 2004). The level of MDA has been 
reported to be high in diabetes, hepatitis C infection and HIV seropositive 
children (Higueras et al., 1994, Jareño et al., 1998, Losada and Alio, 1997). It 
has also been reported that MDA derived from lipid peroxidation in 
chondrocytes mediates oxidation of cartilage collagens and leads to 
alteration of biochemical and biophysical properties of cartilage collagen 
fibrils, making them prone to degradation and initiating the changes observed 
in aging and osteoarthritis (Tiku et al., 2003). The determination of MDA-
modified LDL was reported as a useful marker for identifying patients 
susceptible to coronary heart disease (Holvoet et al., 1999). MDA is found in 
the atherosclerotic plaque deposits promoted by diabetes (Kume et al., 1995). 
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2.2.3 Effect of storage of plasma on TBARS 
Malondialdehyde (MDA) is widely used as oxidative stress biomarker in 
biomedical research (Carone et al., 1993, Requena et al., 1996). During 
clinical studies this parameter is estimated mostly in stored blood/plasma 
samples (Carbonneau et al., 1991). The malondialdehyde concentration in 
plasma increases linearly with time during storage at 4 °C when the sample 
is exposed to air, but the storage of samples treated with antioxidants such 
as EDTA and GSH effectively suppresses this process (Lee, 1980). Another 
study stated that storage of plasma at -20 °C was suitable for only one week 
after which the concentration of MDA decreased (Carbonneau et al., 1991). 
2.3 Aims of the study 
Because few data have been published on serum NTBI levels in T2MD and 
obesity this study aimed to establish: 
1. if higher levels of NTBI are present in patients with Type 2 diabetes 
and obese subjects compared with a control group; 
2. if there a relationship between NTBI and common iron-related 
biomarkers; 
3. if there any correlation between NTBI and inflammatory biomarkers; 
4. if there a relationship between NTBI and oxidative stress biomarkers 
in all groups; 
5. if there a relationship between NTBI and biomarkers of atherosclerosis; 
and 
6. if there is any correlation with age across all parameters in this study. 
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Other objectives were: 
1. to examine the effect of storage at -80 °C, and repeated freezing and 
thawing of samples on the measured level of MDA in human plasma; 
2. to compare the effects of two anticoagulants, EDTA and lithium 
heparin, used during the isolation of plasma, on the measured level of 
MDA; and 
3. to determine the effect of GSH addition on limiting changes in the 
measured level of MDA. 
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2.4. Materials and Methods 
2.4.1 Materials 
Light magnesium carbonate, disodium EDTA, metaphosphoric acid, 
acetonitrile, 95% ethanol, KCl, KH2PO4, NaCl, Na2HPO4•12H2O, FeCl3•6H2O, 
Tris(2-carboxyethyl) phosphine hydrochloride (TCEP), phosphoric acid, 1,2-
dimethyl-3-hydroxy-4(1H)-pyridinone (DHP), nitrilotriacetic acid (NTA), 
butylated hydroxytoluene, thiobarbituric acid and all other laboratory reagents 
were obtained from Sigma-Aldrich (Poole, UK). Amicon Ultra filter units (30 
kDa cut off) were purchased form Merck-Millipore (Fisher Scientific 
Loughborough, UK). 
2.4.2 Venesection and sample handling 
The study was conducted after obtaining appropriate ethics committee 
approval. Signed consent forms (Appendix 8) were obtained for subjects and 
controls before the study to confirm their willingness to take part. All subjects 
were anonymised by numbering them and numbering the blood samples 
taken from them. Blood samples were obtained from 73 subjects: 28 were 
Type 2 diabetics aged >40 y, all patients recruited from Derriford Hospital; 17 
were obese non diabetic subjects aged >40 y; and 28 healthy subjects 
aged >40 y were enrolled as controls. Medical history of alcohol consumption, 
smoking and medications were prime considerations in questionnaire forms 
(Appendix 9). Anthropometric indices were measured which included BMI, 
body fat percentage and waist to hip ratio (Appendix 10). Phlebotomy of each 
subject was conducted using 3 × 4 ml Vacutainers (Becton Dickinson, 
Plymouth, UK), one with lithium heparin as anticoagulant, one with EDTA as 
anticoagulant and one plain tube for serum. Blood samples in EDTA and 
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lithium heparin tubes were centrifuged at 1,000 × g for 5 min to provide 
plasma; the blood in the plain tubes was centrifuged after 30 min at room 
temperature, and then plasma and serum were stored at -80 °C prior to 
biochemical analysis. From the EDTA plasma 400 µl were removed and 
added to 400 µl of 10% metaphosphoric acid (MPA) containing 2 mM EDTA 
and then centrifuged at 20,000 × g at 4 °C for 10 min. The supernatant was 
removed and stored at -80 °C prior to the measurement of ascorbate and 
urate. 
2.4.3 Phlebotomy and experimental design for the effect of glutathione 
on the level of malondialdehyde in stored human plasma 
Blood samples were obtained from six healthy volunteers. Phlebotomy was 
conducted using 4 ml Vacutainers, one anticoagulated with lithium heparin 
and another with EDTA. The blood samples were centrifuged at 1,000 × g for 
5 min to provide plasma. Each plasma sample was divided into two parts; 
one part was spiked with 1 mM GSH, and the other without GSH. After this 
all samples were divided into six × 100 µl aliquots and stored at -80 °C before 
measurement of MDA levels on different days as described below. At various 
points during the experiment samples were kept at room temperature until all 
the plasma had thawed and then they were stored on ice until the analysis 
was complete (up to 8 h), after which they were stored again at -80 °C. 
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2.4.4 Determination of serum iron 
Different methods have been used to measure the concentration of iron. The 
method used here was adapted from Bothwell et al. (1971). 
2.4.4.1 Principle of method 
Ferric iron is dissociated from its carrier protein, transferrin, and other iron 
binding proteins in an acidic medium and simultaneously reduced to the 
ferrous form. The ferrous iron forms a complex with the chromogen ferene, 3-
(2-pyridyl-5-6-bis-[2-(5-furyl sulfonic acid)]-1,2,4-triazine, a sensitive and low-
cost iron indicator (Pieroni et al., 2001), to produce a blue chromophore 
which absorbs maximally at 593 nm. 
2.4.4.2 Method 
Protein precipitation solution (400 μl of 0.6 M TCA and 0.4 M thioglycolic acid 
in 1 M HCl) was added to 400 µl of sample, iron standards (10 to 100 μM 
made up in PBS) and blanks. These were mixed thoroughly for 1 min, and 
then heated at 56 °C for 15 min in a water bath. Samples were then 
centrifuged at 1,000 × g for 5 min, and 500 μl of the resulting supernatant 
were removed and added to 500 μl of 0.5 mM ferene solution. After 
incubation for 5 min at room temperature the absorbance was read at 593 
nm using a CamSpec M302 UV/vis spectrophotometer (Cambridge, UK). 
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Figure 2.2 Standard curve for detection of iron (as FeCl3) using the method of Bothwell et al. 
(1971). 
2.4.5 Determination of total iron-binding capacity (TIBC) of plasma 
samples 
2.4.5.1 Principle of method 
A colorimetric method was used to determine the total iron-binding capacity 
(TIBC) in plasma with LiH anticoagulant or in serum samples. An excess of 
iron was added to the serum to saturate the transferrin. The unbound iron 
was then precipitated with basic magnesium carbonate, and after 
centrifugation the iron in the supernatant was determined. The procedure 
was adapted from the method of Ramsay (1957). 
2.4.5.2 Method 
To 350 µl of the serum or heparinised plasma were added 350 µl of iron 
saturating solution (100 μM ferric chloride dissolved in 5 mM HCl, made up 
from a 1:10 dilution of a stock ferric chloride solution of 1 mM in 50 mM HCl). 
This was mixed and incubated for 5 min at room temperature. To this were 
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added 35 mg of light magnesium carbonate. This was agitated frequently and 
thoroughly over 30-60 min, and then centrifuged at 1,000 × g for 5 min. The 
supernatant was removed and re-centrifuged at 1,000 × g for 5 min. The 
resulting supernatant was removed and analysed for iron as in the 
measurement of total iron (Section 2.4.4). 
2.4.6 Unsaturated iron binding capacity (UIBC) 
The UIBC was determined by subtracting the serum iron from the TIBC, i.e. 
TIBC - total serum iron = UIBC. 
2.4.7 Transferrin saturation (TSAT) 
Transferrin saturation is given as a percentage. It is the ratio of serum iron to 
total iron-binding capacity (Beilby et al., 1992). It is a more sensitive and 
specific indicator of iron status than serum iron alone (Bainton and Finch, 
1964). 
2.4.8 Non-transferrin-bound iron (NTBI) 
NTBI was measured using a slight modification of the HPLC methods of 
Kime et al. (1996b) and Paffetti et al. (2006). Plasma (300 µl) was mixed with 
30 µl of 0.8 mM NTA which removes and complexes all low molecular weight 
iron, and iron non-specifically bound to serum proteins. The mixture was 
incubated at room temperature for 20 min, and the placed in 30 kDa Amicon 
ultrafilters (Millipore) to separate the chelated NTBI from transferrin-bound 
iron. The filters were centrifuged at 13,000 × g for 30 min at 4 °C. The 
ultrafiltrate was removed and the volume measured. For every 100 µl, 10 µl 
of 50 mM 1,2-dimethyl-3-hydroxy-4(1H)-pyridinone (DHP) was added. Finally 
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the sample was incubated for 5 min at room temperature before injection into 
the HPLC system (20 μl sample loop). The mobile phase consisted of 5 mM 
PIPES buffer, pH 7.0, containing 3.5 mM 3-hydroxy-1-propyl-2-methyl-
pyridon-4-one and 5% acetonitrile. The column was a PEEK-lined 100 mm × 
5 mm C18 column (Hichrom, Reading, UK). All tubing was composed of 
PEEK. The mobile phase was pumped at a flow rate of 1 ml min-1 using a 
Dionex pump (P580). The absorbance of the iron-chromophore complex was 
determined using a Dionex UV/VIS detector (UVD170S) at a wavelength of 
450 nm and the chromatography conducted using Chromeleon software 
(Thermo Fisher Scientific, Loughborough, UK). The concentration of NTBI 
was computed from blanks and standards taken through the whole procedure 
along with each batch of samples. This method was validated in our 
laboratory (White, 2012) (see Appendix 7). Chromatograms of a standard 
and a plasma sample for NTBI are shown in Figure 2.3. 
  
  90  
 
 
 
Figure 2.3 Representative chromatograms showing (A) 5 µM NTBI standard and (B) 
NTBI in a plasma sample. 
2.4.9 Estimation of total antioxidant activity 
Total antioxidant activity was measured using the ‘Ferric-Reducing Ability of 
Plasma’ (FRAP) assay of Benzie and Strain (1996) with slight modifications. 
2.4.9.1 Ferric-Reducing Ability of Plasma (FRAP) assay 
This assay depends on the reduction of ferric tripyridyltriazine (Fe3+ TPTZ) to 
ferrous tripyridyltriazine (Fe2+ TPTZ) at low pH, producing an intense purple 
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colour which can be measured at 595 nm. The colour intensity depends on 
ability of components in the plasma to reduce Fe3+ TPTZ to Fe2+ TPTZ. 
2.4.9.2 Preparation of FRAP reagent 
FRAP reagent was prepared by adding 3.4 ml of 300 mM acetic acid to 100 
ml of water and then adjusting the pH to 3.6 by adding 2 mM NaOH. The 
solution was then made up to 250 ml with water, and then 0.081 g of FeCl3 
were added, followed by 0.039 g of TPTZ which had been dissolved in dilute 
acid (10% hydrochloric acid). The FRAP reagent was stored for up to two 
weeks at 4 °C. 
2.4.9.3 Procedure 
The samples, standards and FRAP reagent were warmed to 25 °C and then 
10 μl of sample or the standard were added to 260 μl of FRAP reagent. 
Water was used as a blank. The absorbance at 595 nm was measured for 45 
min in a plate reader (Versamax, Molecular Devices, Sunnyvale, CA). The 
measurements were compared to a standard curve prepared using 0-2 mM 
FeSO4•7H2O. 
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2.4.10 Determination of total and reduced ascorbate 
Total and oxidised ascorbate (DHA) were measured by the method described 
by Sato et al. (2009). Two (90 µl) aliquots of the 10% metaphosphoric acid 
(MPA) extract (Section 2.4.2) were removed from the stored extract. One 
was for the measurement of reduced ascorbate and the other for 
measurement of total ascorbate. For the measurement of total ascorbate, 10 
µl of 350 mM Tris (2-carboxyethyl) phosphine hydrochloride in 5% MPA, 
containing 1 mM EDTA, were added, and the tubes were capped and the 
contents mixed well on a vortex mixer. The mixture was incubated for 20 min 
at room temperature (this is to reduce the oxidised dehydroascorbate back to 
ascorbate). Finally 200 µl of 5% MPA containing 1 mM EDTA were added to 
the mixture, which was injected into the HPLC system. The other 90 µl of 
supernatant was mixed with 10 µl of 5% MPA containing 1 mM of EDTA, and 
then 200 µl of 5% MPA containing 1 mM of EDTA was added. The mixture 
was mixed well on a vortex mixer before injection into the HPLC system. The 
HPLC system consisted of a 150 mm × 4.6 mm ACE 5 AQ C18 column 
(Hichrom, Reading, UK), a Milton Roy Constametric pump (Milton Roy, 
Sunderland, UK) coupled to a BAS LCD40 electrochemical detector (BASi, 
West Lafayette, IN, USA) set at a voltage of +0.6 V. The mobile phase 
consisted of 50 mM potassium phosphate buffer containing 0.54 mM EDTA 
and 2% methanol at pH 2.8. This was pumped at a rate of 1.0 ml min-1.  
This method is in accordance with previous stability studies where MPA-
stabilized plasma samples had been stored at -70 °C from 2 weeks to over 
10 years (Chung et al., 2001). A standard curve for total ascorbate is shown 
in Figure 2.4. 
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Figure 2.4 Standard curve for the detection of total ascorbate. Standards were 
prepared in PBS. The method used was based on that of Mitton and Trevithick 
(1994). 
2.4.11 Thiobarbituric acid reactive substances (TBARS) assay 
The TBA assay is one of the most frequently used methods for the 
measurement of MDA and other products of lipid peroxidation in fatty acids, 
food products, membrane systems, plasma and tissue samples (Halliwell and 
Gutteridge 1990a; Draper and Hadley 1990). The general procedure simply 
involves heating the material under test with TBA under acidic conditions and 
measuring the absorbance of the resulting pink chromogen, either 
spectrophotometrically or using High Performance Liquid Chromatography 
(HPLC). The chromogen, which forms by the condensation of two molecules 
of TBA and one molecule of MDA, absorbs light at 532 nm and fluoresces at 
553 nm. 
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2.4.11.1 Measurement of malondialdehyde in plasma 
MDA is routinely measured by reacting it with thiobarbituric acid (TBA) which, 
under appropriate conditions, gives a pink coloured product that absorbs light 
at 532 nm. The method of Agarwal and Chase (2002) was followed. Plasma 
(50 µl) or standard (up to 2 µM) or blank was mixed with 50 µl of BHT (0.05% 
in 95% ethanol), 400 µl of phosphoric acid (0.44 M) and 100 µl of TBA (42 
mM). The tubes were capped and the contents mixed well on a vortex mixer. 
All tubes were heated for 1 h at 100 °C in a dry block, and then were 
removed and placed on ice to cool. Butan-1-ol (300 µl) was added and mixed 
well using the vortex mixer. The mixture was centrifuged for 5 min at 13,000 
× g to separate the aqueous and butanol phases. Two hundred microliters of 
the butanol extract were removed carefully and placed in tubes ready for 
injection directly into a Dionex Ultimate 3000 HPLC system (Thermo Fisher 
Scientific) comprising an Ultimate 3000 pump and Ultimate 3000 
fluorescence detector. Chromatography was conducted using a 100 mm × 
4.6 mm Hichrom C18 column, protected by a guard column of the same resin 
and a 2 μm inline filter (Hichrom). Chromatography was controlled using 
Chromeleon software (version 6.8) (Thermo Fisher Scientific). The mobile 
phase (50 mM potassium phosphate/methanol 80:20 v/v, pH 6.8) was 
pumped at a rate of 1.0 ml min-1. MDA was detected using an excitation 
wavelength of 515 nm and an emission wavelength of 553 nm. 
2.4.11.2 Interference with the method 
Determination of MDA, which is the most abundant of lipid peroxidation 
products, is a convenient and sensitive method for quantitative estimation of 
lipid peroxide concentration in many types of samples including drugs, food 
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products and human and animal tissues (Lykkesfeldt, 2007). However, 
although this technique is easy to use (mainly the spectrophotometric assay), 
its use to assess oxidative stress status in human fluids is problematic for 
several reasons: (a) aldehydes other than MDA may react with TBA to 
produce a compound that absorbs light in the same wavelength range as 
MDA; (b) decomposition of lipid peroxides during the test itself may mask the 
actual MDA content in the fluid before testing; (c) the presence or absence of 
metal ions or other undefined radicals may affect the rate of this 
decomposition, making reliability a problem; and (d) most TBARS, including 
MDA, in human body fluids are not specific products of lipid peroxidation and 
may produce false-positive results (Halliwell and Whiteman, 2004). Several 
compounds including bile pigments, carbohydrates and amino acids have 
also been found to react with TBA (Esterbauer et al. 1982; Knight et al. 1988) 
and generate interfering chromogen. Use of HPLC has enabled the 
separation of these compounds from the true MDA-TBA adduct, thereby 
increasing the specificity of the assay (Volpi and Tarugi, 1998). 
Several precautions were taken in order to minimize interference with this 
assay. These included collecting blood samples in tubes containing EDTA 
and LiH, and rejecting any samples showing signs of haemolysis. Since 
platelets are sources of lipid peroxides, care was taken to avoid the ‘buffy 
coat’ layer whilst separating the plasma from the red cells. Finally, the purest 
source of HPLC grade water (Elga-Purelab Q7/15) was sought and used for 
the preparation of all samples and solutions. 
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2.4.12 Background information on human E-selectin 
E-selectin (Endothelial Leukocyte Adhesion Molecule-1, ELAM-1) is a 
member of the selectin family of adhesion molecules (Hogg, 1992, Lasky, 
1991). Together with LECAM-1 (L-selectin) and GMP-140 (P-selectin), E-
selectin mediates the initial interactions of leukocytes and platelets with 
endothelial cells (Shimizu et al., 1991, von Andrian et al., 1992). E-selectin 
belongs to the single-chain glycoprotein selectin family which includes E, L 
and P-selectins that mediate the initial step of leukocyte recruitment in the 
inflammatory process. E-selectin is a 58.6 kDa protein containing 535 amino 
acid residues. It is synthesised by endothelial cells in response to cytokines 
including interleukin-1 beta (IL-1β) and TNF-α, and to bacterial 
lipopolysaccharide (Bevilacqua et al., 1989, Suárez et al., 2010). E-selectin 
expression begins after 1-2 h and shows peak expression after 3-4 h, and 
decay after 16-24 h, in response to activation. E-selectin ligands, expressed 
on neutrophils, monocytes and a subset of memory T cells are sialylated, 
fucosylated molecules which bind to the lectin domain of E-selectin. 
Immunocytochemical techniques have demonstrated the expression of E-
selectin on healthy and diseased tissue. 
E-selectin mediates the attachment of flowing leukocytes to the blood vessel 
wall during inflammation by binding to E-selectin ligands on leukocytes 
(Vestweber and Blanks, 1999). These interactions are labile and permit 
leukocytes to roll along the vascular endothelium in the direction of blood flow. 
This initial interaction is followed by a stronger interaction involving ICAM-1 
and VCAM-1 that leads eventually to extravasation of the leukocytes through 
the blood vessel wall into the extracellular matrix tissue. ELISA techniques 
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have shown that detectable levels of soluble E-selectin are present in the 
biological fluids of apparently normal individuals. Furthermore, a number of 
studies have reported that levels of E-selectin may be elevated in subjects 
with a variety of pathological conditions including kidney inflammation, 
rheumatoid arthritis, hypertension, dyslipidaemia, diabetes, obesity, and 
smoking (Roldán et al., 2003, Matsumoto et al., 2002b). Several studies 
reported that E-selectin levels are elevated in patients with T2DM (Boulbou et 
al., 2004, Pasini et al., 1995). Up-regulation of endothelial adhesion 
molecules, including endothelial-leukocyte adhesion molecule (E-selectin), 
intercellular cell adhesion molecule-1 (ICAM-1), and vascular cell adhesion 
molecule-1 (VCAM-1), play a pivotal role in the earliest phases of 
atherosclerosis by mediating the binding and subsequent recruitment of 
monocytes into arterial intima.  
2.4.12.1 Principle of measurement of human E-selectin by enzyme-
linked immunosorbent assay (ELISA) 
The human E-selectin ELISA kit is based on standard sandwich enzyme-
linked immunosorbent assay technology. Human E-selectin specific 
polyclonal antibodies are precoated onto 96-well plates, and the human 
specific detection monoclonal antibodies are biotinylated. The test samples 
and biotinylated detection antibodies are added to the wells and then 
followed by washing with PBS or TBS buffer. Avidin-biotin-horseradish 
peroxidase (HRP) conjugate is added and unbound conjugate washed away 
with PBS. The HRP substrate TMB is used to visualize the bound HRP via 
the peroxidase enzymatic activity. The oxidation of TMB by H2O2 is catalyzed 
by HRP to produce a blue coloured product that changes into yellow after 
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adding an acidic stop solution. The absorbance of the yellow product is 
proportional to the amount of human E-selectin in the sample captured on the 
plate. 
2.4.12.2 Procedure 
The assay was carried out according to the manufacturer’s instructions 
(Biorbyt, UK). Briefly, 100 μl of standard, control, and samples were added 
per well, and the plate was then covered and incubated for 90 min at 37 °C. 
The liquid in each well was removed followed by incubation with 100 μl of 
biotinylated anti-human E-selectin antibody for 60 min at 37 °C. The plate 
was then washed three times using 0.01 M phosphate-buffered saline (PBS) 
and each time the buffer was left in the well for 1 min to wash. The liquid was 
discarded each time and the plate was blotted onto adsorbent material. After 
that, 100 µl of prepared avidin-biotin-peroxidase complex (ABC) working 
solution were added into each well and the plate was incubated for 30 min at 
37 °C. The plate was washed five times with 0.01 M PBS, the washing 
solution being left for 1-2 min each time before being discarded. The plate 
was then blotted onto absorbent material after which 90 µl of TMB were 
added to each well, which was then incubated for 8-12 min at 37 °C. Finally 
100 µl of TMP stop solution were added to each well. The absorbance of the 
contents of each well was determined within 30 min after adding the stop 
solution, using a micro plate reader (Versamax, Molecular Devices, 
Sunnyvale, CA) set to 450 nm. The detection range of the kit was 62.5-4000 
pg ml-1. A standard curve for E-selectin is shown in Figure 2.5. 
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Figure 2.5 ELISA calibration curve for Human E-selectin. The curve is a 4-
parameter fit to the data. 
2.4.13 C-reactive protein (CRP) structure and function 
CRP was first discovered in 1930 in the sera of patients acutely infected with 
pneumococcal pneumonia, and named after its reactivity with polysaccharide 
C from Streptococcus pneumonia (Tillett and Francis Jr, 1930). It is a 
calcium-binding pentameric protein consisting of five identical non-
glycosylated 23 kDa polypeptide subunits. 
CRP is an acute phase reactant, increasing 1000-fold in response to infection, 
ischaemia, trauma and burns (Westhuyzen and Healy, 2000). In 
inflammatory conditions it is produced predominantly in the liver in response 
to interleukin (IL)-6, which is one of several cytokines released by activated 
leukocytes and smooth muscle cells in atherosclerotic plaques within hours 
of an injury or in the presence of inflammation (Li and Fang, 2004). However, 
adipose tissue is also a significant source of IL-6, which partially explains the 
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strong correlation between obesity and CRP (Yudkin et al., 2000). CRP may 
also be produced away from the liver by vascular sources including cells 
residing in atherosclerotic plaques (Lind, 2003). Its levels remain elevated 
throughout the acute phase response until normal tissue function and 
structure are restored. Normal CRP levels are generally defined as being < 
10 mg l-1 and healthy individuals generally have < 1 mg l-1 (Armani and 
Becker, 2005). 
The role of CRP is not fully understood, but two functional properties of CRP 
including the ability to activate the complement system (Volanakis, 1982) 
through the classical complement pathway, and the ability to modulate the 
function of phagocytic cells (Li and Fang, 2004) have been demonstrated (Li 
and Fang, 2004). CRP is also known to bind in a wide variety of substances 
such as microbial polysaccharides and damaged cell membranes. 
2.4.13.1 Storage of samples 
CRP is stable during storage both in whole blood for a short period and in 
serum or plasma for longer times. Samples containing CRP should be stored 
at 4 °C for short periods of time or at -70 °C for longer periods (Aziz et al., 
2003). Comparable results were obtained by Ishikawa et al. (2007) for 
plasma (heparin and EDTA treated) and serum samples, and levels were 
unaffected by delays in sample processing and storage temperature. They 
also found that CRP levels were unaffected by up to seven freeze-thaw 
cycles (Ishikawa et al., 2007). 
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2.4.13.2 High sensitivity C-reactive protein (hs-CRP) 
CRP has been assayed for many years as a non-specific marker of acute 
inflammatory diseases, infections, neoplastic diseases, and other conditions 
where inflammation occurs. It is still assayed in this manner as a marker of 
inflammation by immunoassay methods that are sensitive to concentrations 
of 5-20 mg l-1. Atherosclerosis is a subclinical chronic inflammatory condition. 
Highly sensitive measurements of CRP have been developed to detect this 
protein at lower levels (0.5-10.0 mg l-1). This assay is referred to as high 
sensitivity C-reactive protein (hs-CRP), and there are commercially available 
kits for this purpose that provide similar results in stored, fresh or frozen 
plasma (Koenig, 2005). 
2.4.13.3 High sensitivity C-reactive protein as a biomarker 
atherosclerosis 
CRP is an important inflammatory biomarker and a risk factor for 
cardiovascular disease. Much evidence indicates that the CRP contributes to 
the atherosclerosis development process (Epstein and Ross, 1999). An 
inflammatory process plays a central role in the initiation, progression, and 
the final steps of this pathology as vulnerable plaques rupture. 
2.4.13.4 Procedure 
The assay was carried out according to the manufacturer’s instructions 
(Biorbyt, UK). To each well of a 96 well plate 100 µl of standard or samples 
were added and incubated at room temperature for 1 h. The contents of the 
plate were then discarded and the plate was tapped on a clean paper towel 
to remove residual solution in each well, after which it was washed three 
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times with washing buffer (300 µl). The plate was then tapped with paper 
towel to remove residual wash buffer. This was followed by the addition of 
100 µl of detection antibody solution to the plate which was then incubated at 
room temperature for 1 h. Again the contents of plate were discarded and it 
was washed with washing buffer 4 times, after which it was also tapped with 
clean paper towel. Then 100 µl of substrate solution were added and 
incubated for 15 min in the dark, after which 100 µl of stop solution were 
added and the contents of the plate mixed gently The absorbance of the 
contents of each well was determined immediately after adding the stop 
solution, using a Versamax micro plate reader (Molecular Devices, 
Sunnyvale, CA) set to 450 nm. A standard curve for CRP is shown in Figure 
2.6. 
 
Figure 2.6 ELISA calibration curve for Human C-RP. The curve is a 4-parameter fit  
to the data. 
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2.4.14 Soluble transferrin receptor 
Many parameters have been used to indicate the body iron status in clinical 
studies such as Hb, serum iron, TIBC, transferrin saturation and serum 
ferritin. Serum ferritin and serum iron are the most commonly used markers 
of iron status (Thomas and Thomas, 2002). Unfortunately, some of these 
parameters are influenced by a number of non-related conditions, e.g. acute 
phase reactions, which may complicate the clinical interpretation of their 
results and create an inaccurate picture of the body iron status. 
Recently, soluble transferrin receptor concentration has been recognized as 
a useful indicator of iron status. Soluble transferrin receptor is a soluble 
protein that is produced by proteolytic cleavage of the membrane-bound 
transferrin receptor. Both the expression of transferrin receptor on the cell 
surface and its intracellular concentration are inversely related to intracellular 
iron concentration (Baynes and Cook, 1996). 
Soluble transferrin receptor (sTfR) reflects the number of iron receptors 
expressed on cell membranes and is raised once tissue iron starts to become 
limited (Koulaouzidis et al., 2009). Soluble transferrin receptor results from 
the proteolysis of TfR at a specific site in the extracellular domain, producing 
monomers that are measurable in plasma and serum (Shih et al., 1990). 
Major advantages of measuring serum transferrin receptors involve the fact 
that the assay is not significantly affected by infection or inflammatory 
processes, and it does not vary with age, gender or pregnancy (Kohgo et al., 
1986, Carriaga et al., 1991). However, sTfR levels may be elevated when 
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there is increased red cell production, turnover, or both, such as in the case 
of haemolytic anaemia (Kohgo et al., 1987). 
2.4.14.1 Principle of test 
According to manufacturer’s instructions for the human sTfR ELISA kit 
(BioVendor, UK), standards, quality controls and samples are incubated in 
microplate wells pre-coated with monoclonal anti-human sTfR antibody. After 
90 min incubation and washing, monoclonal anti-human sTfR antibody 
conjugated with horseradish peroxidase (HRP) is added to the wells and 
incubated for 60 min with captured. Following another washing step, the 
remaining HRP conjugate is allowed to react with the substrate solution 
(TMB). The reaction is stopped by addition of acidic solution and the 
absorbance of the resulting yellow product is measured. The absorbance is 
proportional to the concentration of sTfR. A standard curve is constructed by 
plotting absorbance values against concentrations of standards, and 
concentrations of unknown samples are determined using this standard 
curve. 
2.4.14.2 Procedure 
To each well of a 96 well plate 100 µl of diluted standard, quality control, 
dilution buffer (blank) and sample were added. The plate was incubated at 
25-30 °C for 1 h. After that the plate was washed 3 times with 350 µl of 
washing solution and after the final wash the plate was inverted and tapped 
strongly against a paper towel. Then 100 µl of conjugate solution were added 
to each well and the plate was incubated at 25-30 °C for 1 h. Then the wells 
were washed 3 times with 350 µl of washing buffer and after the final wash 
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the plate was inverted and tapped strongly against a paper towel. Then 100 
µl of substrate solution was added to plate and the plate was incubated for 
10 min at room temperature after the plate was covered with aluminium foil to 
avoid direct sunlight. After that the colour development was stopped by 
adding 100 µl of stop solution the absorbance was determined by using a 
Versamax plate reader (Molecular Devices, Sunnyvale, CA) set to 450 nm. 
2.4.14.3 Stability of sTfR 
Previous experiments (Erhardt et al., 2004) have shown that undiluted serum 
samples containing sTfR could be thawed and refrozen a few times without 
any change in analyte concentration. Diluted serum samples also appear to 
be stable to freeze-thawing. A standard curve for sTfR is shown in Figure 2.7. 
 
Figure 2.7 ELISA calibration curve for Human sTfR. The curve is a 4-parameter fit 
to the data. 
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2.5 Statistical analysis 
Conventional statistical methods were used to calculate the means, standard 
deviation (SD) and standard error (SE). The data were analysed using a 
General Linear Model (GLM) with subject age as a quantitative factor and 
subject group as a qualitative factor. In all cases there was no significant 
interaction between subject age and subject group, so the interaction term 
was omitted from the model. This was followed by Tukey’s test. This allowed 
differences between the groups to be distinguished from the any relationship 
between parameters and subject age. Correlation among the different 
parameters was also investigated. All statistical analysis was carried out 
using StatGraphics version 16.2.04 (StatPoint Technologies, Inc.) or Minitab 
(Minitab Ltd, Coventry, UK). 
  
  107  
 
2.6 Results 
2.6.1 Effect of glutathione on the level of malondialdehyde in stored 
human plasma 
2.6.1.1 Method development and improvement 
Measurement of malondialdehyde (MDA) is an important contribution to the 
assessment of oxidative stress. Initially quantification of MDA to get precise 
results without interfering peaks posed difficulties in our laboratory. The 
original Agarwal and Chase (2002) method used 40:50 (v/v) methanol/buffer 
as the mobile phase, but with this method an interfering peak was found 
close to the MDA. However, with 20:80 (v/v) methanol/buffer as the mobile 
phase a single sharp peak corresponding to MDA was obtained; this mobile 
phase caused the interfering peak to shift, such that the method now worked 
properly. Many trials were followed in order to obtain chromatograms with a 
sharp peak corresponding to MDA (Figure 2.8 A and B). This was eventually 
achieved following studies in which the ratio of aqueous to organic solvent in 
the mobile phase was varied, ultimately arriving at the method described 
above. Figure 2.9 shows a representative chromatogram for a plasma 
samples obtained using this method. 
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Figure 2.8 Representative chromatograms showing multiple peaks obtained with the original 
Agarwal and Chase (2002) method with 40:50 (v/v) methanol/buffer as mobile phase (A). 
However, with 20:80 (v/v) methanol/buffer as mobile phase a single sharp peak corresponding 
to MDA was obtained (B). 
Due to the increase in the polarity of the mobile phase the other peaks took more time to appear. 
The retention time for MDA with a 2 µM standard was 2.30 min. CVs within and between days 
were 4-6% and 6-7%, respectively. This finding was obtained by repeating measurements of 
standard solutions (1,1,3,3-tetraethoxypropane) (n = 5) of MDA (0.2 to 2 µM) within days and 
between days. 
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Figure 2.9 Representative chromatogram showing sharp peak for a plasma sample using 20:80 
(v/v) methanol/buffer as mobile phase. 
2.6.1.2 Determination of MDA standards 
The reagent 1,1,3,3-tetraethoxypropane was used in preparing MDA 
standards during the MDA assay which yields equivalent amounts of MDA 
under the conditions of the reaction (Section 2.4.12.1). A linear standard 
curve was obtained (R2 = 0.9995) (Figure 2.10). 
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Figure 2.10 Standard curve for detection of MDA using the method of Agarwal and Chase (2002). 
MDA standards (0.2-2 µM) were prepared in PBS. The line was obtained by linear regression. 
The data shown are means of triplicate measurements. 
2.6.1.3 Changes in the level of measured MDA with time of storage 
Higher levels of MDA were found in plasma stored in tubes treated with LiH 
compared with to those in tubes treated with EDTA. The combination of GSH 
with EDTA reduced the level of MDA compared with EDTA without GSH, as 
did the combination of GSH with LiH compared to LiH without GSH but this 
reduction was less than that seen with the combination of EDTA and GSH. 
The level of MDA in samples treated with GSH increased over time so that by 
day 7 the effect of GSH was lost (Figure 2.11 A and B). Using GLM analysis 
a significant interaction between time and treatment was found (P < 0.0005). 
There were also significant differences between treatments in that there were 
significantly higher (P < 0.0005) levels of MDA in the plasma samples that 
were treated with EDTA compared with plasma samples that were treated 
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with LiH. To investigate the interaction in relation to the effects of GSH pair-
wise paired t tests were used. 
There were significant differences (P = 0.001; paired t test) in the levels of 
MDA at time zero between plasma that was stored in EDTA with and without 
GSH (Figure 2.11 A), but there were no significant differences (P = 0.199) in 
the levels of MDA in plasma that was stored in EDTA with and without GSH 
on day 21 (Figure 2.11B). There were significant differences (P = 0.002) in 
the levels of MDA at time zero between plasma that was stored in LiH with 
and without GSH (Figure 2.12 A), but there was no significant difference (P = 
0.099) in the levels of MDA in plasma that was stored in LiH with and without 
GSH on day 21 (Figure 2.12 B). There were no significant differences (P = 
0.075 and 0.286, respectively; paired t test) between the levels of MDA at 
time zero and on day 21 between plasma that was stored in EDTA without 
GSH and plasma that was stored in LiH without GSH. There were no 
significant differences (P = 0.054 and 0.379, respectively; paired t test) 
between the levels of MDA at time zero and on day 21 between plasma that 
was stored in EDTA with GSH and plasma that was stored in LiH with GSH. 
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Figure 2.11 Effect of storage at -80 °C on the MDA concentration in human plasma samples. 
Data shown are means  SEM. (A) samples stored in EDTA with or without GSH; (B) samples 
stored in LiH with or without GSH. Effects of time and treatment were analysed using GLM. 
There was no significant difference between days (P > 0.05). However, there was a significant 
interaction between time and treatment (P < 0.0005) and a significant difference between 
treatments (P < 0.0005, n = 6). 
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Figure 2.12 MDA (means ± SEM) in plasma of 6 subjects stored with EDTA or with LiH, with or 
without GSH (A) at time zero and (B) on day 21. Bars with different letters are significantly 
different (P < 0.05; paired t tests; n = 6). 
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2.6.2 Results of the in vivo study 
Venous blood samples (5 ml) were drawn from all subjects. These subjects 
were categorised in to three groups: T2DM, obese non-diabetic and control 
groups. Although originally intended, the groups were not age matched due 
to problems with recruitment of subjects for all the groups and the exclusive 
recruitment criteria used in this study. There were 28 subjects in the T2DM 
group (10 female and 18 male; 36% and 54%, respectively), aged from 41 to 
76 y (mean ± SD, 58 ± 7 y); 28 subjects in the control group (7 female and 21 
male; 25% and 75%, respectively), aged from 41 to 64 y (mean ± SD, 52 ± 7 
y); and 17 subjects in the obese non-diabetic group (9 female and 8 male; 53% 
and 47%, respectively), aged from 40 to 74 y (mean ± SD, 50 ± 9 y). See 
Appendix 3 to find more detail about all the parameters measured in the 
study. 
2.6.2.1 Iron indices in different groups 
There were no correlations between age and iron indices except for a 
positive correlation between TIBC and age (see Section 2.6.2.2 and 
Appendix 1). For those indices where there was no correlation, the data were 
analysed using one-way ANOVA. Total serum iron levels were significantly 
lower (P = 0.005) than controls in both the diabetes and obese groups, but 
there was no significant difference (P > 0.05) between the obese and 
diabetes groups (Figure 2.13). The percentage iron saturation was 
significantly higher (P < 0.01) in the diabetes group than the control and 
obese groups, but there was no significant difference (P > 0.05) between the 
control and obese groups (Figure 2.14). The NTBI levels were significantly 
higher (P < 0.001) in the diabetes group than in the control and obese groups. 
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There was a slightly higher level of NTBI in the obese group compared to 
controls, but this was not significant (Figure 2.15). Serum soluble transferrin 
receptor levels were significantly lower (P < 0.05) in the controls than in the 
obese and diabetic groups, and the level in the obese group was significantly 
higher (P < 0.05) than that of the diabetic group (Figure 2.16). 
 
Figure 2.13 Total serum iron (means ± SEM) for control, T2DM and obese groups. 
There was a significant difference between the control group, and both the diabetes and obese 
groups (P < 0.05; Tukey’s HSD), but there was no significant difference between the diabetes 
and obese groups. Bars with the same lower case letter are not significantly different (control, n 
= 28; T2DM, n = 28; and obese, n = 17). 
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Figure 2.14 % transferrin saturation (means ± SEM) for control T2MD and obese groups. 
There was a significant difference between the diabetes group, and both the control and obese 
groups (P < 0.05; Tukey’s HSD), but there was no significant difference between the control and 
obese groups. Bars with the same lower case letter are not significantly different (control, n = 
28; T2DM, n = 28; and obese, n = 17). 
 
Figure 2.15 NTBI (means ± SEM) between control,T2MD and obese groups. 
There was a significant difference between the diabetes group, and both the control and obese 
groups (P < 0.05; Tukey’s HSD), but there was no significant difference between the control and 
obese groups. Bars with the same lower case letter are not significantly different (control, n = 
28; T2DM, n = 28; and obese, n = 17). 
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Figure 2.16 STR (means ± SEM) between control, T2MD and obese groups. 
There was a significant difference between the control group, and both the diabetes and obese 
groups (P < 0.05; Tukey’s HSD), and between diabetes and obese groups (P < 0.05; Tukey’s 
HSD). Bars with the same lower case letter are not significantly different (control, n = 28; T2DM, 
n = 28; and obese, n = 17). 
2.6.2.2 Correlations between age and iron indices 
As noted above there was a positive correlation between TIBC and age for all 
groups (P = 0.032); R2 = 0.344, 0.057 and 0.101 for theT2DM, control and 
obese groups, respectively (Figure 2.17). GLM analysis of these data 
showed total iron binding capacity was significantly higher (P < 0.005) in the 
control group than in the diabetes and obese group, but there were no 
significant differences (P > 0.05) between the diabetes and obese groups. 
0
100
200
300
400
500
600
700
Control Diabetes Obese
S
T
R
 (
µ
g
/m
l)
 
b 
c 
a 
  118  
 
Age (year)
40 50 60 70
T
IB
C
 (
µ
M
)
20
30
40
50
60
70
80
90
Diabetes
Control
Obese
 
Figure 2.17 Correlations between age and TIBC. 
P = 0.032; R
2
 = 0.344, 0.057 and 0.101 for theT2DM, control and obese groups, respectively 
(control, n = 28; T2DM, n = 28; and obese, n = 17). 
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2.6.2.3 Correlation between age and all oxidative stress 
There were no correlations between age and all oxidative stress indices (see 
Appendix 2) except for a positive correlation with MDA (P = 0.017); R2 = 
0.347, 0.131 and 0.378 for the T2DM, control and obese groups, respectively 
(Figure 2.18). GLM analysis of these data showed that MDA levels were 
significantly lower (P < 0.001) in controls than in obese and diabetic groups, 
and that of the diabetic group was significantly higher (P < 0.05) than that in 
the obese group. 
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Figure 2.18 Correlations between age and MDA 
P = 0.017, R
2
 = 0.347, 0.131 and 0.378 for the T2DM, control and obese groups, respectively 
(control, n = 28; T2DM, n = 28; and obese, n = 17). 
2.6.2.4 Oxidative stress indices in different groups 
The data for the remaining indices were analysed by one-way ANOVA. Total 
ascorbate (i.e. ascorbate + DHA) was significantly lower (P = 0.0077) in the 
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diabetic group compared to controls and obese subjects, but there was no 
significant difference between total ascorbate in control and obese subjects 
(P > 0.05) (Figure 2.19). Ascorbate was significantly lower (P < 0.05) in the 
diabetic group compared to the control and obese groups but there was no 
significant difference between the control and obese groups (P > 0.05) 
(Figure 2.20). DHA was a significantly lower in the control group (P < 0.01) 
compared to both the diabetic and obese groups, and also significantly lower 
in the diabetic group compared to the obese group (P < 0.05) (Figure 2.21). 
Total antioxidant capacity was significantly higher in the control compared to 
the diabetic group (P < 0.05) but there were no significant differences 
between control and obese, and obese and diabetic groups (P > 0.05) 
(Figure 2.22). The percentage of ascorbate in the oxidised form (DHA) was 
significantly greater than that of the control group in the diabetes and obese 
groups, but there was no difference between the diabetes and obese groups. 
(Table 2.1). 
Table 2.1 the concentrations of DHA  
DHA Control Diabetes Obese 
DHA [µmol l-1] 
(mean ± SD) 
6.51 ± 3.32Ɵ† 10.34 ± 7.13Δ 16.14 ± 13.13 
Significant differences between groups are shown as follows: Ɵ, between controls and 
diabetics; Ɵ†, between controls and obese; Δ, between diabetics and obese. 
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Figure 2.19 Total ascorbate (means ± SEM) between control, T2MD and obese groups. 
There was a significant difference between both control and obese groups and diabetes group 
(P < 0.05; Tukey’s HSD), and there was no significant difference between control and obese 
groups. Bars with the same lower case letter are not significantly different (control, n = 28; 
T2DM, n = 28; and obese, n = 17). 
 
 
Figure 2.20 Ascorbate (means ± SEM) between control, T2MD and obese groups. 
There was a significant difference between both control and obese groups and diabetes group 
(P < 0.05; Tukey’s HSD), and there was no significant difference between control and obese 
groups. Bars with the same lower case letter are not significantly different (control, n = 28; 
T2DM, n = 28; and obese, n = 17). 
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Figure 2.21 DHA (means ± SEM) between control, T2MD and obese groups. 
There was a significant difference between the control group and both the diabetes and obese 
groups (P < 0.01), and between diabetes and obese groups (P < 0.05; Tukey’s HSD). Bars with 
the same lower case letter are not significantly different (control, n = 28; T2DM, n = 28; and 
obese, n = 17). 
 
Figure 2.22 Antioxidant capacities (means ± SEM) between control, T2MD and obese groups. 
There was a significant difference between the control and diabetes groups (P < 0.05; Tukey’s 
HSD), and there was no significant difference between control and obese and obese and 
diabetes groups. Bars with the same lower case letter are not significantly different (control, n = 
28; T2DM, n = 28; and obese, n = 17). 
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2.6.2.5 E-selectin and high sensitivity C-reactive protein level 
differences between groups 
There were no correlations between age, and either E-selectin or hs-CRP 
(Appendix 3), and so one-way ANOVA was used for the analysis of the data. 
E-selectin was significantly lower (P < 0.001) in the control and obese groups 
compared to the diabetic group but there was no significant difference (P > 
0.05) between the obese and control groups (Figure 2.23). hs-CRP was 
significantly lower (P < 0.01) in the control group compared to the diabetic 
and obese groups but there was no significant difference between diabetic 
and obese groups (P > 0.05) (Figure 2.24). 
2.6.2.6 Correlations between NTBI and other iron indices 
There were no correlations between NTBI and total serum iron, TIBC 
and %TS (Appendix 4), but there was a significant correlation between NTBI 
and soluble transferrin receptor (Figure 2.25). 
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Figure 2.23 E-selectin (means ± SEM) between control, T2MD and obese groups. 
There was a significant difference between both control and obese groups and diabetes group 
(P < 0.05; Tukey’s HSD), and there was no significant difference between control and obese 
groups (control, n = 28; T2DM, n = 28; and obese, n = 17). 
 
Figure 2.24 Plasma hs-CRP levels (means ± SEM) between T2MD, obese and control groups. 
There was a significant difference between the control group and both the diabetes and obese 
groups (P < 0.01; Tukey’s HSD), but there was no significant difference between the diabetic 
and obese groups (control, n = 28; T2DM, n = 28; and obese, n = 17). 
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Figure 2.25 Correlations between NTBI and sTfR 
P = 0.050, R
2
 = 0.238, 0.099 and 0.346 for theT2DM, control and obese groups, respectively 
(control, n = 28; T2DM, n = 28; and obese, n = 17). 
2.6.2.7 Correlation between NTBI and biomarkers of oxidative stress 
There were no correlations between NTBI and MDA, total ascorbate, 
ascorbate DHA and total antioxidant capacity (Appendix 5). 
2.6.2.8 Correlation between NTBI and biomarkers of inflammation 
There was a significant correlation at the 90% confidence level between 
NTBI and a biomarker of inflammation, hs-CRP (Figure 2.26). 
2.6.2.9 Correlation between NTBI and biomarkers of atherosclerosis 
There was a significant correlation between NTBI and a biomarker of 
atherosclerosis, E-selectin (Figure 2.27), but there was no correlation 
between E-selectin and hs-CRP (Appendix 6). 
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Figure 2.26 Correlations between NTBI and hs-CRP 
P = 0.054, R
2
 = 0.338, 0.098 and 0.256 for theT2DM, control and obese groups, respectively 
(control, n = 28; T2DM, n = 28; and obese, n = 17). 
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Figure 2.27 Correlations between NTBI and E-selectin 
P = 0.001, R
2
 = 0.469, 0.017 and 0.232 for the diabetes, control and obese groups, respectively 
(control, n = 28; T2DM, n = 28; and obese, n = 17). 
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2.6.2.10 Correlation between NTBI and HbA1c 
There was significant correlation between NTBI and level of HbA1c  in 
subjects from the T2DM group (Figure 2.28). 
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Figure 2.28 Correlation between NTBI and HbA1c (P < 0.0005; R
2
 = 0.742) in the T2DM group (n = 
28). 
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2.7 Discussion 
2.7.1 Storage of plasma with and without GSH 
This study showed a significant difference in the level of MDA on day zero 
between plasma samples that were stored in EDTA and LiH with and without 
GSH. MDA levels on day zero were higher in EDTA without GSH compared 
with those in plasma stored in EDTA with GSH. The explanation of this result 
may be due to the combination of GSH with EDTA attenuating the oxidation 
of lipids and lipoproteins in the plasma sample during the time in storage. 
Addition of GSH should reduce the rate of oxidation and formation of MDA. 
This appeared to be the case on day zero, but after that the action of GSH 
gradually diminished with time (Figure 2.4A). Diminution of the action of GSH 
may explain the non-significant result on day 21 of storage. The results of the 
present study agree with the results of (Kumar et al., 2012). Kumar et al. 
stored samples for long periods (708 days) and they found little change in 
MDA on storage at -80 °C over the first 28 days. 
Many studies have shown that addition of antioxidants to the reaction mixture 
may inhibit metal-catalyzed autoxidation of coexisting polyunsaturated fatty 
acids (Lepage et al., 1991, Bonnefont et al., 1989, Lee, 1980, Arshad et al., 
1991). Hendriks and Assmann (1988) showed that addition of GSH at a final 
concentration of 0.65 mmol l-1 had no significant influence on serum TBARS 
concentration. Similar results were obtained for GSH concentrations in the 
range 0.32-7.80 mmol l-1. Also, they showed that short-time storage of 
plasma at either 4 °C or -20 °C induces large day to day variations in TBARS 
results, and that addition of GSH plus EDTA prevented this variation. 
However, in a study by Hendriks and Assmann (1988) samples were stored 
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at -80 °C. It is proposed to use untreated plasma and to perform the assay 
immediately after collection of plasma or to add both glutathione and EDTA 
before storage. Some studies disagree on the value of the addition of 
antioxidant; for example, Richard et al. (1992) stated that addition of an 
antioxidant such as BHT did not change the results for TBARS determination. 
On the other hand, Richard et al. report quite high values for native TBARS 
because of their use of an acidic pH during reaction and extraction at low pH 
leads to an increased yield of MDA. 
The present study also showed a significant difference in the level of MDA in 
day zero between plasma samples was stored in LiH with and without GSH. 
This was probably due to the action of GSH in reducing lipid peroxidation 
during storage. However, this action of GSH gradually declined with storage 
time (Figure 3.4B) such that no significant differences in MDA were seen on 
day 21. Combination of LiH with GSH was associated with a reduced level of 
MDA but the combination of EDTA with GSH showed a greater effect. 
Glutathione is a tripeptide thiol found in virtually all cells. It is one of the most 
important biological antioxidants. GSH plays an important role in the 
protection of cells and tissue structures by scavenging free radicals, and 
participating in several redox and detoxification reactions. It protects cells 
against the destructive effects of reactive oxygen intermediates (Meister, 
1983). GSH is also important for the maintenance of -tocopherol and 
ascorbate in the reduced state (Scholz et al., 1989). Therefore, release of 
reduced and oxidized glutathione (GSH and GSSG) into the plasma and the 
ratio of GSH/GSSG are considered a reliable index to evaluate the status of 
oxidative stress in biological systems. Irreversible cell damage results when 
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the cell is no longer able to maintain its GSH content (Griffith and Meister, 
1978). Glutathione not only protects cell membranes from oxidative damage, 
but also helps to maintain the sulfhydryl groups of many proteins in the 
reduced form, a requirement for their normal function (Reed and Fariss, 
1984). Alternatively, GSH can be lost by autoxidation which occurs with a 
half-time of about 5 min in plasma at room temperature (Anderson and 
Meister, 1980). Only partial inhibition of autoxidation of GSH is achieved by 
EDTA or potassium cyanide in human plasma. In vitro, autoxidation of GSH 
is less at pH < 6 and may be attributed to the catalytic action of traces of 
heavy-metal ions such as copper and iron. These actions could account for 
the transient effect of GSH seen in the present study. It should be noted that 
in the present study, in order to measure MDA samples were thawed and 
stored on ice for up to 8 h while analysis was carried; during this time 
autoxidation of GSH may have occurred. 
2.7.2 Storage of plasma in EDTA and LiH without GSH 
In this work there was no significant difference between the level of MDA in 
plasma that was stored in EDTA and LiH without GSH on both days zero and 
21, but the mean value in EDTA was less than in LiH on both days. Although 
this was not statistically significant, it is in agreement with the findings of 
Knight et al. (1987) who showed that plasma from liquid EDTA-
anticoagulated blood had significantly lower TBARS concentrations than that 
in serum or plasma from blood treated with LiH, sodium citrate or a ‘“citrate, 
phosphate, dextrose, adenine” solution. The explanation of this result is that 
EDTA is known to protect samples against autoxidation; EDTA may chelate 
free iron in the plasma sample which would limit iron-induced free radical 
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generation and reduce lipid peroxidation. EDTA also reduced the artefactual 
formation of MDA during sample processing (Nielsen et al., 1997). However, 
the formation of Fe3+-EDTA may promote oxidative effects, possibly later 
during storage. The results of this study disagree with those of Lee (1980) 
and also with those of Carbonneau et al.(1991); this disagreement may be 
due to the difference in the storage conditions (Lee used 4 °C for storage of 
samples and Carbonneau et al. used -20 °C and 4 °C). 
On the other hand, the combination of EDTA with transition metals such as 
iron and copper when present in the presence of low concentrations of 
ascorbate may induce the pro-oxidant activity of ascorbate. Fe3+-EDTA can 
be reduced to Fe2+ by ascorbate to generate the ascorbate radical thereby 
enhancing lipid peroxidation (Buettner and Jurkiewicz, 1996). 
2.7.3 Iron indices in Type 2 diabetes 
In the present study, the concentration of the NTBI and other parameters 
were determined in the plasma of Type 2 diabetic, obese (non-diabetic) and 
control subjects. Levels of NTBI in T2DM have been investigated by several 
groups, using different methods and reporting a range of results. Results 
from this study indicate that the concentration NTBI was significantly higher 
in the diabetes group compared with the control group. Our finding is 
supported by the studies of Sulieman et al. (Sulieman et al., 2004, Lee et al., 
2006). However, another study found that NTBI is not present in significant 
amounts in all cases of T2DM (Van Campenhout et al., 2006b). Lee et al. 
(2006) found NTBI to be present in 92% of a known diabetic group and 59% 
of newly diagnosed diabetic group compared with a control group. Sulieman 
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et al. (2004) found a labile iron pool (LIP) in diabetic patients that was 
significantly different compared with the control. The non-significant result for 
some diabetic cases in the study of Van Campenhout et al.(2006b) may be 
due to the method which was used to measure NTBI and may be due to the 
unstable nature of NTBI in vivo or differences in the molecular masses within 
the plasma which are capable of binding different NTBI species. There is no 
‘gold standard’ method for the measurement of NTBI (Jacobs et al., 2005a), 
and variations between studies often occur. The method used in this study 
was similar to that used by Van Campenhout et al. (2006b), so the results 
should be reasonably comparable. The reason for the differences between 
the two studies may therefore reside elsewhere, possibly in the treatments 
received by the two populations studied, and the extent to which the 
hyperglycaemia was controlled. For example, on-going studies in our 
laboratory (unpublished) indicate that the rise in NTBI levels in diabetic 
patients may be attenuated by statin treatment. Thus the small number of 
subjects receiving statins (11%) could have influenced the overall levels of 
NTBI measured in the current study. Without knowing more about these 
potential interactions there is little strong data to provide a convincing 
argument for the cause of the differences seen between the two studies. A 
very interesting relationship between the use of statins and ferritin levels was 
found recently by Zacharski et al. (2013). 
The level of total iron in the diabetic group was lower than in the control 
group while Lee et al. (2006) found no significant difference between diabetic 
and control groups, and also between newly diagnosed and control groups. 
The reason behind the decrease in the level of total iron in T2DM may be the 
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increased production of hepcidin due to the inflammatory conditions in T2DM, 
which in turn hinders iron absorption. The reason that hepcidin levels are 
increased in T2DM may be the increase in ferritin and IL-6 levels; the 
elevated hepcidin might have adaptive value through down-regulation of iron 
absorption, and plays an important role in the pathogenesis of T2DM (Jiang 
et al., 2011). 
The reason for the presence of NTBI in T2DM patients may be due to the 
effects of glycation of proteins such as Hb and transferrin, which is consistent 
with the strong correlation (R2 = 0.741) between HbA1c and NTBI in T2DM 
subjects (Figure 4.38). Persistence of hyperglycaemia allows more glycation 
to occur, not only of Hb, but of other proteins such as transferrin, albumin and 
immunoglobulins, and this can lead to abnormal consequences for the 
structure and function of these proteins. The major step in the modification of 
proteins by glucose is Schiff base formation, followed by Amadori 
rearrangement (Cohen and Wu, 1994). Hyperglycaemia induces H2O2 
formation by different pathways which promote more iron release from HbA1c 
than that from non-glycated haemoglobin. This free iron, acting as a Fenton 
reagent, might catalyse the production of free radicals and lead to 
degradation of cell constituents (Sen et al., 2005). In addition to haemoglobin 
glycation, transferrin is also prone to glycation, and glycation of haemoglobin 
and transferrin induced by the higher glucose levels can impair iron binding 
and promote even higher levels of free iron in the body (Kar and Chakraborti, 
1999, Van Campenhout et al., 2004). Another explanation for the presence of 
NTBI in T2DM may be related to the decreased lifespan of red blood cells 
(RBCs) in diabetic patients (Cohen et al., 2004, Engström et al., 2014). The 
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decrease in the lifespan of RBCs in diabetic patients may be due to alteration 
in their cell membranes (Mazzanti et al., 1992). Increased lipid peroxidised in 
T2DM interferes with chemical and physical properties of the cell membrane 
which lead to increased rigidity and decreased fluidity. Erythrocytes are 
considered as prime targets for oxidative stress due to free radical attack 
owing to the presence of both high membrane concentrations of 
polyunsaturated fatty acids (PUFA) and the O2 transport. This may induce 
alterations in protein and lipid structures and compositions of the RBC 
membranes, leading to damage to RBCs (Nayak et al., 2008). In addition, the 
serum transferrin (Tf) concentration is often diminished in diabetes as a 
consequence of decreased synthesis and/or increased loss (Telci et al., 
2000). T2DM is closely correlated with chronic inflammation, with increased 
levels of circulatory acute response proteins and cytokines in affected 
subjects. Immune responses and inflammation are suggested to play roles in 
the development and complications of T2DM (Dandona et al., 2004). 
This study also showed a significantly decreased TIBC in the T2DM group 
compared with the control group. Our results are supported by the study of 
(Van Campenhout et al., 2006b). In diabetes iron metabolism is disturbed. 
The reason for the low TIBC in T2MD may be a decrease in the capacity of 
transferrin to hold iron due to the glycation process which is increased in 
T2DM patients, or more likely due to Tf being a negative acute phase protein. 
There was a significant increase in % transferrin saturation in the T2DM 
group compared with the control group. Our results are supported by those of 
(Ellervik et al., 2011, Thomas et al., 2004). The reason for the increased the 
transferrin saturation in T2DM may be due to oxidative damage to the 
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proteins which hold iron. This study showed that the concentration of sTfR 
significantly increased in T2DM compared with the control and supported the 
studies of (Fernández-Real et al., 2007, Van Campenhout et al., 2006a), 
although other studies showed no difference between T2MD and the control 
(Hernández et al., 2005, Abou-Shousha et al., 2005). Another study showed 
sTfR decrease in T2DM (Yamada et al., 2000). The reason for increased 
sTfR in the current study may be due to hyperinsulinaemia which contributes 
to the inappropriately high sTfR concentration because insulin is known to 
cause a rapid and marked stimulation of iron uptake by fat cells, redistributing 
sTfR from an intracellular membrane compartment to the cell surface (Davis 
et al., 1986). Also, production of cytokines such as IL-6 and tumour necrosis 
factor α (TNFα) is elevated in T2DM (Pickup et al., 2000). Blood has the 
capacity to produce cytokines in diabetes which contributes to the 
augmented acute-phase response which may cause an increase in 
transferrin receptors on the cell surface, tissue deposition of iron and insulin 
resistance (Hirayama et al., 1993, Fernandez-Real et al., 2001). 
2.7.4 Oxidative stress in Type 2 diabetes 
Previous studies have demonstrated that oxidative stress, induced by 
elevated concentrations of both glucose and free fatty acids, plays a 
significant role in causing insulin resistance and β-cell dysfunction (Evans et 
al., 2002, Kajimoto and Kaneto, 2004). In the present study the concentration 
of MDA (a marker of lipid peroxidation) was significantly higher compared 
with the control group. Similar results were reported by (Bhutia et al., 2011, 
Gallou et al., 1993, Uzel et al., 1987, Aydın et al., 2001, Bikkad et al., 2014). 
A possible explanation for the increased concentration of MDA in T2DM is 
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due to increased lipid peroxidation, and the decline in antioxidant defences 
which may appear early in T2DM. Hyperglycaemia can induce oxidative 
stress by several different mechanisms such as autooxidation of glucose and 
the non-enzymatic glycation of proteins to generate superoxide (O2
•-) 
(Baynes, 1991). 
In addition, levels of antioxidants decrease in diabetes. For example, 
ascorbate is an antioxidant vitamin which plays an important role in 
protecting against free radical induced damage, and a decrease in basal 
ascorbate levels has been documented in T2DM in contrast to normal 
subjects (Padayatty et al., 2003, Mullan et al., 2002). This study observed a 
significant decrease in the level of total ascorbate, and supported the studies 
of (Som et al., 1981, Sinclair et al., 1994, Bode et al., 1993, Will et al., 1999, 
Madhikarmi et al., 2013). Several reasons may explain the reduction in 
ascorbate levels such as decreased intake, increased renal loss or increased 
utilization in the face of oxidative stress. Ascorbate reacts with free radicals 
to produce dehydroascorbate. Dehydroascorbate is then reduced to 
ascorbate via dehydroascorbate reductase, at the expense of GSH present in 
the blood, back to the functional ascorbate. Reduction of dehydroascorbate 
may also be non-enzymatic or catalysed by other proteins with 
dehydroascorbate reductase activity. An increased concentration of 
dehydroascorbate in T2DM compared with control subjects was found here, 
supporting the study of (Hisalkar et al., 2012). This result may be explained 
by the finding of low ascorbate levels in this study and is consistent with a 
higher turnover rate of ascorbate, with increased oxidation to the oxidised 
form, dehydroascorbate. 
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Compared with control subjects, T2DM subjects are subjected to severe 
oxidative stress identifiable as a depletion of the total antioxidant capacity. In 
this study the total antioxidant capacity of plasma measured by the FRAP 
assay was decreased significantly for T2DM compared with control subjects, 
consistent with the study of (Korkmaz et al., 2013). The reason for the 
decrease in total antioxidant capacity in T2DM may be to disturbance in the 
balance in cells between the formation of reactive oxygen species and the 
protection against the damage they can cause. 
2.7.5 Endothelial dysfunction in Type 2 diabetes 
Endothelial dysfunction in the current study was assessed using E-selectin 
as a biomarker. Our study showed significantly increased levels of E-selectin 
in T2DM compared with control subjects, and is supported by the studies of 
(Steiner et al., 1994, Ryysy and Yki-Järvinen, 2001, Boulbou et al., 2005). 
The reason for the increase in E-selectin in T2DM subjects may be insulin 
resistance, which increases vasoconstriction factors which in turn increases 
levels of circulating soluble adhesion molecules. Insulin stimulates the 
vascular endothelium to cause the release of NO and hence vasodilation. 
Insulin resistant states are extremely useful in explaining the mechanisms 
underlying the increased macrovascular risk. Inhibition of NO production 
leads to increased circulating soluble adhesion molecules and increased 
platelet and leukocyte adhesion (Adams et al., 1997, Ding et al., 2000). The 
currently observed relationship between NTBI and plasma E-selectin is 
consistent with the suggestion that NTBI causes an increased risk of 
atherosclerosis. Adhesion molecules such as E-selectin play a critical role in 
the monocyte recruitment to the extravascular compartment by mediating 
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adhesion and transmigration of the cells to the vascular endothelial wall 
(Adams and Shaw, 1994). 
2.7.6 Inflammation in Type 2 diabetes 
In present study the biomarker of chronic inflammation, hs-CRP, was 
significantly higher compared with the control, supporting the study of (Tan et 
al., 2004). The increased level of hs-CRP in T2DM may due to increased 
oxidative stress. Another reason for increased hs-CRP in T2DM may be that 
insulin resistance causes changes in the plasma lipid profile, the 
consequence of which is enhanced cytokine production in adipose tissue. 
This would lead to increased systemic inflammation with higher levels of 
inflammatory markers such as C-reactive protein (CRP), tumour necrosis 
factor- (TNF-), and interleukin 6 (IL-6) (Garcia et al., 2010). 
2.7.7 Iron indices in obese non diabetic subjects 
The levels of NTBI in obese non diabetic subjects were increased compared 
with the control but not significantly. The presence of NTBI in obese non 
diabetic subjects, even though the level of total serum iron is significantly 
lower compared with the control, may be due to reduced transferrin 
concentration. Inflammation is associated with changes in serum levels of the 
acute-phase proteins that can be used to stage the inflammatory process and 
be used as biomarkers to evaluate the impact of treatment. Some acute-
phase proteins are increased during inflammation, while others, such as 
albumin, transferrin, and transthyretin, are decreased (Ritchie et al., 1999). 
The association of iron deficiency with obesity has been confirmed in other 
populations that include children and adults of both sexes (Cepeda-Lopez et 
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al., 2011, Yanoff et al., 2007). The mechanism which explains this 
relationship remains unknown but may be due to an increased iron 
requirement as the result of larger blood volumes and poor iron absorption, 
and low iron intake due to restrictive dietary practices aimed at promoting 
weight loss (O'Connor et al., 2011). Another reason for low iron in obese 
subjects may be increased hepcidin production. Hepcidin is a pro-
inflammatory adipokine and may play an important role in hypoferraemia of 
inflammation in obesity (Bekri et al., 2006). 
Obese non diabetic subjects in this study also had significantly decreased 
TIBC compared with the control group. Low TIBC in obese subjects may be 
due to changes in the iron binding sites due to glycation of proteins which 
hold iron such as transferrin and Hb. Study of the degree of protein glycation 
in obese non-diabetic subjects showed that there was increased glycation of 
Hb and decreased glycation of albumin (Koga et al., 2007). The reason for 
the reduction in the degree of glycation of albumin in obese non-diabetic 
subjects may be due to the decrease in the concentration of albumin in 
obese subjects compared with the control due to increase turnover of 
albumin in obese subjects (Salas-Salvado et al., 2006). The rate of albumin 
synthesis is decreased and the rate of catabolism is increased as a 
consequence of the increased the state of inflammation (Temelkova-
Kurktschiev et al., 2002). The longer the albumin is present in the plasma, 
the more likely it is to become glycated. Thus, an enhanced turnover will 
reduce the half-life of albumin in plasma and reduce the likelihood of 
glycation. 
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This study also showed a significant difference in % transferrin saturation 
between the obese non-diabetic group and the diabetic group, and between 
the diabetic group and controls. The level of transferrin saturation was, 
however, not significantly different in obese subjects compared with the 
controls. The increased transferrin saturation seen in the diabetic group is 
consistent with the enhanced NTBI also seen in this group. The greater the 
occupancy of the iron binding sites on the transferrin molecule, the less there 
are available for binding any circulating non-sequestered iron. Consequently 
NTBI will increase. 
There was also a significant increase in the level sTfR in the obese group 
compared with the control. sTfR is a truncated form of the membrane-
associated transferrin receptor, and is considered to be a sensitive indicator 
of iron deficiency that is not an acute phase reactant such as ferritin (Mast et 
al., 1998). The circulating level of sTfR is proportional to the cellular 
expression of membrane-associated transferrin receptors. Cellular 
expression of transferrin receptors increases with increased cellular iron 
needs, such as in iron deficiency. This finding is consistent with that of Yanoff 
et al. (2007) and supports the consistently reported observation of lower iron 
status of obese subjects. 
2.7.8 Oxidative stress in obese non-diabetic subjects 
Obesity may induce systemic oxidative stress such as increased production 
of free radicals in accumulated fat (Furukawa et al., 2004). Increased 
markers of oxidative stress have been observed in obese humans (Urakawa 
et al., 2003). The present study showed that the level of an oxidative stress 
biomarker, MDA, was significantly higher compared with the control group, 
  141  
 
consistent with the findings of (Zwirska-Korczala et al., 2003, Yesilbursa et al., 
2005, Prázny et al., 1999). The level of MDA in the T2DM group was 
significantly higher than in the obese group. Various mechanisms can induce 
the oxidative stress in T2DM such as increased formation of AGEs (Brownlee 
et al., 1988); enhanced polyol pathway (Williamson et al., 1993); increased 
superoxide release from mitochondria (Desco et al., 2002); and activation of 
NAD(P)H oxidase (Inoguchi et al., 2000). Obese individuals have a 
micronutrient deficiency compared to normal weight controls of the same age 
and sex (Kimmons et al., 2006, Kaidar-Person et al., 2008). In the present 
study ascorbate was significantly lower in the obese group compared with the 
control. The depletion of ascorbate in obese subjects may be due to role of 
ascorbate in scavenging of reactive molecular species, protection against 
protein glycation and prevention of lipid peroxidation (Garcia-Bailo et al., 
2011, Calder et al., 2009). 
2.7.9 Inflammation in obese non-diabetic subjects 
There was a significant difference in hs-CRP between the obese and control 
groups. Our result is supported by studies of (Fröhlich et al., 2000, Yudkin et 
al., 1999, Visser et al., 1999). Obese subjects have low-grade of systemic 
inflammation which may lead to increase the level of hs-CRP. Increased hs-
CRP in obesity is probably due to the increased production of inflammatory 
cytokines by adipose tissue such as IL-6. These cytokines induce acute-
phase protein production in the liver (Papanicolaou et al., 1998). 
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2.7.10 Endothelial dysfunction in obese non-diabetic subjects 
The level of E-selectin in the present study was significantly higher in the 
obese group compared with the control group, consistent with previous 
observations (Ferri et al., 1999, Pontiroli et al., 2004, Bošanská et al., 2010). 
The increased concentration of E-selectin in obese subjects may be due to 
an increased state of inflammation in obese subjects which may lead to the 
secretion of a variety of factors such as IL-6 which cause endothelial 
dysfunction and induce release of E-selectin. Obesity may induce endothelial 
activation or increased shedding of cell surface E-selectin that leads to 
subsequent increase in soluble E-selectin levels. The high serum 
concentrations of E-selectin closely correlated with increased total fat volume 
(Matsumoto et al., 2002a). 
2.7.11 Correlations between age and measured parameters 
In the present study, we did not find any significant correlation between age 
and all parameters, except for MDA and TIBC. One of the reasons for a lack 
of any association in our study may be the small sample size. Many factors 
may cause a positive correlation between age and level of MDA. 
Accumulation of free radical mediated oxidative stress increases with age, 
and thus may overwhelm the natural repair systems in the elderly (Kowald 
and Kirkwood, 2000). Hyperglycaemia can induce oxidative stress, which 
increases with age, via several mechanisms including glucose autoxidation, 
the formation of AGEs, and activation of the polyol pathway. Other circulating 
factors that are elevated in diabetics such as free fatty acids and leptin also 
contribute to increased ROS (Jay et al., 2006). Oxygen free radicals react 
with all biological substances; however, the most susceptible ones are 
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polyunsaturated fatty acids. Reactions with these cell membrane constituents 
lead to lipid peroxidation. Membrane phospholipids, specifically esterified 
polyunsaturated fatty acids, are converted by peroxidation to MDA. The 
results for MDA are in concordance with previous studies of (Mutlu-Türkoğlu 
et al., 2003, Mecocci et al., 1999). Mecocci et al. (1999) found age-
dependent significant increases in the level of malondialdehyde. Bhatia et al. 
(2003) found positive correlation between HbA1c and MDA in T2DM. The 
increase in MDA with age may be linked to a number of factors reflecting 
increased oxidative damage during aging (Ozcankaya and Delibas, 2002). A 
correlation of TIBC with age was also found, supported by the study 
(Mukhopadhyay and Mohanaruban, 2002). The reason for correlation TIBC 
with age may due to increase may be due to increased inflammation with age. 
People with advancing age may be developing chronic inflammatory disease 
which leads to iron deficiency and increased TIBC. 
2.7.12 Correlations between NTBI and measured parameters 
The present study also showed correlations between NTBI and E-selectin, 
hs-CRP and sTfR. The positive correlation of E-selectin with NTBI in this 
study is supported by the study of (van Tits et al., 2007). The reason for this 
result may be because increased NTBI induces oxidative stress, which leads 
to endothelium dysfunction. Zhang et al. (2010b) found that the use of 
deferoxamine (DFO) for chelation of iron leads to decreased induction of E-
selectin, VCAM-1 and ICAM-1 in endothelial cells. The finding of this study 
showed that the correlation between hs-CRP and NTBI, supported by the 
study of Marx et al (2006). The reason behind this our finding may be due to 
role of NTBI in increasing ROS production through the Fenton reaction. 
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2.7.13 Correlations between NTBI and HbA1c in T2DM 
Positive correlation between NTBI and HbA1c was found in T2DM group in 
this study this result was in agreement with the results of Shetty et al (2008). 
Shetty et al. also found a positive relation between poor glycaemic control 
and increase in glycation of Hb, which contributes to the increase in free iron 
pool which is known to increase oxidant generation. 
A major purpose of this study was to examine the potential relationship 
between iron, oxidative stress and vascular dysfunction in both obese non-
diabetic subjects and those with T2DM. Both conditions predispose towards 
vascular disease, but previous studies have indicated that while diabetic 
subjects may present with symptoms of iron overload, obese subjects tend to 
be iron deficient (Yanoff et al., 2007). Also, obese subjects are at risk of 
developing T2DM. In the transition stage from obesity to diabetes there need 
to be some changes in iron homeostasis. Findings from this study suggest 
that the presence of protein glycation may be a major factor in the process. 
With regard to diabetes, the initial step in linking iron dysregulation, 
atherosclerosis and vascular disease may be the glycation of proteins such 
as Hb, transferrin, albumin and others. Albumin will non-specifically bind iron, 
while Hb and transferrin are specific iron-containing proteins. Glycation of the 
latter two proteins leads to the loss of some of the iron contained within the 
structure which may lead to oxidative damage to DNA, phospholipid and 
protein (Sen et al., 2005). The iron released from Hb and transferrin may 
drive a number of oxidative reactions with the potential to damage 
indiscriminately a number of tissue types. This study is particularly interested 
in the relationship between oxidative stress and endothelial function. 
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Endothelial dysfunction is the first stage in the development of 
atherosclerosis. Interestingly this study showed a strong positive correlation 
between NTBI and E-selectin in all groups studied. Although it is not possible 
to determine a causal relationship between these two parameters, it remains 
a possibility that iron released from its binding sites could initiate oxidative 
damage to the endothelial cells and begin the process of atherogenesis. 
While it is relatively easy to relate this to diabetic patients and obese non-
diabetic patients who show both enhanced NTBI relative to controls, it is less 
easy to relate endothelial dysfunction to NTBI in control subjects. Thus, the 
question is, does enhanced NTBI drive endothelial dysfunction, or endothelial 
dysfunction influencing NTBI release? There seems little evidence of the 
latter, so at present it may be proposed that enhanced NTBI, through the 
generation of ROS may initiate atherogenesis by damaging endothelial cells. 
While there was good correlation between NTBI and endothelial dysfunction 
in the obese group, there was no difference in NTBI or E-selectin between 
the control and obese group. Thus, the link between obesity and 
macrovascular disease may be mechanistically different from that proposed 
for the diabetic patients where the evidence is strong, not from this study, but 
from others (Kuo et al., 2014). 
The one parameter where the obese group stands out as different from the 
other two groups is in the sTfR data. The high levels of sTfR indicate an 
overall state of iron deficiency. However, sTfR is mainly a biomarker of 
overall iron status and not the situation in individual cells in which the number 
of membrane-associated transferrin receptors available is increased in obese 
subjects. Thus, intracellular iron in some cells may be increased which may 
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induce intracellular oxidative damage. The data from this study is not able to 
develop this prospect further, or to relate this to endothelial dysfunction in 
obese individuals. 
The link between obesity and endothelial dysfunction is more likely to be due 
to changes in adipokine production in adipose tissue, and the production of 
inflammatory cytokines by the inflammatory cells that invade developing 
adipose tissue. The strong link between NTBI and E-selectin seen in this 
group of patients and in control subjects remains a mystery. 
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Chapter 3: Effects of glycation of transferrin in vitro 
on iron binding 
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3.1 Introduction 
The majority of proteins are multi-functional. Transferrins are examples of 
proteins that have many functions (Gomme et al., 2005). The transferrins (Tfs) 
are a group of non-haem iron-binding glycoproteins that are widely 
distributed in a variety of fluids in both invertebrates and vertebrates. The 
main function of transferrins is to act as extracellular proteins which are 
responsible for transporting iron between sites of absorption, storage and 
utilization, and to control the level of free iron in physiological fluids by 
binding this element (Sun et al., 1999). The main proteins of this group are 
serum transferrins (Tf) the prototype found in blood serum; in other bodily 
secretions there are lactotransferrin (LTf), ovotransferrin (OTf) and a fourth 
class of transferrins, melanotransferrins, which was first identified in human 
skin cancer cells (Woodbury et al., 1980). Lf is found in secretory fluids such 
as milk or tears, and also in white blood cells, while OTf is present in egg 
white. Interestingly, there appears to be no iron transport role for transferrins 
such as LTf and OTf. Instead, the major function appears to be to keep the 
iron concentration low in bodily fluids and to prevent invading bacteria from 
acquiring iron due to high affinity of transferrins to sequester iron (Brock, 
2002). However, some bacteria can avoid the resultant iron-deficient 
environment created by transferrins by expressing outer membrane proteins 
that can bind and remove the iron from transferrins. The ability of transferrins 
to sequester free iron leads to a reduction in infection (Bonsdorff et al., 2006). 
In addition, apoTf has the effect of reducing the adhesion of Gram-positive 
and Gram-negative bacteria to the surface of cells (Ardehali et al., 2003). 
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3.1.1 Serum transferrin structure 
Serum transferrin (Tf) is the most important extracellular protein that plays a 
crucial role in the homeostasis and transport of iron. Tf is a glycoprotein with 
a molecular weight of ~79 kDa consisting of a single polypeptide chain 
containing approximately 700 amino acids arranged in two independent 
metal ion-binding globular domains (Parkkinen et al., 2002). The molecule is 
stabilized by 19 intra-chain disulphide bonds and protected by two 
carbohydrate side chains called glycans, with terminal sialic acid residues 
(De Jong et al., 1990); each glycan has been shown to consist of two sialic 
acids residues, two galactose, three mannose and four N-acetylglucosamine 
residues (Gomme et al., 2005). The carbohydrate moiety sites occur in the C-
terminal domain and not in the N-terminal domain. The biological function of 
the glycans in transferrin is not fully understood. However, it has been 
suggested that they might play a role in Tf solubility and binding to its 
receptor (Hemmaplardh and Morgan, 1976). 
The polypeptide chain of transferrin has a combination of alpha helices and 
beta sheets to form two structurally similar but functionally different lobes, the 
N-lobe and C-lobe. Each lobe consists of two domains (NI, residues 1-92 and 
247-331; NII, residues 93-246; CI, residues 339-425 and 573-679; CII, 
residues 426-572). These lobes are held together by a short peptide linker 
(residues 332-338) and each creates a deep hydrophobic site to hold iron in 
the ferric state. A common feature of all Tf family members is the large 
conformational changes that take place upon the binding and release of iron 
in each lobe. The amino acids residues that bind the ferric ion are the same 
for both lobes: two tyrosines, one aspartic acid and one histidine. The binding 
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of iron also needs an anion which is usually carbonate (CO3
2-). The uptake of 
the metal by Tf is initialized by the binding of the carbonate ion to the apoTf 
present in blood serum (Rinaldo and Field, 2003), then the metal reaches the 
metal-binding site of the protein, and the complex is recognized by the 
transferrin receptor (TfR) and internalized in the cytoplasm by receptor-
mediated endocytosis (Dautry-Varsat et al., 1983). There the release of the 
metal from Tf is influenced by the Tf-TfR interaction (Eckenroth et al., 2011) 
and modulated by the lower endosomal pH of 5.5, which is significantly lower 
than the serum pH (7.4). Crystallography shows that conformational changes 
in the structures of the transferrins depend on iron binding or release. There 
are two different conformations, an open conformation when they are metal 
free (Wally et al., 2006), and a closed conformation upon the binding of Fe3+ 
(Guha Thakurta et al., 2003). 
Human serum transferrin (hTf) is synthesized in the liver and secreted into 
the plasma. Because each domain contains an Fe3+-binding site, serum 
transferrin exists as four molecular forms: apotransferrin (Fe0-Tf or apoTf), 
with no Fe3+; one Fe3+ ion bound to the C-terminal lobe (Fe1C-Tf); one Fe3+ 
ion bound to the N-terminal lobe (Fe1N-Tf); and both binding sites occupied 
(Fe2-Tf) (De Jong et al., 1990), but all transferrin-bound iron can be 
considered physiologically as a single homogeneous pool. Isoelectric 
focusing is a technique used to separate these isoforms in human blood 
because each isoform has a different isoelectric point (pI) due to differences 
in the iron. In addition to differences in iron content there are also different 
isoforms based on differences in sialic acid content (van Eijk and van Noort, 
1992). 
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3.1.2 Transferrin glycation 
Many plasma proteins such as immunoglobulins, albumin and lipoproteins 
are prone to glycation reactions. These reactions are increased in diabetic 
patients who have poor glycaemic control compared with normal subjects 
(Austin et al., 1987). Like other proteins, transferrin may lose its function 
when glycated and may contribute to diabetic complications such as 
cardiovascular disease, via a reduction in antioxidant capacity, and the 
potential occurrence of redox-active plasma iron (Fujimoto et al., 1995, van 
Eijk and van Noort, 1992). Fujimoto et al. (2002) found that the total level of 
iron and the iron-binding capacity decreased in the serum of rats when rat 
serum was incubated with glucose, and the degree of glycation increased 
with time of incubation. 
Many in vitro studies have observed that glycation of transferrin leads to 
increased oxidative stress by impairing iron-binding antioxidant capacity. 
Fujimoto et al. (1995) used bovine holotransferrin and apotransferrin (Wako 
Pure Chemicals); van Campenhout et al. (2004) used human apotransferrin 
(Sigma); and Goudarzi and Rashidi (2010) used human apotransferrin 
(Sigma). All these researchers used different glucose concentrations, times 
of incubation and also different methods for measuring iron, iron-binding 
capacity and for assessment of glycation. All three groups found positive 
associations between glucose concentrations, degree of glycation, and 
reduction in function, with significant differences between glucose 
concentration and controls, and between different concentrations or 
increased incubation time. 
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3.1.3 LDL and atherosclerosis 
An increase in plasma levels of triacylglycerol and low density lipoprotein 
cholesterol (LDL-C), and a decrease in high density lipoprotein cholesterol 
(HDL-C) have been shown to play a central role and are considered powerful 
risk factors for atherosclerosis in T2DM (Temelkova-Kurktschiev and 
Hanefeld, 2004). Elevated levels of LDL, for example, due to genetic 
abnormalities in the LDL receptor, is a well-known risk factor for 
atherosclerotic disease and accelerated coronary artery disease (Goldstein 
and Brown, 1977, Brown and Goldstein, 1986). Determination of the structure 
of LDL has been a difficult task because of its heterogeneous structure. LDL 
particles contain a variable and changing number of fatty acid molecules. 
There is a distribution of LDL particle mass and size (Segrest et al., 2001). 
LDL particles are sensitive to oxidative damage because of their complex 
lipid-protein composition. Each LDL particle contains about 700 molecules of 
phospholipids; 600 of free cholesterol; 1600 of cholesteryl esters; 185 of 
triglycerides; and 1 molecule of apolipoprotein (apo) B, which in turn is 
composed of 4536 amino acid residues. 
Analysis of data for atherosclerotic lesions has emphasised that the transition 
metals such as iron and copper are likely to play a central role as triggers of 
LDL oxidation in vivo (Smith et al., 1992). The concentration of copper is low 
in the blood system appearing in the form of ceruloplasmin, which is not 
considered a pro-oxidant (Burkitt, 2001), while, the concentration of iron in 
blood is extremely high (millimolar) compared with other transition elements. 
A possible link between iron and atherogenesis has been suggested by the 
finding that iron chelation blocks oxidation of LDL, whereas iron released 
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from the protein-bound form causes oxidation of LDL (Abdalla et al., 1992). 
Oxidative modification of low-density lipoprotein (LDL) plays a causal role in 
human atherogenesis and the risk of atherosclerosis is increased in patients 
with diabetes by approximately three-fold (Lyons et al., 1986). One 
hypothesis is that increased modification of LDL by oxidation and/or glycation 
may induce endothelial cell injury and accelerate foam cell formation in the 
arterial intima (Steinberg et al., 1989). 
Hyperglycaemia induces lipoprotein modification through the glycation of 
apolipoproteins. Glycated lipoproteins are more prone to oxidation than 
native lipoproteins (Sobal et al., 2000). Glycation itself has been 
demonstrated to be more toxic than oxidation in the case of LDL (Galle et al., 
1998). The toxic properties of glycated LDL include the inhibition of NO 
production in endothelial cells (Posch et al., 1999); alteration of the 
antithrombotic properties of vascular endothelium (Wen et al., 2002); 
enhanced expression of adhesion molecules; and also increased platelet 
aggregation (Takeda et al., 1992). 
Glycation and glycoxidation of LDL have been shown to occur under similar 
conditions of hyperglycaemia. Glycation and oxidation of LDL reduces its 
affinity for the LDL receptor, leading to reduced hepatic catabolism, increased 
accumulation of cholesteryl esters in macrophages and altered endothelial 
function (Steinberg, 1989, Witztum and Steinberg, 1991, Lopes-Virella et al., 
1988). 
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3.2 Aim 
The aim of the work described in this chapter was to investigate, in vitro, the 
effects of half saturation of apotransferrin with iron on transferrin and LDL 
glycation and oxidation, and on iron-binding capacity of transferrin. 
3.3 Methods 
3.3.1 Transferrin loading with iron 
3.3.1.1 Preparation of Fe(NTA)2 solution 
Due to the low solubility of Fe3+ at pH 7.4, the iron was loaded into transferrin 
using iron nitrilotriacetic acid, Fe(NTA)2. The solution was prepared by 
dissolving 22.25 µmol of FeCl3•6H2O and 45 μmol of nitrilotriacetic acid in 2 
ml of 1 M HCl, adjusting the pH to 4.0 with 1 M NaOH solution and diluting to 
10 ml. This solution was freshly prepared (Battin et al., 2009). 
3.3.1.2 Preparation of human apotransferrin solution 
Human apotransferrin (20 mg, ~0.25 μmol; Sigma-Aldrich) was dissolved in 3 
ml of Tris buffer (50 mM Tris, 150 mM NaCl, 20 mM NaHCO3; pH adjusted to 
7.4), and the UV/vis spectrum was taken from 250 nm to 750 nm (Figure 3.1); 
Tris buffer was used as a reagent blank. The concentration of transferrin was 
calculated by measuring the protein absorbance at 280 nm (Figure 3.1) and 
using an extinction coefficient of 87.2 mM-1 cm-1 (Battin et al., 2009). 
3.3.1.3 Exposure of 50% loaded transferrin to glucose 
Fe(NTA)2 solution (0.4 equivalents per transferrin protein) was added to 800 
μl of apotransferrin solution, and, after 5 min incubation, the UV/vis spectrum 
was scanned. This process was repeated every 5 min until no further 
changes in the UV/vis spectra were observed (Figure 3.2). Tris buffer was 
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used as a reagent blank. The percentage of iron loading in the transferrin 
was estimated by measuring the absorbance at 470 nm, and using an 
extinction coefficient of 4.86 mM-1 cm-1 (Ando et al., 2002). 
Based this data, the volume of Fe(NTA)2 solution which made the 
apotransferrin half saturated was known. Aliquots (250 µl) of human 
apotransferrin solution were freshly prepared as described in Section 3.3.1.2, 
after which Fe(NTA)2 solution freshly prepared as described in Section 
3.3.1.1 was added to make transferrin half saturated with iron. Glucose 
solutions in Tris buffer were added to this half saturated transferrin to give 1 
ml of 0, 250, 500, 750 and 1000 mM glucose. All solutions nominally 
contained 0.4 µg l-1 transferrin. The Tris buffer was prepared with Milli-Q 
HPLC grade water, and all plastic tubes and tips were autoclaved (at 121 °C 
for 15 min at 15 PSI). The transferrin solutions were transferred to 2 ml HPLC 
sample containers (Fisher Scientific, UK), which were then tightly sealed with 
a small gas phase (200 µl) at the top. After this the containers were 
incubated at 37 °C for 14 days. For each container, the absorbance spectrum 
of the transferrin was taken every day. Selection of containers and their 
orientation was done based on comparison of the spectrum of a food dye 
between a normal quartz cuvette and the sealed HPLC containers. 
3.3.2 Buffer exchange 
The transferrin solutions were removed from the incubator on day 14 and 
placed on ice, prior to buffer exchange into glucose-free Tris buffer. A 
Sephadex G-25 column (10 ml) was used for the exchange. This volume of 
column was found to give a good separation of protein from glucose, with 1 
ml fractions. The recovery of protein was tested using bovine serum albumin 
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(BSA) (Figure 3.6). An example of buffer exchange and the separation of 
protein from glucose are shown in Figure 3.7. 
3.3.3 Measurement of protein 
The protein concentration was measured by the Bradford method (Bradford, 
1976). As a control a solution of fresh apotransferrin (1 mg ml-1), was made 
up in Tris buffer. 
3.3.3.1 Preparation of Bradford reagent 
Bradford stock solution (30 ml) was prepared by mixing 35 mg of Coomassie 
Blue G-250 (Fisher Scientific, UK Ltd) with 10 ml of 95% ethanol and 10 ml of 
88% phosphoric acid. From this stock solution, 6 ml was mixed with 6 ml of 
88% phosphoric acid, 3 ml of 95% ethanol and 85 ml of distilled water to 
produce a working reagent. The working reagent was filtered through 
Whatman Grade No. 1 filter paper before use. After filtration the solution was 
stored in a brown bottle at room temperature for several weeks. 
3.3.3.2 Procedure 
For each sample, blank and control, 100 µl were added to 1 ml of Bradford 
working solution. After 5 min the absorbance was measured at 595 nm. A 
calibration curve was established each time a protein assay was performed 
with apotransferrin dilutions of known concentrations. Using the standard 
curve (Figure 3.5), the concentration of each sample was determined 
according to its absorbance. 
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3.3.4 Measurement of glucose in samples 
The glucose concentration was measured by method of Miller (1959), using 
the colorimetric reagent dinitrosalicylate. The results for glucose standards 
are shown in Figure 3.4. 
3.3.5 Assessment of glycation 
The degree of glycation was measured using the 2,4,6-trinitrobenzene 
sulfonic acid (TNBSA, also known as picrylsulfonic acid) assay, which reacts 
with NH2 groups at pH 8, to form adducts detectable at 335 nm. TNBSA is a 
rapid and sensitive assay for the determination of free amine groups (Habeeb, 
1966). 
To 25 μl of glycated transferrin, L-lysine standards and blanks, the following 
were added: 25 μl of 4% Na2HCO3 and 25 μl 0.1% TNBSA. The samples 
were incubated at 37 °C for 2 h and then the following were added: 25 μl of 
10% SDS, 12.5 μl of 1 M HCl and 787.5 μl of distilled H2O, to make a final 
volume of 900 μl. After that, 300 µl of sample, control and standards were 
transferred to a 96-well plate. The absorbance of the resulting solution was 
read immediately in plate reader (Versamax, Molecular Devices, Sunnyvale, 
CA) at 340 nm. Calibration results are shown in Figure 3.8. 
3.3.6 Measurement of total iron 
The method used was as described in Section 2.4.4. 
3.3.7 Measurement of total iron-binding capacity 
The method used was as described in Section 2.4.5. 
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3.3.8 Electrophoresis 
3.3.8.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(PAGE) 
Sodium dodecyl sulphate (SDS) polyacrylamide gels were prepared 
according to the method of Laemmli (1970) using a 8% separating gel and a 
4% stacking gel. The procedure used was as follows. 
Plates and combs were cleaned with 70% ethanol, and then the plates were 
set up on the plate rack according to Bio-Rad instructions, with the bottom 
edges of the two plates flush to avoid leakage. The plates were locked in the 
green holder, and the holder placed on the rack. Separating gel mix 
containing 2.7 ml of solution A (30% acrylamide/bis-acrylamide), 2.5 ml of 
solution B (1.5 M Tris-chloride, 0.4% SDS, pH 8), 4.8 ml H2O, 50 µl of 10% 
ammonium persulfate (APS) and 5 µl of tetramethylethylenediamine (TEMED) 
was prepared. All these materials were mixed in advance except the TEMED 
which was added just before pouring the gel into the vertical glass. The main 
gel mix was poured between the assembled gel plates until the level was just 
below where the comb sat, after which it was overlaid with 150 µl H2O. The 
gel mix was allowed to polymerise for about 30 min, and then the water was 
removed from the top of the gel. 
The stacking gel mixture was prepared using 0.67 ml of solution A, 1.0 ml of 
solution C (0.5 M Tris-chloride, 0.4% SDS, pH 6.8), 2.3 ml H2O, 30 µl of 10% 
APS and 5 µl of TEMED. The stacking gel mix was poured carefully on top of 
main gel, and the comb inserted, avoiding air bubbles. The gel mix was 
allowed to polymerise for about 30 min. 
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Gels were run using a running buffer consisting of Tris base (12 g), glycine 
(57.6 g), and SDS (4 g) made up to 1 l. The running buffer was added to 
cover the top of the gel in the Bio-Rad system, before the comb was removed 
and the wells rinsed out with running buffer using a Pasteur pipette. The tank 
of the Bio-Rad system was then filled with the desired running buffer volume. 
The gel was run at 200 V for 45-50 min until the blue tracking dye ran off the 
end. 
Protein concentration for the sample load was assessed as in Section 5.3.3, 
and then 10 µl containing 50 µg of protein was mixed with 10 µl loading 
buffer prepared by mixing 1 ml of 0.5 M Tris-chloride buffer, pH 6.8, 0.8 ml 
glycerol, 16 ml of 10% SDS and 0.32 ml 0.05% bromophenol blue with 4.18 
ml distilled water. The samples were heated at 95 °C for 5 minutes before 
loading them into the gel wells. 
Gels were visualised by using Coomassie blue. The dye was prepared by 
dissolving 0.2% Coomassie Brilliant blue R-250 in 30% methanol and 10% 
acetic acid. The dye was poured on the gel in a suitable container and left on 
an orbital shaker (17 rpm) overnight. The gel was then washed with destain 
solution consisting of 40% methanol and 10% acetic acid for 2 or 3 times until 
it became clear. Finally the gel was imaged using visible light (Universal 
Hood 11, Bio-Rad Laboratories, Italy). 
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3.3.9 LDL incubation with half-saturated transferrin and glucose 
3.3.9.1 Preparation of LDL suspension 
The LDL used was supplied as a lyophilized powder (Sigma). At first an 
attempt was made to resuspend the lyophilized LDL in 1 ml of distilled water 
following the manufacturer’s (erroneous) instructions. However, this was 
unsuccessful. Eventually a solution containing 150 mM NaCl and 0.01% 
EDTA, pH 7.4, was used following reference to an internet forum. This 
resuspended material was homogenised manually using an all-glass Potter 
homogeniser over a period of about 3 h. This process was carried out under 
oxygen-free nitrogen gas to avoid LDL oxidation. 
3.3.9.2 Procedure 
LDL suspension was incubated in the same tubes as were used for the 
previous experiment Section 3.1.1 with combinations of 50% ITf plus glucose, 
iron, apoTf and glucose the experimental design shown in Table 3.1. 
Table 3.1 LDL incubated with 50% ITf, iron, apoTf and glucose. The concentration of Tf, where 
present, was 0.44 µM, and the pH was 7.4. 
Tubes 
50% 
ITf (l) 
LDL 
(l) 
500 mM 
glucose 
in Tris 
buffer (l) 
Tris 
buffer 
(l) 
Fe(NTA)2 
(l) 
(0.14 µM) 
apoTf 
(l) 
(0.4 µg l-1) 
50% ITf + LDL 
+ glucose 
250 100 650    
LDL + iron  100  650 250  
apoTf + LDL  100  650  250 
LDL  100  900   
LDL + glucose  100 900    
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All tubes were incubated at 37 °C for 14 days. After this the tubes were 
placed on ice before the LDL was separated by ultracentrifugation using a 
Beckman Coulter Optima XPN-100 ultracentrifuge (125000 g at 15 °C for 
5 h). 
3.4 Results 
3.4.1 Spectrum of human apotransferrin solution 
UV/visible spectra were taken from 250 nm to 750 nm for 1 ml of human 
apotransferrin solution prepared as described in Section 3.3.1.2. Tris buffer 
was used as the reagent blank. The concentration of transferrin was 
calculated by measuring the protein absorbance at 280 nm (Figure 3.1). 
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Figure 3.1 UV/visible spectrum of human apotransferrin. 
A solution of apotransferrin was prepared as described in Section 3.3.1.2. This was diluted 10 
fold in Tris buffer. Based on the A280 and an extinction coefficient of 87.2 mM
-1
 cm
-1
 the 
concentration of transferrin in the stock solution was 136 µM. This was higher than expected 
(83 µM) based on the nominal mass of protein supplied by Sigma. 
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3.4.2 Apotransferrin titration with iron 
UV/visible spectra were taken from 250 nm to 750 nm for human iron 
transferrin (ITf) freshly prepared as described in Section 3.3.1.3. The spectra 
are shown in Figure 3.2. The red line represents apotransferrin; the other 
lines represent different levels of iron saturation of transferrin. 
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Figure 3.2 UV/visible spectra of transferrin during titration with iron. 
As described in Section 3.3.1.3. Based on A470 and an extinction coefficient of 4.86 mM
-1
 cm
-1
 for 
iron-loaded transferrin the concentration of the stock solution was 120 µM, which is in good 
agreement with the value obtained from the data in Figure 3.1. 
3.4.3 Use of HPLC sample vials as cuvettes 
Visible spectra between 400 to 700 nm were taken of a food dye solution in a 
quartz cuvette (blue line) to compare with the spectra of the same solution in 
the containers (2 ml HPLC sample vials) which were to be used in the 
incubation of apotransferrin with different concentrations of glucose. Different 
orientations of the vials were used in order to find orientations that gave 
spectra comparable to that obtained in the quartz cuvette. Inappropriate 
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orientations were labelled to ensure that reliable spectra were obtained 
(Figure 3.3). 
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Figure 3.3 Comparison of the visible spectrum of a food dye. 
The solution in a quartz cuvette (blue line) was compared with those of the same solution in an 
example of the containers used for incubation of transferrin with glucose, in different 
orientations (other coloured lines). The orientation represented by the red line shows the most 
similar spectrum compared with that obtained with a quartz cuvette after used same dye in 
quartz cuvette. 
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3.4.4 Glucose standards 
The results for glucose standards are shown in Figure 3.4. Glucose was 
determined using the dinitrosalicylic colorimetric method. The absorbance 
was measured for each concentration in triplicate for two sets of standards. 
 
Figure 3.4 Calibration graph for the determination of glucose (means ± SEM) as described in 
Section 3.3.4. 
3.4.5 Protein standards 
The results for protein standards are shown in Figure 3.5. Protein was 
determined using the Bradford assay. The absorbance was measured for 
each concentration in triplicate for two sets of standards. 
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Figure 3.5 Calibration graph for the determination of protein using the Bradford assay (means ± 
SEM). Bovine serum albumin was used for the standards. 
3.4.6 Recovery of protein following buffer exchange, and the separation 
of protein from glucose 
The recovery of protein from the 10 ml Sephadex G-25 column (Section 3.3.2) 
was tested using 1 ml of a 2 mg ml-1 bovine serum albumin (BSA) solution. 
Following loading of the BSA solution, 1 ml aliquots of Tris buffer were added 
to the column to elute the BSA and 1 ml fractions were collected (Figure 3.6). 
The protein was recovered in three 1 ml fractions (fractions 3-5). The 
experiment was repeated using a solution containing BSA and 1 mM glucose. 
Figure 3.7 shows the recovery of protein following the buffer exchange and 
separation of protein from glucose. Fractions 3, 4 and 5 were found to be 
suitable for use in the experiments with transferrin. 
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Figure 3.6 The recovery of bovine serum albumin (inexpensive compared to Tf) following 
application of 1 ml of 2 mg ml
-1
 of protein to a 10 ml Sephadex G-25 column. 
 
Figure 3.7 The separation of bovine serum albumin (red) from glucose (blue), following 
application of 1 mg ml
-1
 of protein in Tris buffer containing 1 mM glucose (1 ml) to a 10 ml 
Sephadex G-25 column. 
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5.4.7 L-lysine standards 
The results for lysine standards are shown in Figure 3.8. L-lysine was 
determined by detection of free -NH2 groups using the TNBSA assay. The 
absorbance was measured for each concentration in triplicate for two sets of 
standards. 
 
 
Figure 3.8 Calibration graph for the determination of –NH2 groups using the TNBSA assay 
(means ± SEM). 
Lysine was used as a source of amine groups. Despite being carried out in Tris buffer the 
absorbance of the blank (0.0123) was low indicating that Tris does not react with TNBSA. 
3.4.8 Exposure of 50% ITf to different concentrations of glucose 
50% ITf was exposed to a range of concentrations (0-1000 mM) of glucose 
as described in Section 3.3.1.3, after which a range of parameters relating to 
glycation and iron binding were determined. 
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3.4.8.1 Effect of glucose on the absorbance spectrum 50% ITf 
On incubation of 50% ITf with glucose changes in the absorbance spectrum 
of Tf over time were seen; there was a shift in the 280 nm absorption band 
towards higher wavelengths (Figure 3.9). Unfortunately a writing error when 
transferring the spectra for the control (50% ITf without glucose) meant that 
these were lost. However, the spectrum changes seen in the other samples 
were not glucose concentration dependent, but may be due to structural 
changes caused by the relatively high concentration of glucose in the 
environment of the protein. Because of the large protein spectral changes it 
was not possible to use to use the 470 nm region to monitor changes in iron 
binding as originally intended. 
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Figure 3.9 Spectra for 50% ITf incubated with 1000 mM glucose on day 1 (red line) 
and on day 14 (black line).  
Insert: difference spectrum (between days 14 and 1) shows the shift of the 280 nm peak toward 
higher wavelength. The absolute spectra were baseline corrected (subtracted average 
absorbance in the range 700-800 nm) and normalized using A280, i.e. A280 was taken to be 
equal to one. 
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3.4.8.2 Assessment of glycation 
The degree of glycation was assessed by measurement of –NH2 groups. 
Figure 3.10 shows the levels of –NH2 groups after the incubation of 50% ITf 
without glucose and with different concentrations of glucose for 14 days. The 
level in 50% ITf incubated with 1000 mM glucose was significantly lower than 
that for 50% ITf without glucose (P = 0.02). Also the level in 50% ITf with 
1000 mM glucose was significantly lower than that in 50% ITf with the other 
concentrations (P < 0.05), but there were no significant differences between 
50% ITf without glucose and 50% ITf with 250, 500 and 750 mM glucose. 
There was Inverse relationship between concentration of glucose and 
number of amine groups found after incubation of 50% ITf with different 
concentrations of glucose (Figure 3.11). 
 
Figure 3.10 Glycation of 50% ITf (means ± SEM)  incubated with different 
concentrations of glucose for 14 days.  
Bars with different letters are significantly different (P < 0.05, n = 3 replicate measurements). 
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Figure 3.11 Inverse relationship between concentration of glucose and number of 
amine groups found after incubation of 50% ITf with different concentrations of 
glucose for 14 days. R
2
 = 0.851. (P = 0.021). n = 3 replicate measurements. 
3.4.8.3 Assessment of transferrin iron-binding capacity 
The iron binding capacity of transferrin was measured by the method used 
previously for the TIBC of plasma (Section 2.4.5). The iron-binding capacity of 
transferrin was reduced significantly with increasing glucose concentration. There 
was a significant difference (P < 0.01) between 50% ITf without glucose and with all 
the concentrations of glucose. There were also significant differences (P < 0.01) 
between 50% ITf with 1000 mM of glucose, and 250 and 500 mM glucose. There 
were no significant differences (P > 0.05) between 50% ITf with 750 mM glucose 
and with 250 or 500 mM glucose (Figure 3.12). There was an inverse relationship 
between TIBC concentration and the different concentrations of glucose (Figure 
3.13). 
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Figure 3.12 TIBC of 50% ITf (means ± SEM) incubated with  different concentrations 
of glucose for 14 days. 
Bars with different letters are significantly different.  n = 3 replicate measurements.  
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Figure 3.13 correlation between TIBC and different concentrations of glucose . 
Incubated with 50% ITf. R
2
 = 0.875, P = 0.020, n = 3 replicate measurements. 
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3.4.8.4 Free iron levels 
Loss of iron from transferrin increased with increasing concentration of 
glucose but the increase was not significant (P > 0.05) between 50% ITf 
without glucose and 50% ITf with different concentrations of glucose (Figure 
3.14). There was a positive relationship between free iron and different 
concentrations of glucose (Figure 3.15). 
 
Figure 3.14 Free iron (means ± SEM) ‘released’ from 50% ITf incubated for 14 days 
with different concentrations of glucose. 
Bars with different letters are significant differen t. n = 3 replicate measurements.  
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Figure 3.15 Correlation between free iron and different concentrations of glucose 
incubated with 50% ITf. R
2
 = 0.837, P = 0.022, n = 3 replicate measurements. 
3.4.8.5 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate (SDS) polyacrylamide gels were prepared according 
to the method of Laemmli (1970) using an 8% separating gel and a 4% 
stacking gel as described in Section 3.3.8.1. The gels showed no evidence of 
fragmentation of the 50% ITf incubated with different concentrations of 
glucose (Figure 3.16). However, unexpectedly more than one band was 
found. While it is possible that this is because of impurity arising from the 
manufacturing process, another possibility is that it relates to differences in 
the glycoprotein component. It is known that there are isoforms of Tf that 
differ in the sialic acid component (van Eijk and van Noort, 1992). 
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Figure 3.16 SDS PAGE of 50% ITf incubated for 14 days at 37 °C with different concentrations of 
glucose. 
Lane 1, apoTf; lane 2, 50% ITf without glucose; lane 3, 50% ITF with 1000 mM glucose; lane 4, 50% 
ITf with 750 mM glucose; lane 5, 50% ITf with 500 mM glucose; and lane 6, 50% ITf with 250 mM 
glucose. 
3.4.9 Co-exposure of LDL and 50% ITf to glucose 
LDL and 50% ITf were incubated with 500 mM glucose as described in 
Section 3.3.9.2. In addition, as controls, LDL was incubated with apoTf, a low 
level of free iron, 500 mM glucose and in isolation. 
5.4.9.1 Assessment of oxidation of LDL using MDA 
There was an increase in LDL oxidation when LDL was co-incubated with 50% 
ITf and glucose compared to LDL alone, but this was not significant (P > 0.05) 
(Figure 3.17). 
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Figure 3.17 Levels of MDA (means ± SEM) from oxidation of LDL. 
After incubation with 50% ITf plus 500 mM glucose, free iron, apoTf and 500 mM glucose. There 
were no significant differences in MDA levels (P > 0.05). n = 3 replicate measurements. 
3.4.9.2 Free iron 
There was a significantly (P < 0.01) higher level of free iron in 50% ITf with 500 mM 
glucose co-incubated with LDL compared to LDL incubated with iron, apotransferrin 
or glucose alone (Figure 5.18). 
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Figure 3.18 Free iron (means ± SEM) ‘released’ from incubation of LDL with 50% ITf plus 500 
mM glucose, free iron, apoTf and 500 mM glucose. 
Bars with different letters are significantly different (P < 0.01, n = 3 replicate measurements). 
 
Figure 3.19 TIBC (means ± SEM) after incubation of LDL with 50% ITf plus 500 mM glucose, free 
iron, apoTf and 500 mM glucose. 
Bars with different letters are significantly different (P < 0.01), nd = not detectable. Note that the 
LDL was removed by ultracentrifugation before measurement of TIBC of the remaining Tf. n = 3 
replicate measurements. 
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Figure 3.20 Glycated LDL (means ± SD) after incubation LDL with 50% ITf plus 500 mM glucose, 
iron, apoTf and 500 mM glucose. 
Bars with different letters are significantly different (P < 0.01). Note that these measurements 
were carried out on LDL separated from the other components by ultracentrifugation. n = 3 
replicate measurements. 
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3.5 Discussion 
The reactions of glucose and other reducing sugars with proteins have been 
thoroughly studied in vitro and in vivo. These reactions change functions, 
activities and structure of proteins. Many studies have focused on the effects 
of glycation on protein structure and function in the extracellular proteins, 
such as collagens (Guilbert et al., 2013), lens crystallins (Katta et al., 2009), 
Hb (Bose et al., 2013) and albumin (Rondeau and Bourdon, 2011). Glycation 
of albumin significantly impairs its antioxidant properties (Baraka et al., 2013), 
and reduces its drug-binding capacity (Baraka et al., 2012). Glycated albumin 
shows changes in the ability to bind fatty acids and bilirubin, and 
demonstrates conformational changes, shown by a reduction in tryptophan 
fluorescence at 295 nm suggesting the sole tryptophan residue was in a 
more hydrophobic environment, and presumably more buried due to the 
protein glycation (Shaklai et al., 1984). 
Most studies have focused on haemoglobin glycation and the use of HbA1C 
as a biomarker of glycaemic control in the diagnosis of diabetes. Other 
studies use albumin as an alternative to HbA1C (Chujo et al., 2006), because 
it represents 60% of total plasma protein and has a shorter half-life, ranging 
from 12 to 19 days for glycated albumin (Yatscoff et al., 1984). 
Due to the importance of transferrin in iron transport and its acting as 
antioxidant because of its ability to sequester iron in inactive redox form, 
Austen et al. (1987) started their work on transferrin glycation in vivo and 
demonstrated that transferrin is prone to glycation and that this may affect 
iron binding to transferrin especially in diabetes. 
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The present work was aimed at demonstrating the effect on glycation of in 
vitro incubation of transferrin half saturated with iron (50% ITf) with different 
concentrations of glucose, and the consequent effects on the iron binding 
sites and iron release. Previous studies on the effects of glycation on the 
release of free iron from Tf have been done with 100% ITf (holoTf). With 
holoTf if there is any release of iron from Tf then there is no remaining iron-
binding capacity to take up this free iron, thereby potentially exacerbating the 
effects of high concentrations of glucose on the release of further iron. The 
current experimental scenario is more physiologically relevant because the 
plasma transferrin is usually only about 33% saturated. 
The study showed that the glycation of 50% ITf without glucose was 
significantly lower than 50% ITf incubated with 1000 mM glucose. This study 
also showed a positive linear relationship between concentration of glucose 
and degree of glycation. Association between glucose concentration and the 
degree of glycation in this study is supported by the studies of the (Fujimoto 
et al., 1995, Van Campenhout et al., 2004, Goodarzi, 2010). Fujimoto et al. 
(1995) used bovine holoTf and apoTf (10 mg ml-1 protein with 0 or 1 M 
glucose, in 50 mM phosphate buffer, pH 7.4, at 37 °C for 10 days) and used 
different methods for assessment the glycation (thiobarbituric acid reaction 
using 5-hydroxymethyl-2-furfural (HMF) as a standard compound). Fujimoto 
et al. (1995) found no glycation in zero glucose of both apo and holo bovine 
transferrin but they found a degree of glycation in apo and holoTf with 1 M 
glucose. Van Campenhout et al. (2004) used human apoTf (0-33.3 mM or 
1000 mM glucose, pH 7.4, at 37 °C for 14 days) and used the fructosamine 
method (fructosamine measured by reaction of nitroblue tetrazolium with 
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fructosamine) to assess the glycation and found that glycation of apoTf 
increased with increasing concentration of glucose. Goodharzi et al. (2010) 
used human apoTf (0-200 mM glucose, pH 7.4, at room temperature for 10 
and 20 days). This study also found that the degree of glycation increased 
with increased glucose concentration. 
In the present study the TIBC in 50% ITf without glucose was significantly 
higher than that in 50% ITf incubated with all the different concentrations of 
glucose (15.5% remaining with 1000 mM). This finding was supported by the 
study of (Van Campenhout et al., 2004). Van Campenhout et al. found that 
TIBC decreased with increased glucose concentration (81% remaining with 
33 mM and 1.5% with 1000 mM glucose). The effect of glycation in lowering 
transferrin iron-binding capacity might be due to influence the glycation of 
lysine residues on neighbouring amino acid residues and an overall decrease 
in positive charge, due to the attachment of sugar residues to the protein 
amine groups in the glycation process (Handa and Kuroda, 1999), which 
causes the iron-binding ability of transferrin to be impaired. In this study 
incubation of glucose with 50% ITf showed less effect on loss of TIBC when 
compared with the study of Van Campenhout et al. (2004), who used holoTf; 
this difference in result may arise because of the greater possibility of free 
iron being present in a preparation of holoTf than in 50% ITf. 
In this study denaturing electrophoresis (SDS page) was used to examine the 
effect of glycation on the fragmentation of 50% ITf in the presence of glucose. 
There was no evidence of fragmentation of the protein. Fujimoto et al. (1994) 
used denaturing electrophoresis to further examine Tf samples, finding that 
substantial fragmentation of the protein could be seen only in the glycated 
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holoTf. The fragmentation of the protein only appears in previous studies in 
case of glycated holoTf, which might be due to the high release of iron from 
the holoTf. 
All proteins are glycated when they are exposed to glucose and no exception 
has been reported (Baynes, 1991). In the present study LDL was also 
incubated with 50% ITf with 500 mM glucose. In addition, LDL also was 
incubated with apoTf, iron and with glucose only. Control LDL was prepared 
in the same way without adding glucose and incubated under identical 
conditions. Glycation of LDL was estimated in the present study by the 
number of lysine residues in apolipoprotein B. There was a significant 
difference between glycation of LDL incubated with 500 mM glucose and LDL 
which was used as a control. However, unexpectedly there was no evidence 
of glycation in LDL incubated with 50% ITf and glucose. In addition, LDL 
incubated with apoTf showed an apparent increase in available lysine 
residues. Since only a single run of this experiment was possible due to the 
expense of the reagents, there is a question about the reliability of the results. 
This is particularly the case given the difficulty in handling the LDL, 
distributing it between the tubes and especially recovering it after 
ultracentrifugation. 
In vitro, glycation of LDL occurs easily by the incubation of LDL with glucose. 
The part of LDL that is prone to glycation is side chain amine groups of lysine 
residues in which LDL is rich (Younis et al., 2008). The speed of the reaction 
is dependent on the environment of these residues and not all the residues 
will be glycated to the same extent. The glycation process also depends in 
glucose concentration. 
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Malondialdehyde (MDA) is known to be an end-product of lipid peroxidation 
formed by oxidation of LDL (Requena et al., 1996). In present study MDA 
was used as biomarker of LDL oxidation. MDA was increased but there was 
no significant difference between LDL co-incubated with 50% ITf and LDL 
incubated with iron, apoTf, glucose and LDL that was used as a control. This 
result may be explained by the process of glycation of 50% ITf in the 
presence of LDL changing the binding capacity of transferrin and causing 
release of free iron, which may cause more oxidation of the LDL. Another 
possible reason for the increase in the oxidation of LDL may be due to 
glycation of LDL itself making it more prone to oxidation (Sobal et al., 2000). 
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4.1 General discussion 
Iron is an essential trace element for normal cellular functions, and both iron 
deficiency and overload have deleterious effects. There is significant 
evidence which suggests that accumulation of iron in the cells of the body is 
associated with increased risk of T1DM and T2DM, and this iron has been 
proposed to be involved in the pathophysiological mechanisms of T2DM 
(Cooksey et al., 2004, Thomas et al., 2004, Rajpathak et al., 2009, Ellervik et 
al., 2011, Huang et al., 2011, Montonen et al., 2012). T2DM is more common 
in hereditary haemochromatosis due to a defect in β-cell function resulting 
from iron deposition in these cells (Wood et al., 2014), and patients with β-
thalassaemia, with high serum ferritin levels, are subject to insulin resistance. 
Large prospective cohort studies reported that high iron dietary intake, 
particularly of haem iron derived from meat, is associated with a significant 
increased risk of T2DM (Li et al., 2008), and serum ferritin levels (a 
biomarker of body iron stores) are positively associated with diabetes risk 
(Liu et al., 2009, Fernández-Real et al., 2002a, Zhao et al., 2012). The 
mechanism(s) which explain(s) this relationship is still not clear but some 
plausible reasons may be: 
1. Increased iron status may increase the risk of T2DM by increasing 
ROS production via the pro-oxidant properties of free iron and the 
known relationship between ROS and insulin resistance (Goldstein et 
al., 2005). 
2. Increased iron in the liver may induce insulin resistance by impeding 
the liver’s capacity for insulin extraction thereby increasing hepatic 
glucose production. Iron deposits contribute to impaired insulin 
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metabolism by reducing the insulin extracting capacity leading to 
hepatic insulin resistance (Bugianesi et al., 2004). 
3. Impairment by iron of insulin action and interference with glucose 
uptake in adipocytes and skeletal muscle (Fernández-Real et al., 
2002a, Lepage et al., 1991). 
4. Increased muscle iron stores may enhance fatty acid oxidation and 
therefore could interfere with glucose disposal. Thus increased 
glucose production and decreased utilization may occur with 
increasing the level of iron (Rajpathak et al., 2009). 
5. Excess of body iron may be also cause iron deposition in pancreatic 
β-cells resulting in impaired insulin secretion. 
High plasma glucose levels, as seen in T2DM, cause an increase in the rate 
of protein glycation reactions, such as glycation of haemoglobin, transferrin 
and albumin. This can be the result of the reaction between protein amine 
groups and glucose or by a reaction catalysed by trace amounts of transition 
metals, known as glucose autoxidation (Wolff and Dean, 1987). Initial 
glycation products (Amadori products) are reversible, but further oxidation by 
ROS and RNS (also vulnerable to catalysis by iron) lead to the formation 
AGEs in an irreversible process. AGEs are themselves redox active, and 
may accept a hydrogen atom from nearby biomolecules, leading to their 
autoxidation. In the case of low density lipoproteins, this leads to non-
recognition by cellular LDL receptors, increasing LDL plasma levels and 
subsequent foam cell take-up in atherogenesis, increasing cardiovascular 
risk (Cerami and Ulrich, 2001). 
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In the human body different species of iron are distributed in the extracellular 
and intracellular compartments. The potential one in the extracellular 
compartment is NTBI due to its high tendency to induce ROS which is 
responsible for catalysing redox reaction in the blood and endothelium (Hider, 
2002, Fiorelli et al., 2002, Bonnefont et al., 1989). In addition, NTBI may 
accumulate in cells due to the mechanism of uptake differing from the 
strongly regulated mechanism of uptake of transferrin-bound iron (Chua et al., 
2004). The accumulation of NTBI may cause damage to different intracellular 
organelles such as in endothelial cells, macrophages, and vascular smooth 
muscle cells (Brissot et al., 2012). 
The aim of this study was to evaluate the presence of NTBI in T2DM, obese 
non-diabetic and control subjects, and to examine the association between 
NTBI with other iron parameters, lipid peroxidation and antioxidant status. 
Further to these, this study examined the link between NTBI and biomarkers 
of inflammation and of atherosclerosis in all groups in the study. In addition, 
an in vitro study evaluated the effects of glycation on half saturated 
transferrin (50% ITf) and also the effects of glycation on oxidation of LDL co-
incubated with 50% ITf. 
This study showed a marked increase in the level of NTBI in T2DM 
compared with the control and obese groups. The presence of NTBI in T2DM, 
which is not an iron-overload condition, may be due to impairment of the 
binding capacity of the plasma transporter proteins such as Hb and 
transferrin to hold iron tightly due to structural changes resulting from the 
glycation process (Kisugi et al., 2007). The increased level of NTBI may be 
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due to decreased synthesis or increased loss of Tf in diabetes due to renal 
problem. 
All previous studies used high concentrations of glucose and loaded 
transferrin with iron to high percentages of saturation, which makes these 
studies not physiologically relevant. In this study, use of 50% ITf with high 
concentrations of glucose led to low levels of free iron release which 
suggests that in vivo, where glucose concentrations are much lower, 
glycation of Tf is likely to have little effect on NTBI release, and that the most 
part of the NTBI release is from other proteins such as Hb and albumin. 
In the case of haemoglobin glycation, structural changes occur that destroy 
the haem group and release the iron held within due to increased H2O2 
production, and its steady-state concentration, resulting in the substantial 
changes in protein structures which expose the haem moiety and promote its 
degradation (Cussimanio et al., 2003, Sen et al., 2005, Goodarzi et al., 2014). 
Normally, Hb damage would be prevented by haptoglobin binding to Hb, but 
this function is decreased when haemoglobin is glycated (Asleh et al., 2003). 
The presence of Tf in this study was assessed by measurement of TIBC. 
This was significantly decreased compared with the control; this loss of iron 
binding capacity may result from the stereochemical effects induced by the 
glycation of lysine that prevent the conformational changes (from open to 
closed transferrin forms) required for metal binding (Andre et al., 2014). The 
present study showed significant increase in % transferrin saturation, which 
may be due to process of glycation; it is still not entirely clear why the % 
transferrin saturation would go up. The first possibility is that damage to the 
transferrin would limit its capacity to bind further iron, so the % saturation 
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would appear to increase. The second possibility is that damage to 
transferrin could lead to it being removed, which would mean that the 
remaining transferrin became more saturated with iron. The third possibility is 
due to Tf acting as a negative acute reactive protein. In contrast to the 
situation with T2DM, obesity is generally associated with depletion of iron 
stores. This has been suggested to be linked to hepcidin, which plays the 
role of master regulator of iron metabolism, itself also regulated by iron levels, 
inflammation and erythropoietic activity (Nicolas et al., 2002). Inflammation, 
from cytokine release by adipocytes and invading inflammatory cells, may 
lead to increased hepcidin production, which then down regulates iron 
absorption by the gut and release of iron from macrophages (McClung and 
Karl, 2009). 
Although there are many studies on iron indices in obese non-diabetic 
subjects none of these mentions the presence of NTBI in obese subjects. 
This study found the presence of NTBI in the obese group even though the 
level of total iron in this group was significantly lower compared with the 
control and T2MD groups. That NTBI in obese non-diabetic subjects was 
significantly lower compared with the diabetic group may be explained by 
obese non-diabetic subjects facing levels of protein glycation intermediate 
between control and diabetic subjects, as a result of pre-diabetic changes in 
glucose homeostasis. Previous studies have demonstrated strong, positive 
associations of BMI with fasting glucose and HbA1c with both obese and 
diabetic subjects (Eldeirawi and Lipton, 2003). 
The occurrence of NTBI in direct association with protein glycation is 
supported by studies of Lee et al. (2006) and Leoncini et al. (2008). T2DM is 
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closely correlated with chronic inflammation and increased circulating 
concentrations of IL-6 and TNF-α were found in T2DM (Pickup et al., 2000). 
The inflammation process causes increased hepcidin production which 
inhibits intestinal iron absorption (Arshad et al., 1991), and also inhibits 
release of iron from the liver and macrophages leading to decreased iron 
circulation and also increased iron deposition in the cells. In the present 
study total iron showed a statistically lower concentration in the T2DM group 
compared to the controls. Also soluble transferrin receptor levels were higher 
in the T2DM group possibly due to increased deposition of iron as ferritin in 
cells of T2DM subjects, which may be due to combination age-related 
accumulation of iron (KillileaI et al., 2004) and inflammation which leads to 
increased cytokine production causing an increase in transferrin receptors on 
the cell surface (Hirayama et al., 1993). 
ROS production in T2MD is an inevitable process due to consequences of 
metabolic dysfunction (Hider, 2002, Evans and Williams, 1980). Initially 
antioxidant defence may prevent the detrimental effects of ROS, but later 
these mechanisms may become exhausted and oxidative damage may 
develop. Redox-active iron is tightly controlled in human body, but when 
NTBI is present in the circulation it is more likely to participate in the 
generation of reactive oxygen species and induce lipid peroxidation (Hider, 
2002). In present study there was an increase in plasma MDA in T2DM 
compared with the control, possibly due to the presence of NTBI which could 
be initiating Fenton chemistry in vivo, leading to induction of lipid peroxidation, 
and hence increased MDA. Also increased was the level of DHA which 
indicates the increase in oxidative stress in T2DM. There are several pieces 
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of evidence showing that the concentrations of antioxidants were decreased 
in T2DM. Ascorbate is an antioxidant vitamin which plays an important role in 
scavenging the damage of free radical and sparing other endogenous 
antioxidants from consumption. A decrease in overall ascorbate level was 
documented in T2DM in this study. Antioxidant capacity is an important 
determinant of tissue injury, especially in patients with increased oxidant 
stress. This study showed a significant decrease in total antioxidant capacity 
(as measured using the FRAP assay) in T2DM compared with the control 
group. 
T2DM is characterized by abnormalities in the levels of plasma lipids and 
lipoproteins, including reduced HDL cholesterol, a predominance of small 
dense LDL particles, and elevated triglycerides (Krauss, 2004, Siribaddana et 
al., 1994). In T2DM glycation of lipoprotein fractions might be more important 
than serum lipid and lipoprotein abnormalities (Yegin and Yegin, 1995). One 
common change induced by glycation of lipoproteins is that they are 
rendered more susceptible to oxidation (Sobal et al., 2000). The levels of 
glycated LDL have been shown to be elevated in DM patients (Lyons et al., 
1986). The non-enzymatic glycation of LDL occurs mainly to apolipoprotein B, 
in which lysine is the major amino acid that undergoes glycation. 
(Steinbrecher and Witztum, 1984) have reported levels of 2-17% of LDL-
lysine to be glycated. Transition metal ions prompt LDL glycation (Imanaga et 
al., 2000). The present in vitro study showed an increase in glycation of LDL 
after incubation of LDL with 500 mM glucose; incubation of LDL with 50% ITf 
showed a lower degree of glycation compared with LDL incubated with 500 
mM glucose. The study also showed that the level of MDA was increased in 
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the case of incubation of LDL with 50% ITf compared with LDL incubation 
with 500 mM glucose alone. This may be due to the loss of iron from 
transferrin over time in the incubation, which may in turn increase the 
oxidation of LDL. Also the level of MDA was increased in the case of 
incubation LDL with 50% ITf compared with LDL incubation with low level of 
free iron. This may be due to glycation inducing the oxidation of LDL more 
than that of native LDL (Sobal et al., 2000). 
In the present study the level of the biomarker of atherosclerosis, E-selectin, 
was correlated with levels of NTBI. NTBI, which is present in T2DM subjects, 
may induce the oxidation of glycated LDL in the atherosclerotic plaque. NTBI 
activates the endothelium and increases production of adhesion molecules 
such as E-selectin which may be involved in recruitment of monocytes. 
These monocytes convert to macrophages thus enhancing subendothelial 
LDL retention and macrophage progression to foam cells. It has been 
previously shown that NTBI levels positively correlate with the expression of 
adhesion molecules, ICAM-1, VCAM-1 and E-selectin, but not to the 
inflammatory marker CRP (Kartikasari et al., 2006). 
In people with T2DM there was a correlation between NTBI and HbA1c. This 
maybe indicates that glycation of haemoglobin is a major player in the 
release NTBI in plasma rather than other proteins such as transferrin, the 
focus of this study. Regardless of the sources of NTBI, it plays a major role in 
diabetes complications such as atherosclerosis. NTBI is thought to be easily 
accessible to many cell types within the plaque, likely accumulating in 
endothelial cells, macrophages, and vascular smooth muscle cells (Vinchi et 
al., 2014). 
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Combinations of haem, Hb and NTBI also play major roles in complications 
of diabetes such as atherosclerosis. All these species contribute to the 
oxidation of LDL in plasma and induce the oxidative stress by formation ROS. 
They also promote endothelial activation, by enhancing adhesion molecule 
expression and monocyte recruitment (Figure 6.1). 
 
Figure 4.1 A role for NTBI in atherosclerotic lesions in uncontrolled T2DM. 
NTBI from different sources may be introduced to the endothelium directly and activate the 
endothelium to release different types of adhesion molecules such as E-selectin leading to 
recruitment of monocytes from the circulation. The resulting macrophages uptake oxidised LDL. 
Circulating monocytes may also contain NTBI, and its presence enhances the overall process. 
The present study needs more strength by studying other factors which may 
contribute to NTBI release such as protein glycation in RBC membranes. The 
RBC is unique among cells in that the plasma membrane, its only structural 
component, accounts for all the diverse biochemical and mechanical 
characteristics of the cell (An and Mohandas, 2008). The balance, distribution 
and interplay of the proteins and lipids in the RBC membrane play major 
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roles in the function of the membrane. The lipid bilayer is composed of equal 
proportions by weight of cholesterol and phospholipids. The membrane 
proteins serve numerous functions including transport, cellular interaction 
and, with the lipid component, the structural integrity of the membrane. Both 
proteins and lipids are susceptible to glycation and/or oxidative modification. 
The RBC is therefore particularly susceptible to the consequences of poor 
regulation of circulating glucose levels. Glycation of RBC membrane proteins 
may have an effect on the integrity and function of the RBC. Protein glycation 
may in turn lead to the formation of reactive oxygen species which may 
damage intracellular and membrane associated macromolecules such as 
other proteins and lipids (Resmi et al., 2005). A number of in vitro studies 
have confirmed the damaging effects of glycation on RBC membranes and 
their components, leading to reduced antioxidant protection, enhanced 
fragility, reduced deformability and evidence of haemolysis (Resmi et al., 
2005, Shin et al., 2008, Suravajjala et al., 2013). Few studies have examined 
glycation of proteins in the RBC membrane of diabetic patients in vivo. 
Extensive proteomic analysis of glycation of plasma proteins and proteins of 
the RBC membrane of diabetic patients demonstrated the presence of a 
number of glycated proteins in the erythrocyte membrane (Zhang et al., 
2008). Furthermore, RBC membrane proteins were more extensively 
glycated than plasma proteins (Zhang et al., 2011). Glucose concentration as 
low as 1% can induce non-enzymatic glycation of cell surface proteins in 
RBC membranes which modifies the visco-elastic properties of the RBCs and 
decreases their deformability (Riquelme et al., 2005). Another study has 
provided evidence of glucose-induced changes in lipid and protein 
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composition and function in RBCs from subjects with T2DM (Starodubtseva 
et al., 2008). Future studies could focus on the glycation of RBC membrane 
proteins and lipids, in association with accompanying free radicals, leading to 
a combination of increased membrane permeability and damage to Hb and 
haem, leading to the enhanced appearance of both compounds in the 
plasma along with free iron. These three components then could contribute to 
the vascular complications of diabetes. It has been suggested that low grade 
haemolysis in conditions such as diabetes may contribute to the vascular 
disease associated with the condition (Kato and Taylor, 2010). 
An-going study in our laboratory has shown that the level of NTBI is reduced 
by using statins. Therefore a study of influence of statins on iron haemostasis 
and RBC membrane integrity would be appropriate in the future, also 
including other drugs such as anti-diabetics (e.g. metformin) which reduce 
protein glycation (Rahbar et al., 2000), and maybe reduce release of NTBI 
and then maybe reduce the consequences of NTBI in the development of 
atherosclerosis in T2DM. 
In addition, an animal model such as the streptozotocin diabetic rat might 
give more information on the role of iron dysregulation. The following is an 
outline of a possible future study using this approach. Wistar rats would be 
randomly divided into five groups, each group containing 30 rats (groups 1, 2, 
3, 4 and 5). Group 1 would be injected with iron-dextran at low dose (200 
mg/kg) as a control group; group 2 would be injected with iron-dextran at low 
dose (200 mg/kg) and injected with the diabetes-inducing drug streptozotocin 
with multiple low doses (60 mg/kg) to induce T2DM; group 3 would be 
injected with iron-dextran at low dose (200 mg/kg), 400 mg/kg of 
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deferoxamine to chelate iron (Wu et al., 2004) and also injected with the 
diabetes-inducing drug streptozotocin with multiple low doses (60 mg/kg) to 
induce T2DM; group 4 would be injected  with iron-dextran at high dose (800 
mg/kg) (Yang et al., 2002), and also injected with the diabetes-inducing drug 
streptozotocin with multiple low doses (60 mg/kg) to induce T2DM; and group 
5 would be injected with iron-dextran at high dose (800 mg/kg) (Yang et al., 
2002), 400 mg/kg of deferoxamine and also injected with the diabetes-
inducing drug streptozotocin with multiple low doses (60 mg/kg) to induce 
T2DM. After three months blood would be taken (5 ml) to measure iron status, 
oxidative stress and endothelium parameters, and HbA1c (as described in 
Chapter 2). Transferrin would be separated from the plasma using an 
Aurum™ Serum Protein Mini Kit in order to investigate transferrin 
fragmentation using two dimensional gel electrophoresis and mass 
spectrometry for all groups. The aims of this study would be: 
1) to test whether there is NTBI in normal and/or diabetic rats by 
comparing the levels in groups 1 and 2; and also comparing other changes in 
all parameters; 
2) to examine the effects of low iron versus high iron (both via injection of 
iron-dextran) on all parameters; 
3) to examine transferrin fragmentation in the four diabetic groups 
compared with control group to give obtain a clear view on changes to the 
structure of transferrin. 
4) to identify any correlations between NTBI and all parameters in the 
study; and 
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5) to identify any correlations between HbA1c and all parameters. 
Predicted outcomes of study 
1) A significant level NTBI should be found in all diabetic groups (2-5) 
compared with the control, group 1. 
2) All iron parameters in groups 2-5 should change due to the different 
levels of iron injected, compared with group 1. 
3) Due to the high dose of iron injected in group 4 without deferoxamine 
this group should show high levels of NTBI and general iron status, 
oxidative stress, elevated E-selectin and cRP and greater 
fragmentation in transferrin. 
4) There should be improvement in HbA1c, significant reduction in NTBI 
and other iron parameters, endothelium parameters (E-selectin and 
cRP) and oxidative stress parameters when the diabetic groups are 
injected with deferoxamine. 
Because NTBI is heterogeneous in nature and there are different methods for 
measuring it, comparison of different methods could be included in future 
studies in order to know the type of iron ligands which predominate in T2DM 
and obese non-diabetic subjects, in addition to measurement of the labile 
iron pool which is thought to be more redox active than NTBI (Cabantchik, 
2014). 
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Appendix 1 correlation of other iron indices with age
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Figure A1.1 Correlations between age and total serum iron levels (P = 0.356). 
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Figure A1.2 Correlations between age and % saturation of transferrin ( P = 0.440). 
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Figure A1.3 Correlations between age and NTBI levels (P = 0.470). 
Age (year)
40 50 60 70
s
T
R
 (
 µ
g
/m
l)
0
200
400
600
800
1000
Diabetes
Control
Obese
 
Figure A1.4 Correlations between age and sTfR (P = 0.616). 
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Appendix 2 correlation other oxidative stress indices with age 
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Figure A2.1 Correlations between age and total ascorbate (P = 0.895). 
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Figure A2.2 Correlations between age and ascorbate (P = 0.985). 
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Figure A2.3 Correlations between age and DHA (P = 0.896). 
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Figure A2.4 Correlations between age and total antioxidant capacity (P = 0.682). 
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Appendix 3 correlation between E-selectin and hsC-RP and age 
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Figure A3.1 Correlations between age and E-selectin levels (P = 0.0997). 
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Figure A3.2 Correlations between age and hs-CRP (P = 0.221). 
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Appendix 4 correlation between NTBI and iron indices 
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Figure A4.1 Correlations between NTBI and total serum iron (P = 0.396). 
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Figure A4.2 Correlations between NTBI and TIBC (P = 0.527). 
  248  
 
NTBI (µM)
0.0 0.5 1.0 1.5 2.0 2.5
%
T
ra
n
s
fe
rr
in
 s
a
tu
ra
ti
o
n
10
20
30
40
50
60
70
80
Diabetes
Control
Obese
 
Figure A4.3 correlation between NTBI and % transferrin saturation (P = 0.328). 
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Appendix 5 correlation between NTBI and oxidative stress indices 
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Figure A5.1 Correlations between NTBI and MDA (P = 0.390). 
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Figure A5.2 Correlations between NTBI and total ascorbate (P = 0.396). 
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Figure A5.3 Correlations between NTBI and DHA (P = 0.865). 
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Figure A5.4 Correlations between NTBI and ascorbate (P = 0.563). 
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Figure A5.5 Correlations between NTBI and total antioxidant capacity (P = 0.593). 
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Appendix 6 correlation between NTBI hsC-RP 
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Figure A6.1 Correlation between hs-CRP and E-selectin (P = 0.801). 
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Appendix 7 Validation of the NTBI method 
 
  254  
 
 
  
  255  
 
Appendix 8 Consent form 
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Appendix 9 Questionnaire forms 
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Appendix 10 Anthropometric indices 
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